AN ABSTRACT OF THE DISSERTATION OF

<u>David A. Schiedler</u> for the degree of <u>Doctor of Philosophy</u> in <u>Chemistry</u> presented on <u>December 2, 2014</u>.

Title: <u>The Development of Aminal Radicals for the Synthesis of Nitrogen-Rich</u> <u>Natural Products</u>.

Abstract approved:

Christopher M. Beaudry

Abstract

Organic compounds which contain one or more nitrogen atoms are especially important as they are disproportionately represented among biologically active molecules. As a result, significant effort has been focused on the development of methods for the synthesis of nitrogenous molecules. We identified the aminal as an under-explored functional group. Despite the presence of the aminal functional group in several biologically active natural products which have attracted the attention of the synthetic community, no bond forming reactions of the aminal functional group had been described in the literature.

This dissertation describes the development of two new carbon-carbon bond forming reactions utilizing aminal radical intermediates (carbon-centered radicals wherein the radical bearing carbon atom has two nitrogen substituents). Additionally, this document describes progress towards the application of aminal radicals in the context of the total synthesis of the alkaloid leuconoxine.

The preliminary investigations centered on the generation of aminal radicals under peroxide initiated conditions similar to those previously reported for the generation of α -aminoalkyl radicals. The treatment of aminal containing molecules with di-*tert*-butyl peroxide in the presence of a radical acceptor (e.g. 1-octene) produced either a complex mixture of products, or no reaction.

Aminal radicals were successfully formed from 2-iodobenzyl substituted *N*-acyl aminals by radical translocation reactions using AIBN and either Bu_3SnH or $(TMS)_3SiH$ as a stoichiometric hydrogen atom donor. It was found that aminal radicals participate in inter- and intramolecular C–C bond forming reactions with electron deficient alkenes. Reactions in the presence of electron rich or unactivated alkenes did not lead to the desired bond formation, instead giving products of dehalogenation. The reaction of *N*-acyl aminals which contained carbon atoms bearing only one nitrogen atom were shown to selectively give the product of bond formation at the aminal carbon. Chemical yields of the radical translocation reactions were as high as 91%.

It was demonstrated that the SmI_2 reduction of *N*-acyl amidines or amidinium ions in the presence of a proton source and an electron deficient alkene yielded products of C–C bond formation. Chemical yields of these transformations were as high as 99% and can lead to diastereoselectivities in excess of 20:1. Mechanistic investigations of this reactivity indicated that the reactions likely proceed through an aminal radical intermediate.

The application of aminal radicals to the total synthesis of the alkaloid natural product leuconoxine has been investigated. It was envisioned that the SmI_2 induced reductive alkylation reaction of a simple bicyclic *N*-acyl amidine would rapidly construct the fully substituted aminal stereocenter present in the natural product. While similar amidines have been reported in the literature, no general strategy to access amidines

of this type was known. Three distinct synthetic strategies towards the preparation of the desired bicyclic *N*-acyl amidine substrate were developed and investigated.

The first strategy relied on the formation of the amidine using the intramolecular aza-Wittig reaction of an imide and an azide. Unexpectedly, these reactions produced a bis-amide product. Attempts to induce an intramolecular condensation reaction of the bis-amide to give the desired amidine were unsuccessful. The second strategy disconnected the desired bicyclic *N*-acyl amidine through an intramolecular *N*acylaiton reaction of an *N*-aryl amidine. It was envisioned that the amidine could be prepared from a bimolecular condensation reaction of an aniline and a lactam derivative. All attempts to form the desired amidine functionality were unsuccessful. The third strategy depended upon an *N*-arylation reaction for the conversion of a known bicyclic *N*-acyl amidine to the desired substrate for the synthesis of leuconoxine. While the desired substrate has remained elusive, a model system of the key *N*-arylation reaction has successfully given the desired *N*-aryl-*N*-acyl bicyclic amidine product. ©Copyright by David A. Schiedler December 2, 2014 All Rights Reserved

The Development of Aminal Radicals for the Synthesis of Nitrogen-Rich Natural Products.

by David A. Schiedler

A DISSERTATION

submitted to

Oregon State University

in partial fulfillment of the requirements for the degree of

Doctor of Philosophy

Presented December 2, 2014 Commencement June 2015 <u>Doctor of Philosophy</u> dissertation of <u>David A. Schiedler</u> presented on <u>December 2</u>, <u>2014.</u>

APPROVED:

Major Professor, representing Chemistry

Chair of the Department of Chemistry

Dean of the Graduate School

I understand that my thesis will become part of the permanent collection of Oregon State University libraries. My signature below authorizes release of my thesis to any reader upon request.

David A. Schiedler, Author

ACKNOWLEDGEMENTS

I would like to express my thanks to my wife, Mindy, for all of the sacrifices she has made in order for me to complete this degree. She has sacrificed career advancement, spent many months living alone, and has endured much emotional and financial hardship during my time in graduate school. I am grateful to family for their continued support of my education. I would also like to thank the members of the Beaudry research group, both past and present for their support. Jessica Vellucci and Yi Lu were instrumental in the completion of this work and I am greatly appreciative of their excellent lab skills and their willingness to collaborate with me on these projects. Finally, I would like to thank my advisor, Professor Chris Beaudry, for his guidance over the last five years. Professor Beaudry has pushed me to learn fundamental chemical principles, to think critically about my research, and has been a constant encourager.

CONTRUBUTION OF AUTHORS

Jessica Vellucci assisted with data collection for chapter 2 and with the writing of chapters 1 and 2. Yi Lu assisted with the data collection for chapter 3 and the writing of chapters 1 and 3.

TABLE OF CONTENTS

| Pag | <u>e</u> |
|---|----------|
| 1 Introduction, Background, and Preliminary Investigations | .2 |
| 1.1 Biologically Active Nitrogen Rich Natural Products | .2 |
| 1.2 Radicals in the Synthesis of Heteroatom Containing Molecules | .3 |
| 1.3 Aminal Radicals as Synthetic Intermediates | .4 |
| 1.4 Preliminary Investigations Using Peroxide Initiated Conditions | .7 |
| 1.5 Radical Translocation Reactions of Non-Acylated Aminals | .9 |
| 1.6 Experimental Section | 13 |
| 2 Formation of Carbon–Carbon Bonds Using Aminal Radicals | 31 |
| 2.1 Introduction | 32 |
| 2.2 α-Amino Radicals and Protective Radical Translocaiton | 33 |
| 2.3 Results and Discussion | 34 |
| 2.4 Conclusion | 38 |
| 2.5 Experimental Section | 38 |
| 3 Reductive Synthesis of Aminal Radicals for Carbon–Carbon Bond Formation1 | 19 |
| 3.1 Introduction | 20 |
| 3.2 Results and Discussion | 21 |
| 3.3 Conclusion | 29 |
| 3.3 Experimental Section | 29 |
| 4 Application of Aminal Radicals in Total Synthesis: Progress Towards the Total | |
| Synthesis of Leuconoxine | 51 |
| 4.1 Isolation and Previous Syntheses | 51 |
| 4.2 Retrosynthetic Analysis | 53 |

TABLE OF CONTENTS (Continued)

| | <u>Page</u> |
|---|-------------|
| 4.3 Progress Towards the Total Synthesis of Leuconoxine | |
| 4.4 Experimental Section | 267 |
| 5 Conclusion and Future Direction | |
| 5.1 Conclusion | 328 |
| 5.2 Future Directions | 331 |

LIST OF FIGURES

| Figure | Page |
|--|------|
| 1.1 Nitrogen-Rich Natrual Products and Pharmaceuticals which Contain Amina | ls2 |
| 2.1 Selected Nitrogen-Rich Alkaloids | 31 |
| 2.2 Scope of the Aminal Radical Reaciton | 36 |
| 4.1 Leuconoxine and its Biologically Acvtive Congeners | 248 |

LIST OF TABLES

| Table | Page |
|---|------|
| 1.1 Reactions using Peroxide-Initiated Conditions | 8 |
| 1.2 Attempted Optimization of Radical Translocation | 10 |
| 2.1 Reactivity of Aminal 60 | 34 |
| 3.1 Development of the Amidine Reduction Reaction | 120 |

LIST OF SCHEMES

| <u>Scheme</u> <u>Pa</u> | <u>ge</u> |
|--|-----------|
| 1.1 Clive's Formal Synthesis of (–)-Epibatidine | 3 |
| 1.2 C–C bond Forming Reactions of Acetal Radicals | 4 |
| 1.3 Proposed Reaction of an Aminal Radical with an Alkene | 4 |
| 1.4 C–C Methods for the Generation of α-Amino Radicals | 6 |
| 1.5 The Attempted Extension of Juveland's Method | 7 |
| 1.6 Extension of Radical Translocation for the Generation of Aminal Radicals | 9 |
| 1.8 Deuterium Incorporation in the Dehalogenated Side Product | .12 |
| 2.1 Radical Translocation | .32 |
| 2.2 Initial Investigations of Aminal Radical Reactivity | .33 |
| 2.3 Plausible Model for Formation of 71 | .37 |
| 3.1 Formation of C–C Bonds with Aminal Radicals1 | 119 |
| 3.2 Scope of the Amidine Reduction Reaction | 121 |
| 3.3 Scope of the Amidine Reduction Reaction (continued)1 | 122 |
| 3.4 Scope of Amidine Substrates1 | 123 |
| 3.5 Amidinum Reduction1 | 124 |
| 3.6 Mechanistic Investigation1 | 125 |
| 3.7 Mechanistic Investigation (continued)1 | 126 |
| 3.7 Possible mechanism for the formation of 140 | 126 |
| 4.1 Zhu's Enantioselective Total Synthesis of (–)-Leuconoxine | 249 |
| 4.2 Tokuyama's Synthesis of (±)-1 | 250 |
| 4.3 Retrosynthetic Analysis of 1 with an Aminal Radical Disconnection | 250 |
| 4.4 Known Methods for the Preparation of Bicyclo[4.4.0]amidines | 251 |

LIST OF SCHEMES (Continued)

| Scheme | Page |
|--|------|
| 4.5 The First Generation Retrosynthetic Analysis of 166 | 253 |
| 4.6 Attempted Synthesis of the Amine 181 | 254 |
| 4.7 Second-Generation Rtrosynthetic Analysis of the Key Intermediate 166 | 255 |
| 4.8 Synthesis of the Amido Lactam 191 | 256 |
| 4.9 Plausible Mechanism for the Formation of the Amido Lactam 191 | 257 |
| 4.10 The Attempted Dehydration of the Amido Lactam 191 | 257 |
| 4.11 Lewis-Acid Catalyzed Amidine Formation | 258 |
| 4.12 Reactions of the Dithioimide Model Systems | 260 |
| 4.13 An Alternate Retrosynthetic Analysis of 166 | 260 |
| 4.14 Attempts to Form the DesiredAmidine From 209 | 261 |
| 4.15 Attempted Addition of Anilines to Activated Lactams | 262 |
| 4.16 Retrosynthetic Analysis of 166 from Wamhoff's Amidine 178 | 263 |
| 4.17 Reactions of Wamhoff's Amidine 178 | 264 |
| 5.1 Future Work on the Synthesis of 1 | 330 |
| 5.2 Additional Reactions to be Developed | 331 |

The Development of Aminal Radicals for the Synthesis of Nitrogen-Rich Natural Products

Chapter 1: Introduction, Background, and Preliminary Investigations

1.1 Nitrogen Rich Natural Product Synthesis

Many biologically active molecules, including pharmaceuticals, contain one or more nitrogen atoms. As a result, nitrogen rich compounds, such as alkaloids and pharmaceuticals, make compelling synthetic targets (Figure 1.1, 1-7).¹ However, the complex reactivity of nitrogen can be problematic in synthesis. The ability to quaternize, the Lewis basic lone pair, and the weakly acidic N–H protons found in nitrogen-containing molecules often give rise to undesired reactivity.





Figure 1.1. Nitrogen-rich natural products and pharmaceuticals which contain aminals

In order to mask the complex Lewis acid-base reactivity of nitrogen, synthetic chemists often resort to the use of protective groups.² Other strategies which have proven successful for the synthesis of nitrogen-containing structures include opting to install nitrogen late in the synthesis³ or in the form of a less reactive functional group (e.g., as a nitro⁴ or nitrile⁵ group).


1.2 Radicals in the Synthesis of Heteroatom Containing Molecules

An alternative means to circumvent the pitfalls of alkaloid synthesis is the use of single electron reactivity (i.e., free radical reactions). Free radicals are known to tolerate heteroatom lone pairs, and N–H bonds are resistive to homolytic cleavage.⁶ The addition of carbon-centered radicals bearing heteroatoms to C–C multiple bonds has been known for over fifty years.⁷ For example, Clive and coworkers generated the α -amido radical intermediate **8** from the *N*,*S*-acetal **9** to construct the bicycle **10** in their formal synthesis of (–)-epipatidine **11** (Scheme 1.1).⁸ α -Aminoalkyl and α -amido radicals, such as **8**, gain stability from the electron lone pair on the adjacent nitrogen atom and react with unsaturated carbon atoms to give products of C–C bond formation.⁹ This reactivity has proven useful for the synthesis of heterocycles and alkaloid natural products as it allows for the strategic disconnection of bonds which would be difficult to form using standard cationic or anionic reaction conditions.¹⁰



Scheme 1.1. Clive's formal synthesis of (-)-epibatidine


Carbon-centered radicals bearing two adjacent heteroatoms are also known to undergo C–C bond forming reactions with C–C multiple bonds. Homolytic C–H bond cleavage of acetal **12** was induced by photosensitized benzophenone to give the aceal radical **13**. Radical **13** then added across the enone **14** to give the observed product **15** after propagation (Scheme 1.2, eq. 1). Reactions of 2-bromobenzoyl enamides **16** with AIBN and Bu₃SnH were presumed to proceed through *N*,*S*- and *N*,*O*- acetal radical intermediates (**17**) during C–C bond forming reactions to give the ring-fused products **18** (Scheme 1.2, eq. 2).¹¹



Scheme 1.2. C-C bond forming reactions of acetal radicals

Carbon-centered radicals bearing two adjacent nitrogen atoms (i.e. aminal radicals) have been implicated as intermediates in the free radical and radiative damage of DNA nucleotide bases,¹² they have been experimentally generated and studied spectroscopically,¹³ and long-lived aminal radicals have been isolated.¹⁴ Applications of aminal radicals include their use as photochromic dyes¹⁵ and as tools for mechanistic investigations.¹⁶ Although there are reports of fragmentation,¹⁷ protonation,¹⁸ and dimerization reactions of aminal radicals, there had been no reports of their synthetic utility prior to recent work from our laboratory.¹⁹

1.3 Aminal Radicals as Synthetic Intermediates




Scheme 1.3. Proposed reaction of an aminal radical with an alkene

Having considered the known reactivity of acetal and α -aminoalkyl radicals, the creation of a new reaction was envisioned wherein a nitrogen-rich starting material

(19) would be converted into an aminal radical intermediate (20) and would undergo addition to an alkene to give the product of C–C bond formation (21, Scheme 1.3). Computational studies predicted that aminal radicals are 1-2 kcal/mol more stable than analogous α -aminoalkyl radicals.²⁰ This suggested that it would be possible to selectively generate aminal radicals in the presence of carbon atoms bearing a single nitrogen atom as depicted in Scheme 1.3. Based on these considerations, we postulated that aminal radical intermediates would be well suited for the construction of the carbon framework in nitrogen-rich molecules.

It was predicted that aminal radical intermediates would react in a manner similar to α -aminoalkyl and α -amido radicals. Following from this prediction, it was reasoned that aminal radicals might be accessible by an extension of a method previously reported for the generation of α -amino radicals. Scheme 1.4 gives a summary of the known methods for the generation of α -amino radicals. One of the most common ways in which α -amino radicals have been generated is by the homolytic cleavage of a C–X bond on the carbon which bears nitrogen (X = SR, SeR, Cl, Br, SiMe₃, or C(O)R). For example, Zhang reported the conversion of the selenide **22** to the spirocyclic compound **23** which presumably results from the 6-*exo*-trig radical cyclization of the aminal radical **24** (eq. 1).²¹ While this strategy allows for completely regioselective radical generation, it was deemed unattractive for the extension to the generation of aminal radicals as it required the synthesis of pre-functionalized aminal substrates.

Another means to generate α -amino radicals involves the addition of a carboncentered radical to an enamine. Renaud reported the conversion of enamine **25** to the alkylated product **26** by addition of an alkyl radical to give the α -amino radical intermediate **27** followed by hydrogen atom abstraction from Bu₃SnH (eq. 2).²² The single electron reduction of iminium ions in the presence of a proton source has been reported for the generation of α -amino radicals. Martin reported the conversion of the iminium ion **28** to the fused bicyclic compound **29** by way of the α -amino radical **30** (eq. 3).²³ This method was attractive for extension to the generation of aminal radicals as it had the potential to generate an aminal radical in a regioselective manner without the poor atom economy exhibited by the C–X bond homolysis strategy.




Scheme 1.4. Methods for the generation of α -amino radicals

 α -Amino radicals have also been obtained from the homolysis of a C–H bond on the carbon bearing nitrogen. One such method, termed protective radical translocation,²⁴ involves the use of a halogen-substituted protecting group. Undheim reported the conversion of 2-iodobenzyl protected amine **31** to the alkylated amine product **32** (eq. 4).²⁵ The reaction proceeded through a phenyl radical which then underwent a 1,5-

hydrogen atom abstraction to produce the aminal radical intermediate **33**. In 1958, Juveland reported the generation of α -aminoalkyl radical intermediate **34** under peroxide initiated conditions (eq. 5).²⁶ Treatment of piperidine (**35**) with di-*tert*-butylperoxide in the presence of 1-octene yielded 2-octyl piperidine (**36**). Similar transformations using Et₃B / O₂²⁷ or a transition-metal catalyzed photo-redox process²⁸ to generate the radical species have also been reported. Reactions of this type were particularly attractive for extension to the generation of aminal radicals because they would not require any pre-functionalization of the aminal substrates.

1.4 Preliminary Investigations Using Peroxide Initiated Conditions

Extension of Juveland's peroxide initiated method for the generation of α -amino radicals to the generation of aminal radicals was chosen for the preliminary investigations. This extension could involve the treatment of an aminal with di-*tert*-butylperoxide in the presence of a suitable radical acceptor (Scheme 1.5). Tetrahydroisoquinazoline (**37**) was chosen because it was easy to prepare, it was chromatographically stable, and it contained a chromophore which allowed for facile monitoring of reaction progress.



Scheme 1.5. The attempted extension of Juveland's method

Following Juveland's procedure, **37** was heated in the presence of di-*tert*butylperoxide and 1-octene in a sealed tube (Table 1, entry 1). The reaction produced an intractable mixture of products and none of the desired product **40** was observed. The ¹NMR spectrum of the product mixture showed additional aryl protons with no additional signals in the alkyl region of the spectrum. In an effort to affect cleaner reactivity, modified reaction conditions were investigated. Increasing the equivalents of the radical acceptor and adding benzene as a solvent had no effect (entry 2). The benzyl protected aminal **41** was subjected to the reaction conditions with methyl acrylate as a radical acceptor, but also gave a mixture of products and none of the desired compound **42** was observed (entry 3). The ¹H NMR spectrum of the product mixture showed new peaks in the aryl region. Lowering the reaction temperature resulted in no reaction (entry 4). The aminal substrate **43** was prepared and subjected to the reaction conditions with carbon tetrachloride, benzene, or solventless conditions (entries 5-7). None of the desired spirocycle **44** was obtained in any case. ¹H NMR analysis of the product mixture revealed that a number of new compounds containing alkenyl signals had formed. This indicated that the newly formed products were not the result of the desired radical cyclization event.





Table 1.1. Reactions using peroxide-initiated conditions

Based on these results, two plausible explanations were formulated. Either the desired aminal radical **39** was generated, and it was reacting in an unselective manner to give the observed decomposition, or aminal radical **39** had not been generated and the observed degradation was arising from other reaction pathways. Unable to easily distinguish between these possibilities, an alternative method for the generation of aminal radicals was sought. Ideally, this method would incorporate a functional handle that could be used to determine whether aminal radicals were being generated.

1.5 Radical Translocation Reactions of Non-Acylated Aminals

Evaluation of the known methods for the generation of α -amino radicals previously discussed led us to consider a radical translocation strategy for the generation of aminal radicals.²⁹ The application of radical translocation as a means to generate aminal radicals was particularly attractive because it would provide a functional handle through which problematic reactivity might be diagnosed. Specifically, the loss of iodide is diagnostic for the formation of a phenyl radical (**45**) (Scheme 1.6). Deuteration experiments could be used to determine whether the desired 1,5-H atom abstraction event had occurred to yield the desired aminal radical **46.** Additionally, the necessary 2-iodobenzyl substituted starting material **47** could be easily prepared by alkylation of **37**. The product of the reaction, proceeding through the radical intermediate **48** after addition to methyl acrylate and subsequent propagation, would be a benzyl protected aminal (**42**).



Scheme 1.6. Extension of radical translocation for the generation of aminal radicals

N-2-Iodobenzyl-tetrahydroquinazoline (**47**) was prepared from **37** and 2-iodobenzyl iodide. Treatment of the protected aminal with AIBN and Bu₃SnH in the presence of methyl acrylate yielded some of the desired aminal radical product **42** (Table 1.2, entry 1). This indicated that the desired aminal radical is synthetically competent. However, in addition to the desired product, isomeric product **49**,³⁰ over addition product **50**, and dehalogenated product **51** were also observed. Formation of the undesired product **49** is competitive with the formation of desired product **42** as a result of the stability of the α -aminobenzylic radical from which it presumably arises. The formation of dehalogenated **51** was not surprising given that similar reaction conditions have been used to perform radical dehalogenation.³¹ Although Curran reported the oxidation of 2-iodobenzyl ethers under similar reaction conditions,³² no amidine formation was observed.


| \bigcirc | ∧ ∧ ↓ ↓ N ↓ ↓ H 47 | | ^{D₂Me} , Bu₃SnH, 80 °C 12 h | NBn N H 42 | + + N | NBn + [| NBn NBn S0 | + CO ₂ Me | NBn NH 51 |
|------------|--------------------------|------------|--|---------------------|---------------|------------------|--------------------|-------------------------|-----------------|
| | entry | Bu₃SnH | acrylate | addition time | concentration | solvent | 42 + 49 (%) | 50 (%) | 51 (%) |
| | 1 | 3.9 equiv. | 3 equiv. | 10 h | 0.1 M | PhH | 32 | 18 | 24 |
| | 2 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | PhH | 28 | 9 | 37 |
| | 3 | 0.9 equiv. | 3 equiv. | 1 h | 0.1 M | PhH | 12 | 8 | 14 |
| | 4 | 2.0 equiv. | 1 equiv. | 1 h | 0.1 M | PhH | 4 | 0 | 34 |
| | 5 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | PhH | 28 | 9 | 37 |
| | 6 | 2.0 equiv. | 5 equiv. | 1 h | 0.1 M | PhH | 16 | 8 | 17 |
| | 7 | 2.0 equiv. | 10 equiv. | 1 h | 0.1 M | PhH | 6 | 4 | 18 |
| | 8 | 3.9 equiv. | 3 equiv. | 10 h | 0.1 M | PhH | 32 | 18 | 24 |
| | 9 | 3.9 equiv. | 3 equiv. | 1 h | 0.1 M | PhH | 12 | 0 | 23 |
| | 10 | 3.9 equiv. | 3 equiv. | 10 h | 0.01 M | PhH | 16 | 19 | 9 |
| | 11 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | PhH | 28 | 9 | 37 |
| | 12 | 2.0 equiv. | 3 equiv. | 1 h | 0.5 M | PhH | 14 | 5 | 25 |
| | 13 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | СуН | 6 | 3 | 12 |
| | 14 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | PhMe | 12 | 6 | 18 |
| | 15 | 2.0 equiv. | 3 equiv. | 1 h | 0.1 M | CCl ₄ | decomposition | | |

Table 1.2. Attempted optimization of radical translocation

Having successfully demonstrated that aminal radical intermediates are generated and add to alkenes using the radical translocation method, efforts were turned to reaction optimization. Variation of the Bu₃SnH equivalents had little effect on the product distribution; however, the yield of 42 decreased when less than two equivalents were added (Table 1, entries 1-3). Adjustment of the acrylate equivalents showed that only trace amounts of the desired products were formed when less than two equivalents were used (entry 4). Increasing the stoichiometry of the acrylate up to five equivalents showed little effect on the product distribution or isolated yield (entries 5, 6). However, using a large excess of the acceptor resulted in a decrease in yield (entry 7). Decreasing the time of addition from 10 hours to 1 hour was found to partially suppress the formation of the over addition product 50 (entries 8, 9). Systematic variation of the reaction concentration showed that the optimal yield was obtained with a concentration of 0.1 M with respect to the aminal, but the reaction remained unselective (entries 10-12). A solvent screen showed that toluene and cyclohexane were also amenable to the desired reactivity while use of carbon tetrachloride resulted in decomposition (entries 13-15). Benzene was chosen as the optimal solvent as it was easily removed by rotary evaporation, provided superior yields, and possessed favorable solubility properties. In total, more than one hundred conditions were screened but all failed to cleanly produce 42 in high chemical yield.

Of the undesired side products formed in the reaction of **47**, the dehalogenation product **51** was always the most abundant. Presumably, **51** results from the reaction of either the phenyl radical **45** or the aminal radical **46** with Bu₃SnH before it has had sufficient opportunity to react with the acrylate. A deuteration experiment was performed in order to probe whether this undesired reduction was occurring before or after the 1,5-H atom transfer event. After homolysis of the C–I bond, the phenyl radical **45** is generated. If the 1,5-H atom transfer is slow and **45** radical reacts with Bu₃SnD³³, then a deuterium atom should be incorporated at the *ortho*-position of the benzyl group (Scheme 1.7, pathway A). However, if the 1,5-H atom transfer event occurs rapidly, then the deuterium would be incorporated on the aminal containing

ring after reaction of either the aminal radical 46 or the α -amino radical 52 with Bu₃SnD (pathway B).



Scheme 1.7. Deuterium incorporation in the dehalotenated side product

A solution of aminal **47** and methyl acrylate was heated to reflux while a solution of Bu_3SnD and AIBN in benzene was added over a period of one hour. Deuterium NMR analysis of the dehalogenated product (**53**) revealed that 79% of the deuterium was incorporated at the *ortho* position of the benzyl group while only 21% was incorporated on the tetrahydroquinazoline ring. Assuming that the 1,5-H atom transfer is irreversible, this result suggested that the aminal radical, once formed, reacted smoothly with the acrylate acceptor and proceeded to the desired product. However, the rate of D atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with the other Bu_3SnD was competitive with the other Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that of 1,5-H atom abstraction from Bu_3SnD was competitive with that Bu_3SnD was competitive with the Bu_3SnD was competitive by Bu_3SnD was competitive by Bu_3SnD was competitive by Bu_3SnD was competitive by Bu_3SnD was compe

Based on this result, it was reasoned that the use of a terminal reductant which undergoes H-atom abstraction at a slower rate than Bu₃SnH would likely decrease the amount of undesired dehalogenation observed. (TMS)₃SiH, a common substitute for tin hydrides in radical processes,³⁴ is known to undergo H-atom abstraction at a rate approximately one fifth than that of Bu₃SnH.³⁵ Unfortunately, substitution of (TMS)₃SiH for Bu₃SnH in the reaction mixture resulted in no reaction. It was reasoned that the rate of H atom abstraction from (TMS)₃SiH may have been insufficient to sustain the radical chain. Ph₃GeH is known to undergo H-atom abstraction at a rate slower than that of Bu₃SnH and faster than that of (TMS)₃SiH.³⁶ However, use of Ph₃GeH as a terminal reductant also failed to give any product formation.

1.6 Experimental Section

General Experimental Details:

All reactions were carried out under an inert Ar atmosphere in oven-dried glassware. Flash column chromatography (FCC) was carried out with SiliaFlash P60, 60 Å silica gel. Reactions and column chromatography were monitored with EMD silica gel 60 F254 plates and visualized with potassium permanganate, iodine, ninhydrin, or vanillin stains. Tetrahydrofuran (THF) was dried by passage through an activated alumina column. Benzene (PhH) was dried over CaH₂, distilled under an atmosphere of argon, and degassed by three freeze - pump - thaw cycles. Methyl acrylate was purified by washing with aqueous NaOH, drying over MgSO₄, and calcium hydride. It was then distilled under vacuum prior to use. Bu₃SnH and BnSH were dried over CaH₂ and distilled under vacuum prior to use. All other reagents and solvents were used without further purification from commercial sources. FT-IR spectra were measured using NaCl plates. Multiplicities are abbreviated as follows: s = singlet, d =doublet, t = triplet, q = quartet, quin = quintet, br = broad, m = multiplet. Melting points are uncorrected.

2-(pent-4-en-1-yl)-1,2,3,4-tetrahydroquinazoline (43). To a solution of hex-5-enal³⁷ (0.2041 g, 2.08 mmol) and NH₄Cl (0.0185 g, 0.346 mmol) in EtOAc (10 mL, 0.1 M) was added 2-aminobenzylamine (0.2109 g, 1.7262 mmol). The mixture was stirred at room temperature for 0.5 h. At this time, TLC indicated the consumption of 2-aminobenzylamine. The reaction mixture was filtered through celite and was then concentrated. A light yellow oil resulted. Flash column chromatography (3:1 Hexanes : EtOAc) gave **43** (0.2501 g, 1.236 mmol, 72%) as a colorless oil.

Data for **43**: $R_f 0.16$ (1:1 hexanes : EtOAc); IR (thin film) 2928, 2849, 1607 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.01 (td, J = 8.0, 0.4 Hz, 1 H), 6.89 (d, J = 7.2 Hz, 1 H), 6.68 (td, J = 7.2, 0.8 Hz, 1 H), 6.51 (d, J = 8.0 Hz, 1 H), 5.83 (dddd, J = 23.6, 10.0, 6.4, 6.4 Hz, 1 H), 4.97-5.07 (m, 2 H), 4.11-4.16 (m, 2 H), 3.95 (d, J = 16.8 Hz, 1 H), 3.88 (br s, 1 H), 2.13 (q, J = 6.8 Hz, 2 H), 1.54-1.66 (m, 4 H); ¹³C NMR (100 MHz, CDCl₃), δ 143.8, 138.4, 127.3, 126.3, 121.7, 118.1, 115.1, 66.9, 46.7, 46.7, 36.1, 33.7, 24.3; HRMS (EI+) calcd for C₁₃H₁₈N₂ [M+]: 202.14700, found 202.14632.

3-(2-iodobenzyl)-1,2,3,4-tetrahydroquinazoline (**47**). To a solution of 2iodobenzyliodide³⁸ (0.2301 g, 0.690 mmol) and K₂CO₃ (0.1819 g, 1.32 mmol) in a mixture of water (0.5 mL, 1.4 M) and THF (2 mL, 0.35 M) was added 1,2,3,4tetrahydroquinazoline³⁹ (0.1800 g, 1.34 mmol). The mixture was stirred at room temperature for 12 h. At this time, TLC indicated the consumption of 2iodobenzyliodide. The reaction mixture was concentrated. Flash column chromatography (9:1 Hexanes : EtOAc) gave **47** (0.2202 g, 0.629 mmol, 91%) as a yellow oil.

Data for **47**: $R_f 0.36$ (4:1 hexanes : EtOAc); IR (thin film) 2928, 2847, 1606 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (dd, J = 7.6, 0.8 Hz, 1 H), 7.47 (dd, J = 7.6, 1.6 Hz, 1 H), 7.34 (td, J = 7.2, 0.8 Hz, 1 H), 7.06 (td, J = 7.6, 1.2 Hz, 1 H), 6.98 (td, J = 7.6, 1.6 Hz, 1 H), 6.73 (td, J = 7.2, 1.2 Hz, 1 H), 6.61 (d, J = 8.0 Hz, 1 H), 4.13 (s, 2 H), 3.94 (s, 2 H), 3.79 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃), δ 142.8, 141.0, 139.6, 130.4, 128.9, 128.2, 127.7, 127.3, 120.1, 118.4, 115.3, 100.7, 63.0, 61.0, 53.2; HRMS (TOF MS ES+) calcd for C₁₅H₁₆N₂I [M+H]: 351.0358, found 351.0347.


methyl 3-(3-benzyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (42), methyl 3-(3-benzyl-1,2,3,4-tetrahydroquinazolin-4-yl)propanoate (49), dimethyl 3,3'-(3benzyl-1,2,3,4-tetrahydroquinazoline-2,4-diyl)dipropionate (50), and 3-benzyl**1,2,3,4-tetrahydroquinazoline** (**51**). (*Representative procedure for the radical translocation reactions of* **47**). **47** (0.2030 g, 0.580 mmol) and methyl acrylate (0.16 mL, 1.8 mmol) were dissolved in PhH (4.6 mL, 0.13 M) and the mixture was heated to reflux. A PhH solution (1.2 mL) containing AIBN (0.0198 g, 0.121 mmol) and Bu₃SnH (0.31 mL, 1.2 mmol) was added by syringe pump to the refluxing solution over a period of 1.2 h. After 15 h, the mixture was cooled to rt, concentrated, and redissolved in MeCN. The MeCN solution was washed with hexanes, concentrated, and purified by flash column chromatography (8:1 Hexanes : EtOAc) to give a 1:1 mixture of **42** and **49** (0.0542 g, 0.1748 mmol, 30%) as a colorless oil, **50** (0.0155 g, 0.0391 mmol, 6.7%) as a colorless oil, and 3-benzyl-1,2,3,4-tetrahydroquinazoline (**51**) (0.0462 g, 0.206 mmol, 36%).

Data for **42**: $R_f 0.28$ (4:1 hexanes:EtOAc); IR (thin film) 2920, 1732 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.23-7.34 (m, 5 H), 7.04 (t, J = 7.7 Hz, 1 H), 6.86 (d, J = 7.0 Hz, 1 H), 6.67 (t, J = 7.7 Hz, 1 H), 6.53 (d, J = 7.7 Hz, 1 H), 4.09 (t, J = 7.7 Hz, 1 H), 4.03 (br s, 1 H), 3.97 (d, J = 16.8 Hz, 1 H), 3.60-3.73 (m, 6 H), 2.44-2.53 (m, 2 H), 2.04-2.09 (m, 1 H), 1.89-1.94 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃), δ 174.1, 142.2, 139.4, 128.9, 128.4, 127.9, 127.4, 127.1, 118.3, 117.8, 114.4, 69.4, 55.2, 51.8, 48.1, 30.0, 29.7; HRMS (TOF MS ES+) calcd for C₁₉H₂₃N₂O₂ [M+H]: 311.1760, found 311.1770.


Data for **49**: $R_f 0.28$ (4:1 hexanes : EtOAc); IR (thin film) 2950, 1732, 1607 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.03-7.35 (m, 4 H), 7.25-7.27 (m, 1 H), 7.05 (td, J = 7.7, 1.4 Hz, 1 H), 6.98 (dd, J = 7.7, 1.4 Hz, 1 H), 6.71 (td, J = 7.0, 1.4 Hz, 1 H), 6.57 (dd, J = 8.4, 1.4 Hz, 1 H), 4.33 (d, J = 11.9 Hz, 1 H), 3.90 (br s, 1 H), 3.83 (d, J = 13.3 Hz, 1 H), 3.81 (dd, J = 11.9, 1.4 Hz, 1 H), 3.63 (s, 3 H), 3.56 (d, J = 13.3 Hz, 1 H), 3.50 (dd, J = 11.2, 4.9 Hz, 1 H), 2.55 (ddd, J = 16.8, 7.7, 6.3 Hz, 1 H), 2.46 (ddd, J = 14.7, 7.7, 7.7 Hz, 1 H) 1.99-2.08 (m, 2 H); ¹³C NMR (176 MHz, CDCl₃,) δ 174.5, 142.6, 139.3, 129.3, 128.9, 128.3, 127.4, 127.2, 122.9, 117.9, 114.8, 59.0, 57.1, 56.0, 51.6,


33.0, 30.92; HRMS (TOF MS ES+) calcd for $C_{19}H_{23}N_2O_2$ [M+H]: 311.1760, found 311.1750.

Data for **50**: $R_f 0.14$ (4:1 hexanes : EtOAc); IR (thin film) 2950, 2851, 1735, 1692, 1493 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.23-7.34 (m, 5 H), 6.99 (td, J = 8.4, 1.6 Hz, 1 H), 6.95 (d, J = 7.2 Hz, 1 H), 6.32 (t, J = 7.6 Hz, 1 H), 5.31 (s, 1 H), 4.37 (t, J = 6.0 Hz, 1 H), 3.94 (d, J = 14.0 Hz, 1 H), 3.66 (s, 3 H), 3.54 (s, 3 H), 3.09 (d, J = 14.0 Hz, 1 H), 2.63 (t, J = 8.0 Hz, 2 H), 2.44 (dt, J = 16.8, 6.8 Hz, 1 H), 2.24-2.32 (m 1 H), 2.09 (q, J = 7.2 Hz, 2 H), 2.93 (q, J = 7.2 Hz, 2 H); ¹³C NMR (100 MHz, CDCl₃), δ 174.1, 173.7, 143.2, 139.5, 129.1, 128.9, 128.3, 127.1, 126.1, 123.0, 118.4, 114.7, 64.1, 58.0, 51.8, 51.4, 49.1, 32.2, 30.4, 29.4, 27.6; HRMS (CI+) calcd for C₂₃H₂₉N₂O₄ [M+H]: 397.2127, found 397.2129.




DAS61301







j


19




| PC CB B C | ====== CPDPRG2 NUC2 PCPD2 PL2 PL12 PL13 SFO2 SFO2 SFO2 SFO2 SFO2 | ====== NUC1 P1 PL1 SF01 | NAME EXPNO PROCNO PROCNO Time Time TNSTRUM PROBHD PULVENT NS SOLVENT NS SOLVENT NS SOLVENT NS SOLVENT NS SOLVENT DE SOL DE DE DE DE DE DI DE DE DI DE DE DI DE DE DI DE DE DI DE DE DE DI DE DE DE DE DE DE DE DE DE DE DE DE DE |
|--------------------|--|---|--|
| 3.00 Hz 1.40 | CHANNEL f2 ====== waltzl6 14 90.00 use -3.00 dB 15.00 dB 15.00 dB 400.246010 MHz 100.6416850 MHz EM | CHANNEL fl ====== 13C 8.30 use -3.00 dB 100.6517495 MHz | DAS1080 2 20100723 2010723 15.47 DPX400 DPX400 DP5440 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD513 CD523 CD5 |

















| PC C B B C B C B C C B C C B C C B C | CPDPRG2 CPDPRG2 NUC2 PCCD2 PL2 PL12 PL13 SFO2 SFO2 SI | SF01 | NAME SROCNO SROCNO SROCNO SROCNO SROCNO SROCNO NUSTRUM NUSTRUM NUSTRUM SOLVENT SOLVEN |
|--|--|--|---|
| .685 3.0 1.4 | Waltz1 90.00 Use -3.00 dB 15.00 dB 15.00 dB 15.00 dB 15.00 dB 15.00 dB 32768 | f1 ===== 13C 8.30 us -3.00 dB 6517495 MH | DAS10732 20100715 12.44 DPX400 DPX400 DPX400 CD513 CD52 CD53 CD53 CD53 CD53 CD52 CD53 CD52 CD53 CD52 CD53 CD52 CD53 CD52 CD52 CD52 CD52 CD52 CD52 CD52 CD52 |

1 Hesse, M. Alkaloid Chemistry; Wiley: New York, 1981; pp 175-200.

2 Wuts, P. G. M.; Greene, T. W. *Protective Groups in Organic Synthesis*; 4th Ed. Wiley: Hoboken, NJ, 2007; pp 696–926.

3 For example: (a) Nicolaou, K. C.; Chakraborty, T. K.; Piscopio, A. D.; Minowa, N.; Bertinato, P. J. Am. Chem. Soc. **1993**, *115*, 4419–4420. (b) Ge, H. M.; Zhang, L.-D.; Tan, R. X.; Yao, Z.-J. J. Am. Chem. Soc. **2012**, *134*, 12323–12325.

4 Tennant, G. in *Comp. Org. Synth.*, Vol 2. (Eds: Barton, D.; Oates, W. D.); Pergamon Press: Oxford, 1979; pp 383–590.

5 Ono, N. The Nitro Group in Organic Synthesis; Wiley-VCH: New York, 2001.

6 For examples, see (a) Urry, W. H.; Juveland, O. O.; Stacey, F. W. J. Am. Chem. Soc. **1952**, *74*, 6155. (b) Bongini, A.; Cardillo, G.; Orena, M.; Sandri, S.; Tomasini, C. J. Org. Chem. **1986**, *51*, 4905–4910. (c) Sibi, M. P.; Ji, J.; Wu, J. H.; Gürtler, S.; Porter, N. A. J. Am. Chem. Soc. **1996**, *118*, 9200–9201.

7 Walling, C.; Huyser, E. S. Org. Reactions 1963, 13, 91.

8 For selected recent examples of radical reactions as key steps in alkaloid synthesis, see: (a) Atarashi, S.; Choi, J.-W.; Ha, D.-C.; Hart, D.-J.; Kuzmich, D.; Lee, C.-S.; Ramesh, S.; Wu, S. C. *J. Am. Chem. Soc.* **1997**, *119*, 6226–6241. (b) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; Gallagher, J. D. J. Am. Chem. Soc. **2006**, *128*, 8678–8693. (c) Movassaghi, M.; Schmidt, M. A. Angew. Chem. Int. Ed. **2007**, *46*, 3725–3728. (d) Zhang, H.; Curran, D. P. J. Am. Chem. Soc. **2011**, *133*, 10376–10378. (e) Palframan, M. J.; Parsons, A. F.; Johnson, P. Tetrahedron Lett. **2011**, *52*, 1154–1156. (f) Clive, D. L. J.; Yeh, V. S. C. Tetrahedron Lett. **1998**, *39*, 4789–4792.

9 Giese, B. Radicals in Organic Synthesis: Formation of Carbon–Carbon bonds; Pergamon: Oxford, 1986.

10 (a) Aurrecoechea, J. M.; Suero, R. *ARKIVOC* **2004**, *14*, 10–35. (b) Renaud, P.; Giraud, L.; *Synthesis* **1996**, 913–926. (c) Bowman, W. R.; Bridge, C. F.; Brookes, P. J. *Chem. Soc. Perkin Trans. 1* **2000**, 1–14. (d) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, B. U. W. *Cem. Eur. J.* **2012**, *18*, 10092–10142.

11 Zhou, A.; Njogu, M. N.; Pittman, C. U. Tetrahedron 2006, 62, 4093-4102.

12 (a) Dogan, I.; Steenken, S.; Schulte-Frohlinde, D.; Icli, S. J. Phys. Chem. 1990, 94, 1887–1894. (b) Novais, H. N.; Steenken, S. J. Am. Chem. Soc. 1986, 108, 1–6. (c) Novais, H. N.; Steenken, S. J. Phys. Chem. 1987, 91, 426–433. (d) Steenken, S.; Telo, J. P.; Novais, H. M.; Candeias, L. P. J. Am. Chem. Soc. 1992, 114, 4701–4709. (e) Vieira, A. J. S. C.; Steenken, S. J. Am. Chem. Soc. 1987, 109, 7441–7448. (f) Novais, H. M.; Telo, J. P.; Steenken, S. J. Chem. Soc. Perkin Trans. 2. 2002, 1412–1417. (g) Vieira, A. J. S. C.; Steenken, S. J. Chem. Soc. Perkin Trans. 2. 2002, 1412–1417. (g) Vieira, A. J. S. C.; Steenken, S. J. Phys. Chem. 1991, 95, 9340–9346. (h) Cullis, P. M.; Malone, M. E.; Podmore, I. D.; Symons, M. C. R. J. Phys. Chem. 1995, 99, 9293–9298. (i) Vinchurkar, M. S.; Rao, B. S. M.; Mohan, H.; Mittal, J. P. J. Chem. Soc. Perkin Trans. 2. 1999, 609–617. (j) Pramod, G.; Mohan, H.; Manoj, P.; Manojkumar, T. K.; Manoj, V. M.; Mittal, J. P.; Aravindakumar, C. T. J. Phys. Org. Chem. 2006, 19, 415–424.

13 (a) Marcinek, A.; Zielonka, J.; Gebicki, J.; Gordon, C. M.; Dunkin, I. R. J. Phys. Chem. A. 2001, 105, 9305–9309. (b) Shi, Z.; Thummel, R. P. J. Org. Chem. 1995, 60, 5935–5945. (c) Sabanov, V. K.; Kibizova, A. Y.; Klimov, E. S.; Berberova, N. T.; Okhlobistin, O. Yu. J. Gen. Chem. USSR Engl. Trans. 1987, 57, 155–157. (d) Sabanov, V. K.; Klimov, E. S.; Bogdanova, I. V.; Trub, E. P.; Berberova, N. T.; Okhlobistin, O. Yu. Chem. Heterocyclic Compounds 1986, 22, 780–787.

14 Tanaseichuk, B. S.; Pryanichnikova, M. K.; Burtasov, A. A.; Dolganov, A. V.; Tsyplenkova, O. A.; Lukin A. M. *Russ. J. Org. Chem.* **2011**, *47*, 1723–1726.

15 (a) Iwahori, F.; Hatano, S.; Abe, J. J. Phys. Org. Chem. 2007, 20, 857–863. (b) Fujita, K.; Hatano, S.; Kato, D.; Abe, J. Org. Lett. 2008, 10, 3105–3108.

16 Ikeda, H.; Matsuo, K.; Matsui, Y.; Matsuoka, M.; Mizuno, K. Bull. Chem. Jpn. 2011, 84, 537–543.

17 (a) Yao, C.; Cuadrado-Peinado, M. L.; Polášek, M.; Tureček, F. *Angew. Chem. Int. Et.* **2005**, *44*, 6708–6711. (b) Cabrera-Riveria, F. A.; Ortĭz-Nava, C.; Escalante, J.; Hernández-Pérez, J. M.; Hô, M. *Synlett* **2012**, *23*, 1057–1063. (c) Qin, X.-Z.; Liu, A.; Trifunac, A. D. J. Phys. Chem. **1991**, *95*, 5822–5826.

18 Candeias, L. P.; Steenken, S. J. Phys. Chem. 1992, 96, 937-944.

19 (a) Schiedler, D. A.; Vellucci, J. K.; Beaudry, C. M. *Org. Lett.* **2012**, *14*, 6092–6095. (b) Schiedler, D. A.; Lu, Y.; Beaudry, C. M. *Org. Lett.* **2014**, *16*, 1160–1163.

20 Song, K.-S.; Liu, L.; Guo, Q.-X. Tetrahedron 2006, 60, 9909–9923.

21 Koreeda, M.; Wang, Y. M.; Zhang, L. M. Org. Lett. 2002, 4, 3329-3332.

22 Renaud, P.; Schubert, S. Angew. Chem. Int. Ed. 1990, 29, 433-434.

23 Martin, S. F.; Yang, C. P.; Laswell, W. L.; Rüger, H. *Tetrahedron Lett.* **1988**, *29*, 6685–6687.

24 (a) Curran, D. P.; Kim, D.; Liu, H. T.; Shen, W. J. Am. Chem. Soc. 1988, 110, 5900-5902. (b) Schwartz, C. E.; Curran, D. P. J. Am. Chem. Soc. 1990, 112, 9272. (c) Snieckus, V.; Cuevas, J. C.; Sloan, C. P.; Liu, H.; Curran, D. P. J. Am. Chem. Soc. 1990, 112, 896. (d) Curran, D. P.; Abraham, A. C.; Liu,H. T. J. Org. Chem. 1991, 56, 4335. (e) Curran, D. P.; Liu, H. T. J. Chem. Soc., Perkin Trans. 1 1994, 1377. (f) Curran, D. P.; Yu, H. S.; Liu, H.T. Tetrahedron 1994, 50, 7343. (g) Yamazaki, N.; Eichenberger, E.; Curran, D. P. Tetrahedron Lett. 1994, 35, 6623. (h) Denenmark, D.; Hoffmann, P.; Winkler, T.; Waldner, A.; De Mesmaeker, A. Synlett 1991, 621. (i) Denenmark, D.; Winkler, T.; Waldner, A.; De Mesmaeker, A. Tetrahedron Lett. 1992, 33, 3613. (j) Esker, J. L.; Newcomb, M. Tetrahedron Lett. 1992, 33, 5913. (k)

Esker, J. L.; Newcomb, M. J. Org. Chem. 1994, 59, 2779. (1) Murakami, M.; Hayashi, M.; Ito, Y. J. Org. Chem. 1992, 57, 793. (m) Brunckova, J.; Crich, D.; Yao, Q. W. Tetrahedron Lett. 1994, 35, 6619. (n) Curran, D. P.; Shen, W. J. Am. Chem. Soc. 1993, 115, 6051. (o) Curran, D. P.; Xu, J. J. Am. Chem. Soc. 1996, 118, 3142–3147. (p) Rancourt, J.; Gorys, V.; Jolicoeur, E. Tetrahedron Lett. 1998, 39, 5339–5342. (q) Giraud, L.; Renaud, P. J. Org. Chem. 1998, 63, 9162–9163. (r) Weinreb, S. M. J. Heterocycl. Chem. 1996, 33, 1437. (s) Ikeda, M.; Kugo, Y.; Sato, T. J. Chem. Soc., Perkin Trans. 1 1996, 1819-1824. (t) Ikeda, M.; Kugo, Y.; Kondo, Y.; Yamazaki, T.; Sato, T. J. Chem. Soc., Perkin Trans. 1 1997, 3339-3344. (u) Andreukiewicz, R.; Loska, R.; Prisyahnyuk, V.; Staliński, K. J. Org. Chem. 2003, 68, 1552–1554. (v) Sakaguchi, N.; Hirano, S.; Matsuda, A.; Shuto, S. Org. Lett. 2006, 8, 3291–3294.

25 Williams, L.; Booth, S. B.; Undheim, K. Tetrahedron 1994, 50, 13697–13708.

26 Urry, W. H.; Juveland, O. O. J. Am. Chem. Soc. 1958, 80, 3322-3328.

27 Yoshimitsu, T.; Atsumi, C.; Iimori, E.; Nagaoka, H.; Tanaka, T. *Tetrahedron Lett.* **2008**, *49*, 4473–4475.

28 (a) McNally, A.; Prier, C. K.; MacMillan, D. W. C. *Science* 2011, *334*, 1114–1117.
(b) Angioni, S.; Ravelli, D.; Emma, D.; Dondi, D.; Fagnoni, M.; Albini, A. *Adv. Synth. Catal.* 2008, *350*, 2209–2214.

29 (a) Snieckus, V.; Cuevas, J. C.; Sloan, C. P.; Liu, H.; Curran, D. P. J. Am. Chem. Soc. 1990, 112, 896–898. (b) Denenmark, D.; Hoffmann, P.; Winkler, T.; Waldner, A.; De Mesmaeker, A. Synlett 1991, 621–624. (c) Denenmark, D.; Hoffmann, P.; Winkler, T.; Waldner, A.; De Mesmaeker, A. Tetrahedron Lett. 1992, 33, 3613–3616.

30 Because the isomeric addition products **42** and **49** were inseparable by flash column chromatography, we have reported combined yields. The ratio of **42:49** was approximately 1:1 in all cases.

31 Wakchaure, P. B.; Easwar, S.; Aryade, N. P. Synthesis 2009, 1667–1672.

32 (a) Curran, D. P.; Yang, F.; Cheong, J.-h. J. Am. Chem. Soc. 2002, 124, 14993–15000. (b) Curran, D. P.; Yu, H. S. Synthesis 1992, 123–127.

33 Green, F. D.; Lowry, N. J. Org. Chem. 1967, 32, 882-885.

34 (a) Giese, B.; Kopping, B. *Tetrahedron Lett.* **1989**, *30*, 681–684. (b) Studer, A.; Armen, S. *Synthesis* **2002**, *7*, 835–849.

35 Chatgilialoglu, C. Helv. Chim. Acta 2006, 89, 2387–2398.

36 Chatgilialoglu, C.; Ballestri, M. Organometallics 1999, 12, 2395–2397.

37 Delso, I.; Merino, P.; Sadaba, D.; Tejero, T.; Delso, I. *Tetrahedron Lett.* 2011, 52, 5976–5979.

38 Duffault, J. M. Synlett 1998, 33–34.

39 Maryanoff, B. E.; McComsey, D. F.; Nortey, S. O. J. Org. Chem. 1981, 46, 355–360.

Chapter 2: Formation of Carbon–Carbon Bonds Using Aminal Radicals

David A. Schiedler, Jessica K. Vellucci, and Christopher M. Beaudry

Organic Letters

http://pubs.acs.org/doi/abs/10.1021/ol3029912

Issue 23

2.1 Introduction

Nitrogenous molecules are ubiquitous in Nature. Pharmaceuticals, molecular catalysts, and secondary metabolites often contain nitrogen. As a result, nitrogenous molecules, such as alkaloids, make compelling targets for synthesis. However, alkaloid synthesis is inherently complicated by the nitrogen atom.⁴⁰ The Lewis basic lone pair found on amines, the presence of weakly acidic N–H hydrogens, and the readiness of amines to quaternize often lead to undesired reactivity. These factors conspire against the synthetic chemist.




Figure 2.1. Selected nitrogen-rich alkaloids; aminals indicated by *


Traditional strategies used to circumvent the Lewis acid-base reactivity of nitrogen include: using protecting groups,⁴¹ installing nitrogen at the end of a synthesis,⁴² or packaging the nitrogen in a less reactive functional group (e.g. as a nitrile⁴³ or nitro⁴⁴ group). Such strategies have enjoyed widespread success in synthesis. However, a conceptually different approach to avoid the acid-base properties of nitrogen is to use single electron processes (i.e. radical reactions) to build the C–C bonds of alkaloid molecular architectures.⁴⁵

Figure 2.1 shows a selection of alkaloids that has attracted considerable interest from the synthetic community.^{46,47} Although more than half of the 55 carbons depicted in Figure 2.1 bear heteroatoms, only five are disubstituted with nitrogen (i.e. diamino- or aminal carbons). Harnessing reactivity specific to the aminal carbon in the presence of heteroatom-bearing carbons could be useful in alkaloid synthesis. Toward this end,

we envisioned creating an aminal radical intermediate that could be used in the formation of C–C bonds. We expected such a radical would be unreactive toward acidic N–H bonds and Lewis basic lone pairs,⁴⁸ and it would be well suited to forging C–C bonds in nitrogen-rich molecular architectures. Aminal radicals have been generated, and their spectral and physical properties have been studied.⁴⁹ However, to the best of our knowledge, they have not been used in synthesis.⁵⁰ Herein, we describe bond-forming reactions of aminal radicals for the first time.

2.2 a-Amino Radicals and Protective Radical Translocation

Carbon-centered radicals bearing one nitrogen (α -amino radicals) are well known.⁵¹ A convenient method for their generation is by radical translocation (Scheme 2.1). For example, homolytic cleavage of a C–I bond in **54** generates intermediate **55**, which undergoes hydrogen-atom transfer to generate stabilized α -amino radical **56**.⁵² The stability provided by the neighboring nitrogen atom is 11 kcal/mol.⁵³ Addition to a radical acceptor such as methyl acrylate leads to **57**, which receives a hydrogen atom from Bu₃SnH to form the product (**58**). Use of iodobenzyl to initiate radical translocation results in a benzyl-protected amine product.




Scheme 2.1. Radical Translocation

Computational methods estimate the stabilization of an aminal radical to be approximately 2 kcal/mol relative to the α -amino radical.⁵³ Thus, it should be possible to selectively form an aminal radical in the presence of other nitrogenbearing carbons.

2.3 Results and Discussion

The first substrate chosen to evaluate this hypothesis was aminal **47**, prepared in two steps from diamine **59** (Scheme 2.2). Reaction of aminal **47** with methyl acrylate as a radical acceptor led to the formation of the desired addition product **42**, presumably via the route shown. Unreacted starting material, isomer **49**, over-addition product **50**, and the product of deiodination (**51**) were present in the reaction mixture. Attempts to improve the yield of **42** by adjusting reagent stoichiometry, concentration, or hydrogen-atom source were unsuccessful. We suspect that competitive formation of **49** is the result of the additional stabilization at the benzylic position (*vide infra*).



Scheme 2.2. Initial Investigations of Aminal Radical Reactivity

We next prepared substrate **60** in order to block reactivity at the benzylic position and simplify the product mixture (Table 2.1, entry 1). Substrate **60** is prepared in two steps and 70% overall yield from inexpensive anthranilamide. Gratifyingly, **60** showed cleaner reactivity giving 61% yield of the desired products (49% yield of **61**, accompanied by 12% of the corresponding lactam **62**). The increased yield may be

partially attributable to the capto-dative effect: one nitrogen is relatively electron poor, and one nitrogen is relatively electron rich.⁵⁴




Table 2.1. Reactivity of aminal **60.** ^a 5 equiv of methyl acrylate used. ^b AIBN was omitted from the reaction mixture.

Thiols are used as polarity-reversal catalysts in radical reactions, and may assist in hydrogen atom transfer events,⁵⁵ and the addition of BnSH increased reaction yields (entry 2). Further increasing the stoichiometry of the thiol had little effect on the overall yield (entry 3), but **61** was formed as the sole product. No product formation occurs in the absence of stannane (entry 4), suggesting the thiol is not the terminal hydrogen atom donor. We also performed a control experiment by omitting the AIBN and observed only modest product formation (entry 5). We speculate that in hot benzene some homolytic cleavage of the C–I bond may occur. The aminal radical reaction is also successful using (TMS)₃SiH as a hydrogen atom donor (entry 6). The yield of the reaction is improved by adding BnSH (entries 7 and 8).

Based on a comparison of the data in entries 2, 3, 6, 7, and 8, it appears that BnSH may also serve to suppress the formation of the imide product **62**. As the loading of BnSH was increased, the ratio of the **61:62** also increased. This hypothesis is

bolstered by the fact that the result shown in entry 3 was obtained after heating at reflux for 15 hours while the result shown in entry 2 was obtained after just 4 hours of heating at reflux. This suggested that the increased formation of **62** observed was not simply the result of increased heating times.

The aminal radical reaction was examined with various aminals and radical acceptors. The aminals were made by condensing the corresponding amino amide with formalin (see Experimental Section). Use of acrylonitrile, *tert*-butyl acrylate, and acrolein as radical acceptors in the reaction with **60** results in good yields of the addition products **63**, **64**, and **65**, respectively (Figure 2.2). Use of Bu₃SnH as a hydrogen atom source gives superior yields compared with (TMS)₃SiH. However, use of the silane often gives synthetically useful yields without the use of heavy metals, and we report yields with both reagents. Attachment of the iodobenzyl group at the amide nitrogen also resulted in products **66**, **67**, and **68**, respectively.

Aliphatic six-membered ring aminals participated in the reaction, provided one nitrogen bears an electron-withdrawing group. The acetamide-derived aminal added to methyl acrylate to give **69** in good yield. We found that trifluoroacetamides also participate in the reaction giving **70**. Note that the aminal radical is generated in the presence of the amino-substituted carbon. In these cases, products derived from formation of the α -amino radicals are not observed. It appears that in the absence of benzylic stabilization (vis-à-vis with substrate **47**), aminal radicals selectively form in the presence of amino-substituted carbons. Substrates that lacked electron-withdrawing carbonyl groups did not participate in the reaction; they gave only complex intractable product mixtures.

Intramolecular reactions were possible, and compound **71** was produced as a single diastereomer, whereas **72** was formed as a diastereomeric mixture. Bicyclic 5-

membered aminals are competent substrates in the reaction. Pipecolic acid-derived aminals react with methyl acrylate and acrylonitrile in good yields and selectivities to form **73** and **74**, respectively. Finally, proline-derived aminals undergo diastereoselective reactions giving **75** and **76**, respectively.





Figure 2.2. Scope of the aminal radical reaction. ^a Method A: 5.0 equiv alkene, 2.0 equiv Bu₃SnH, 0.1 equiv BnSH, 0.2 equiv AIBN, 0.10 M PhH, reflux, 3 h; ^b Method B: 5.0 equiv alkene, 2.0 equiv (TMS)₃SiH, 0.1 equiv BnSH, 0.2 equiv AIBN, 0.10 M PhH, reflux, 12 h; ^c 0.9 equiv BnSH; ^d 3.0 equiv of methyl acrylate; ^e 10 equiv methyl acrylate; ^f 0.2 equiv BnSH.

The relative stereochemistry of **71** was determined by ¹H NMR methods. First, methyne hydrogen H_a is positioned axial as evidenced by NOESY crosspeaks to the indicated hydrogens (Scheme 2.3). The small (2 Hz) coupling constant between H_a and H_b suggests H_b is equatorial. The diastereoselectivity in the formation of **71** may be a result of the model shown in Scheme 2.3. The favored conformation positions the ester away from the benzyl substituent, giving rise to **71**. As the aminal-containing ring becomes more planar, the benzyl substituent should block both faces of the aminal radical equally and the selectivity should decrease. This hypothesis is consistent with the observation that the bicyclic product **72** was produced with only modest diastereoselectivity.⁴⁶ The favored diastereomer of the bicyclic aminal products **73–76** likely results from addition to the convex face of the bicycle. The relative stereochemistry was confirmed using NOESY methods.



Scheme 2.3. Plausible model for formation of 71

2.4 Conclusion

In conclusion, aminal radicals are formed via radical translocation reactions. These carbon-centered radicals react with radical acceptors in C–C bond-forming reactions in good yields with both Bu₃SnH and (TMS)₃SiH as hydrogen atom donors. Aminals can be formed from aromatic or aliphatic diamines, provided that one nitrogen bears an electron-withdrawing carbonyl group. The reactivity of the aminal radical is different than the α -amino radical; specifically it can be formed in the presence of amino-substituted carbon atoms. We believe this reactivity will be useful in the

synthesis of nitrogen-rich alkaloids, and efforts to apply this chemistry in synthesis are underway in our laboratory.

2.5 Experimental Section

General Experimental Details:

All reactions were carried out under an inert Ar atmosphere in oven-dried glassware. Flash column chromatography (FCC) was carried out with SiliaFlash P60, 60 Å silica gel. Reactions and column chromatography were monitored with EMD silica gel 60 F254 plates and visualized with potassium permanganate, ceric ammonium molybdate, molybdate, ninhydrin, or iodine stains. Tetrahydrofuran (THF), methylene chloride (CH₂Cl₂), acetonitrile (MeCN), benzene (PhH), dimethylformamide (DMF), ethanol (EtOH), and methanol (MeOH) were dried by passage through activated columns. Dimethylsulfoxide (DMSO) was stored over 3 Å molecular sieves. Acrylonitrile, acrolein, methyl acrylate, *tert*-butyl acrylate were distilled under reduced pressure to remove BHT and stored under inert atmosphere. Tributyltin hydride (Bu₃SnH) was dried over calcium hydride, distilled under reduced pressure and stored under inert atmosphere. All other reagents and solvents were used without further purification from commercial sources.

Instrumentation: FT-IR spectra were obtained on NaCl plates with a PerkinElmer Spectrum Vision spectrometer. Proton and carbon NMR spectra (¹H NMR and ¹³C NMR) were recorded in deuterated chloroform (CDCl₃) unless otherwise noted on a Bruker 700 MHz Avance III Spectrometer with carbon-optimized cryoprobe and Bruker 400 MHz DPX-400 spectrometer and calibrated to residual solvent peaks. Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet. Melting points were determined with a Cole-Parmer instrument and are uncorrected. **1-(2-iodobenzyl)-2,3-dihydroquinazolin-4(1H)-one (60)**. To a solution of known 2,3-dihydroquinazolin-4(1H)-one⁵⁷ (2.77 g, 18.7 mmol) in THF (43 mL, 0.4 M) were added K_2CO_3 (7.07 g, 51.1 mmol) and known 1-iodo-2-(iodomethyl)benzene (5.86 g, 17.0 mmol). The reaction mixture was heated to reflux for 25 hours. At this time, TLC indicated the consumption of the iodide. The reaction mixture was cooled to rt, diluted with EtOAc, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated. The resulting solids were recrystallized from EtOAc (30 mL) to give **60** (4.45 g, 12.2 mmol, 72%) as a white solid.

Data for **60**: R_f 0.31 (3:1 EtOAc:Hexanes); mp = 149.9-151.1 °C; IR (thin film) 3207, 3057, 2885, 1669, 1606, 1494, 750 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.03 (d, *J* = 7.7 Hz, 1 H), 7.92 (d, *J* = 7.7 Hz, 1 H), 7.34-7.39 (m, 3 H), 7.05 (t, *J* = 7.0 Hz, 1 H), 6.95 (t, *J* = 7.0 Hz, 1 H), 6.64 (d, *J* = 8.4 Hz, 1 H), 6.48 (br s, 1 H), 4.65 (s, 2 H), 4.44 (s, 2 H); ¹³C (176 MHz, CDCl₃) δ 165.4, 148.5, 139.8, 138.1, 134.1, 129.5, 129.1, 128.7, 128.5, 119.4, 117.5, 113.4, 98.2, 60.7, 58.5; HRMS (TOF MS ES+) calcd for C₁₅H₁₄N₂OI [M+H]: 365.0151, found 365.0138.

methyl 3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (**61**) and **4-benzyl-2,3,3a,4-tetrahydropyrrolo[2,1-b]quinazoline-1,9-dione** (**62**). To a solution of **60** (0.168 g, 0.461 mmol) in benzene (4.9 mL, 0.1 M) were added methyl acrylate (0.13 mL, 1.4 mmol), benzyl thiol (0.05 mL, 0.4 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.30 mL, 0.97 mmol), and AIBN (0.0168 g, 0.102 mmol). The reaction mixture was heated to reflux for 16 hours. At this time, TLC indicated the consumption of **60**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC to give **61** (0.108 g, 0.333 mmol, 72%) as a white foam and **62** (0.0233g, 0.0797 mmol, 17%) as a yellow solid.

Data for **61**: $R_f 0.50$ (3:1 EtOAc:Hexanes); IR (thin film) 2951, 1733, 1665, 1492, 753 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.96 (dd, J = 7.7, 1.4 Hz, 1 H), 7.36-7.38 (m, 5 H), 7.31-7.36 (m, 1 H), 6.90 (td, J = 7.7, 1.4 Hz, 1 H), 6.75 (d, J = 7.7 Hz, 1 H), 6.43 (br s, 1 H) 4.72 (dt, J = 7.7, 4.9 Hz, 1 H), 4.66 (d, J = 15.4 Hz, 1 H), 4.35 (d, J = 16.1 Hz, 1 H), 3.63 (s, 3 H), 2.36-2.43 (m, 2 H), 2.11 (sextet, J = 7.0 Hz, 1 H), 1.98-2.02 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 173.2, 164.3, 146.6, 136.9, 134.1, 128.9, 128.6, 127.7, 127.5, 119.1, 117.5, 115.0, 68.5, 53.9, 51.8, 29.0, 28.9; HRMS (TOF MS ES+) calcd for C₁₉H₂₁N₂O₃ [M+H]: 325.15523, found 325.15497.

Data for **62**: $R_f 0.21$ (2:1 EtOAc:Hexanes); mp = 146-147 °C; IR (thin film) 2926, 1768, 1385, 754 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.15 (dd, J = 7.7, 1.4 Hz, 1 H), 7.37-7.40 (m, 3 H), 7.31-7.34 (m, 3 H), 6.96 (td, J = 7.7, 0.7 Hz, 1 H), 6.71 (d, J = 8.4 Hz, 1 H), 5.40 (dd, J = 8.4, 5.6 Hz, 1 H), 4.72 (d, J = 17.5 Hz, 1 H), 4.48 (d, J = 17.5 Hz, 1 H), 2.67 (ddd, J = 17.5, 9.8, 1.4 Hz 1 H), 2.55-2.60 (m, 1 H), 2.45-2.49 (m, 1 H), 2.24-2.30 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 172.4, 160.8, 149.1, 136.6, 135.5, 130.4, 129.1, 127.7, 126.2, 119.8, 116.7, 113.7, 72.6, 49.0, 30.6, 25.3: HRMS (TOF MS ES+) calcd for C₁₈H₁₇N₂O₂ [M+H]: 293.12901, found 293.12867.

methyl 3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (**61**). To a solution of **60** (0.167 g, 0.459 mmol) in benzene (3.9 mL, 0.12 M) were added methyl acrylate (0.13 mL, 1.4 mmol), benzyl thiol (0.05 mL, 0.4 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.26 mL, 0.97 mmol), AIBN (0.0155 g, 0.0944 mmol), and benzene (0.9 mL, 1.1 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 1 hour. The mixture was heated at reflux for an additional 14 hours. At this time, TLC indicated the consumption of **60**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (2:3 hexanes:EtOAc) to give **61** (0.112 g, 0.344 mmol, 75%) as a white foam.

3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (63). To a solution of 60 (0.176 g, 0.482 mmol) in benzene (2.9 mL, 0.17 M) were added acrylonitrile (0.16 mL, 2.4 mmol), 10% benzyl thiol in benzene (0.06 mL, 0.05 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.26 mL, 0.97 mmol), AIBN (0.0177 g, 0.108 mmol), and benzene (1.9 mL, 0.51 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of 60. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (1:2 hexanes:EtOAc) to give 63 (0.110 g, 0.378 mmol, 79%) as a white foam.

Data for **63**: R_f 0.44 (3:1 EtOAc:hexanes); IR (thin film) 2928, 2250, 1666, 1606, 1492, 755 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.98 (dd, J = 7.7, 1.4 Hz, 1 H), 7.52, (s, 1 H), 7.44 (dddd, J = 9.1, 8.4, 7.7, 2.1 Hz, 1 H), 7.39-7.41 (m, 4 H), 7.34-7.36 (m, 1 H), 7.00 (td, J = 8.4, 1.4 Hz, 1 H), 6.91 (d, J = 7.7 Hz, 1 H), 4.70 (dddd, J = 10.5, 7.0, 6.3, 4.9 Hz, 1 H), 4.66 (d, J = 14.7 Hz, 1 H), 4.37 (d, J = 14.7, 1 H), 2.37 (td, J = 8.4, 1.4 Hz, 2 H), 2.08 (sextet, J = 7.0, 1 H), 2.02 (sextet, J = 7.7 Hz, 1 H); ¹³C (176 MHz, CDCl₃) δ 164.6, 146.5, 136.5, 134.4, 129.0, 128.5, 128.0, 127.7, 120.1, 118.9, 117.9, 116.3, 67.9, 55.1, 30.0, 13.0 HRMS (TOF MS ES+) calcd for C₁₈H₁₈N₃O [M+H]: 292.1450, found 292.1448.

3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (**63**). To a solution of **60** (0.162 g, 0.446 mmol) in benzene (4.5 mL, 0.1 M) were added acrylonitrile (0.15 mL, 2.3 mmol), a 10% solution of benzyl thiol in benzene (0.04 mL, 0.034 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.28 mL, 0.91 mmol), and AIBN (0.0165 g, 0.100 mmol). The reaction mixture was heated to reflux for 16 hours. At this time, TLC indicated the consumption of **60**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred.

Purification by FCC (1:2 hexanes:EtOAc) to give **63** (0.0727 g, 0.250 mmol, 56%) as a white foam.

tert-butyl 3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (64). To a solution of 60 (0.165 g, 0.453 mmol) in benzene (2.5 mL, 0.18 M) were added *tert*-butyl acrylate (0.33 mL, 2.3 mmol), 5% benzyl thiol in benzene (0.10 mL, 0.043 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.24 mL, 0.89 mmol), AIBN (0.0155 g, 0.0944 mmol), and benzene (2.0 mL, 0.45 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of 60. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (1:2 hexanes:EtOAc) to give 64 (0.108 g, 0.295 mmol, 65%) as a white foam.

Data for **64**: $R_f 0.63$ (3:1 EtOAc:hexanes); IR (thin film) 2977, 1724, 1668, 1492, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98 (dd, J = 8.0, 1.6 Hz, 1 H), 7.29-7.40 (m, 6 H), 6.89 (t, J = 7.6 Hz, 1 H), 6.74 (d, J = 8.4 Hz, 1 H), 6.49 (d, J = 4.0 Hz, 1 H), 4.66-4.72 (m, 2 H), 4.33 (d, J = 15.6 Hz, 1 H), 2.29 (t, J = 7.2 Hz, 1 H), 1.99-2.10 (m, 1 H), 1.19-1.99 (m, 1 H), 1.41 (s, 9 H); ¹³C (176 MHz, CDCl₃) δ 172.1, 164.4, 146.6, 136.9, 134.0, 128.9, 128.6, 127.7, 127.3, 118.7, 117.3, 114.5, 80.8, 68.9, 53.5, 30.3, 29.0, 28.1; HRMS (TOF MS ES+) calcd for C₂₂H₂₇N₂O₃ [M+H]: 367.2022, found 367.2012.

tert-butyl 3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (64). To a solution of 60 (0.164 g, 0.450 mmol) in benzene (4.5 mL, 0.1 M) were added *tert*-butyl acrylate (0.33 mL, 2.3 mmol), a 5% solution of benzyl thiol in benzene (0.10 mL, 0.043 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.28 mL, 0.91 mmol), and AIBN (0.0147 g, 0.0895 mmol). The reaction mixture was heated to reflux for 23 hours. At this time, TLC indicated the consumption of 60. The reaction

mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC (2:1 hexanes:EtOAc) to give **64** (0.0369 g, 0.101 mmol, 22%) as a white foam.

4-benzyl-1-hydroxy-2,3,3a,4-tetrahydropyrrolo[**2,1-***b*]**quinazolin-9**(**1***H*)-one (**65a** and **65b**). To a solution of **60** (0.160 g, 0.440 mmol) in benzene (2.4 mL, 0.18 M) were added acrolein (0.15 mL, 2.2 mmol), 5% benzyl thiol in benzene (0.10 mL, 0.043 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.24 mL, 0.89 mmol), AIBN (0.0150 g, 0.0913 mmol), and benzene (2.0 mL, 0.45 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of **60**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (2:3 hexanes:EtOAc) to give a 1:1 mixture of **65a** and **65b** (0.0735 g, 0.250 mmol, 57%) as a colorless oil.

Data for **65a** and **65b**: $R_f 0.25$ and $R_f 0.43$ (3:1 EtOAc:Hexanes); IR (thin film) as a mixture of diastereomers 2949, 1645, 1605, 1485, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (td, J = 6.4 1.2 Hz, 2 H), 7.27-7.36 (m, 12 H), 6.85-6.89 (m, 2 H), 6.66 (d, J = 8.4 Hz, 1 H), 6.61 (d, J = 8.4 Hz, 1 H), 5.98 (td, J = 6.0, 1.6 Hz, 1 H), 5.89 (dd, J = 5.6, 1.2 Hz, 1 H), 5.34 (dd, J = 9.2, 4.8 Hz, 1 H), 5.05 (dd, J = 10.0, 5.2 Hz, 1 H), 4.39-4.71 (m, 3 H), 4.09 (br s, 1 H), 2.36-2.54 (m, 3 H), 2.25 (quintet, J = 5.6 Hz, 1 H), 1.95-2.13 (m, 3 H), 1.80-1.90 (m, 1 H); ¹³C (126 MHz, CDCl₃) δ 163.4, 163.0, 149.0, 148.8, 137.0, 136.9, 134.1, 133.9, 128.9, 128.4, 127.4, 127.3, 126.6, 126.4, 118.9, 118.8, 117.9, 117.1, 113.0, 112.9, 112.8, 81.9, 80.2, 73.9, 73.8, 72.5, 72.4, 50.2, 31.3, 29.6, 29.3; HRMS (TOF MS ES+) calcd for C₁₈H₁₉N₂O₂Na [M+Na]: 317.1266, found 317.1277.

tert-butyl 3-(1-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (65a and 65b). To a solution of 60 (0.166 g, 0.456 mmol) in benzene (4.6 mL, 0.1 M) were added acrolein (0.15 mL, 2.2 mmol), a 5% solution of benzyl thiol in benzene (0.10 mL, 0.043 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.28 mL, 0.91 mmol), and AIBN (0.0151 g, 0.0920 mmol). The reaction mixture was heated to reflux for 5.5 hours. At this time, TLC indicated the consumption of 60. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC (2:3 hexanes:EtOAc) to give a mixture of 65a and 65b (0.0265 g, 0.0900 mmol, 20%) as a colorless oil.

3-(2-iodobenzyl)-2,3-dihydroquinazolin-4(1H)-one (S1). To a solution of known 2,3-dihydroquinazolin-4(1H)-one (2.84 g, 19.2 mmol) in THF (58 mL, 0.3 M) were added NaOH (0.806 g, 20.2 mmol) and known 1-iodo-2-(iodomethyl)benzene (5.97 g, 17.4 mmol). The reaction mixture was heated to reflux for 34 hours. At this time, TLC indicated the consumption of the iodide. The reaction mixture was cooled to rt, diluted with EtOAc, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated. The resulting solids were recrystallized from EtOAc (20 mL) to give **S1** (3.01 g, 8.27 mmol, 48%) as a white solid.

Data for **S1**: R_f 0.45 (1:2 EtOAc:Hexanes); mp = 134.5-135.5 °C; IR (thin film)3295, 1636, 1462, 750 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, J = 8.0, 1.6 Hz, 1 H), 7.87 (dd, J = 8.0, 1.2 Hz, 1 H), 7.45 (dd, J = 8.0, 1.6 Hz, 1 H), 7.34 (td, J = 8.8, 1.6 Hz, 2 H), 7.00 (td, J = 8.0, 1.6 Hz, 1 H), 6.94 (td, J = 8.0, 1.2 Hz, 1 H), 6.72 (dd, J = 8.0, 0.4 Hz, 1 H), 4.80 (s, 1H), 4.61 (s, 1H), 4.35 (br s, 1 H); ¹³C (100 MHz, CDCl₃) δ 163.8, 147.5, 139.6, 138.7, 133.4, 129.3, 129.2, 128.7, 128.6, 119.6, 117.4, 115.0, 98.8, 59.3, 53.1; HRMS (TOF MS ES+) calcd for C₁₅H₁₄N₂OI [M+H]: 365.0151, found 365.0139.

methyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (66). To a solution of **S1** (0.195 g, 0.534 mmol) in benzene (4.5 mL, 0.12 M) were added methyl acrylate (0.15 mL, 1.7 mmol), benzyl thiol (0.06 mL, 0.5 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.30 mL, 1.1 mmol), AIBN (0.0186 g, 0.113 mmol), and benzene (1.1 mL, 1.0 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 1 hour. The mixture was heated at reflux for an additional 13 hours. At this time, TLC indicated the consumption of **S1**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (3:1 hexanes:EtOAc) to give **66** (0.126 g, 0.387 mmol, 72%) as a colorless oil.

Data for **66**: $R_f 0.21$ (3:1 EtOAc:hexanes); IR (thin film) 2950, 1733, 1628, 1495, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, J = 7.6, 1.2 Hz, 1 H), 7.29-7.39 (m, 6 H), 6.91 (td, J = 8.0, 0.8 Hz, 1 H), 6.57 (d, J = 8.0 Hz, 1 H), 5.58 (d, J = 15.2 Hz, 1 H), 4.66 (dt, J = 9.2, 3.6 Hz, 1 H), 4.48 (d, J = 2.8 Hz, 1 H), 4.05 (d, J = 15.2 Hz, 1 H), 3.65 (s, 3 H), 2.34-2.38 (m, 2 H), 2.11-2.20 (m, 1 H), 1.96-2.04 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 173.2, 162.5, 144.5, 137.1, 133.5, 128.8, 128.7, 128.0, 127.6, 119.6, 117.0, 115.6, 67.1, 51.9, 47.4, 29.7, 27.9; HRMS (TOF MS ES+) calcd for C₁₉H₂₁N₂O₃ [M+H]: 325.1552, found 325.1554.

methyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (66). To a solution of **S1** (0.168 g, 0.461 mmol) in benzene (4.6 mL, 0.1 M) were added methyl acrylate (0.21 mL, 2.3 mmol), a 5% solution of benzyl thiol in benzene (0.10 mL, 0.043 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.28 mL, 0.91 mmol), and AIBN (0.0154 g, 0.0938 mmol). The reaction mixture was heated to reflux for 18 hours. At this time, TLC indicated the consumption of **S1**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC (3:1 hexanes:EtOAc) to give **66** (0.111 g, 0.342 mmol, 75%) as a colorless oil.

3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (67). To a solution of **S1** (0.160 g, 0.439 mmol) in benzene (2.4 mL, 0.18 M) were added acrylonitrile (0.14 mL, 2.1 mmol), 10% benzyl thiol in benzene (0.05 mL, 0.04 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.24 mL, 0.89 mmol), AIBN (0.0143 g, 0.0871 mmol), and benzene (2.0 mL, 0.45 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of **S1**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (2:1 hexanes:EtOAc) to give **67** (0.0916 g, 0.314 mmol, 72%) as a colorless oil.

Data for **67**: $R_f 0.16$ (1:2 EtOAc:hexanes); IR (thin film) 2930, 2250, 1632, 1497, 756 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.03 (dd, J = 8.4, 1.4 Hz, 1 H), 7.36-7.39 (m, 5 H), 7.31-7.34 (m, 1 H), 7.00 (td, J = 7.7, 1.4 Hz, 1 H), 6.78 (dd, J = 7.7, 0.7 Hz, 1 H), 5.42 (d, J = 14.7 Hz, 1 H), 4.72 (ddd, J = 9.8, 4.9, 3.5 Hz, 1 H), 4.50 (br s, 1 H), 4.17 (d, J = 15.4 Hz, 1 H), 2.33-2.43 (m, 2 H), 2.16-2.21 (m, 1 H), 1.86-1.90 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 162.2, 143.3, 136.8, 133.8, 129.0, 128.9, 128.1, 127.9, 120.7, 118.7, 117.9, 116.9, 66.5, 47.8, 28.2, 13.6; HRMS (TOF MS ES+) calcd for C₁₈H₁₈N₃O [M+H]: 292.1450, found 292.1436.

3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (67). To a solution of **S1** (0.169 g, 0.464 mmol) in benzene (4.6 mL, 0.1 M) were added acrylonitrile (0.15 mL, 2.3 mmol), a 5% solution of benzyl thiol in benzene (0.11 mL, 0.047 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.29 mL, 0.94 mmol), and AIBN (0.0160 g, 0.0974 mmol). The reaction mixture was heated to reflux for 23 hours. At this time, TLC indicated the consumption of **S1**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred.

Purification by FCC (2:1 hexanes:EtOAc) to give **67** (0.0342 g, 0.117 mmol, 25%) as a colorless oil.

tert-butyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (68). To a solution of S1 (0.159 g, 0.437 mmol) in benzene (2.4 mL, 0.18 M) were added *tert*-butyl acrylate (0.32 mL, 2.2 mmol), 5% benzyl thiol in benzene (0.10 mL, 0.043 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.24 mL, 0.89 mmol), AIBN (0.0147 g, 0.0895 mmol), and benzene (2.0 mL, 0.45 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of S1. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (4:1 hexanes:EtOAc) to give 68 (0.1071 g, 0.292 mmol, 67%) as a colorless oil.

Data for **68**: $R_f 0.52$ (1:1 EtOAc:hexanes); IR (thin film) 3305, 2978, 1722, 1632, 755 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.00 (dd, J = 7.7, 1.4 Hz, 1 H), 7.28-7.39 (m, 6 H), 6.91 (td, J = 7.7, 0.7 Hz, 1 H), 6.66 (dd, J = 8.4, 0.7 Hz, 1 H), 5.58 (d, J = 14.7 Hz, 1 H), 4.65 (dt, J = 9.1, 3.5 Hz, 1 H), 4.51 (br s,1 H), 4.04 (d, J = 15.4 Hz, 1 H), 2.23-2.29 (m, 2 H), 2.10-2.14 (m, 1 H), 1.96-2.01 (m, 1 H), 1.43 (s, 9 H); ¹³C (176 MHz, CDCl₃) δ 172.0, 162.6, 144.8, 137.2, 133.5, 128.8, 128.7, 127.9, 127.5, 119.3, 116.7, 115.4, 81.0, 67.3, 47.4, 31.1, 28.1, 26.0; HRMS (TOF MS ES+) calcd for C₂₂H₂₇N₂O₃ [M+H]: 367.2022, found 367.2026.

tert-butyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (68). To a solution of S1 (0.166 g, 0.457 mmol) in benzene (4.6 mL, 0.1 M) were added *tert*-butyl acrylate (0.33 mL, 2.3 mmol), a 5% solution of benzyl thiol in benzene (0.11 mL, 0.047 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.28 mL, 0.91 mmol), and AIBN (0.0155 g, 0.0944 mmol). The reaction mixture was heated to reflux for 19 hours. At this time, TLC indicated the consumption of S1. The reaction

mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC (4:1 hexanes:EtOAc) to give **68** (0.0731 g, 0.199 mmol, 44%) as a colorless oil.

 N^{1} -(2-iodobenzyl)propane-1,3-diamine (S2). To a solution of known 1,3propanediamine (10 mL, 120 mmol) in THF (20 mL, 6.0 M) were added K₂CO₃ (3.30 g, 23.9 mmol), and 1-iodo-2-(iodomethyl)benzene (4.09 g, 11.9 mmol) dropwise as a solution in THF (20 mL, 0.60 M). The reaction mixture was stirred at rt for 0.5 hours. At this time, TLC indicated the consumption of the iodide. The reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated to give S2 (3.36 g, 11.6 mmol, 97%) as a colorless oil.

Data for **S2**: $R_f 0.31$ (4:1 EtOAc:10% NH₄OH in MeOH); IR (thin film) 2933,1464, 749 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.81 (dd, J = 8.4, 1.4 Hz, 1 H), 7.37 (dd, J =7.0, 1.4 Hz, 1 H), 7.31 (dd, J = 7.7, 0.7 Hz, 1 H), 6.95 (td, J = 7.7, 1.4 Hz, 1 H), 3.79 (s, 2 H), 2.85 (t, J = 7.0 Hz, 2 H), 2.71 (t, J = 7.0 Hz, 2 H), 1.72 (quintet, J = 7.0 Hz, 2 H); ¹³C (176 MHz, CDCl₃) δ 141.9, 139.5, 129.8, 128.9, 128.4, 99.8, 58.2, 47.1, 40.3, 32.0; HRMS (TOF MS ES+) calcd for C₁₀H₁₅F₃IN₂ [M+H]: 291.03585, found 291.03462.

1-(2-iodobenzyl)hexahydropyrimidine (S3). To a solution of S2 (3.98 g, 13.7 mmol) in 95% EtOH (35 mL, 0.4 M) were added 30% aqueous NaOH (0.36 mL, 2.7 mmol), and 36% aqueous formaldehyde (1.95 g, 23.4 mmol). The reaction mixture was heated to reflux for 1 hour. At this time, TLC indicated the consumption of the diamine. After cooling to rt, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated. Purification by FCC (9:1 EtOAc:10% NH₄OH in MeOH) to give S3 (2.86 g, 9.48 mmol, 69%) as a colorless oil.

Data for **S3**: $R_f 0.48$ (4:1 EtOAc:10% NH₄OH in MeOH); IR (thin film) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (dd, J = 8.0, 0.8 Hz, 1 H), 7.42 (dd, J = 7.6, 1.2 Hz, 1 H), 7.33 (td, J = 7.6, 0.8 Hz, 1 H), 6.95 (td, J = 7.6, 1.6 Hz, 1 H), 3.50 (s, 2 H), 3.45 (s, 2 H), 2.87 (t, J = 5.2 Hz, 2 H), 2.67 (t, J = 4.6 Hz, 2 H) 1.63 (quintet, J = 5.2 Hz, 2 H); ¹³C (100 MHz, CDCl₃) δ 140.6, 139.5, 130.2, 128.7, 128.0, 100.6, 69.6, 63.6, 53.1, 45.2, 27.2; HRMS (TOF MS ES+) calcd for C₁₁H₁₆F₃IN₂ [M+H]:3030358 , found 303.0353.

1-(3-(2-iodobenzyl)tetrahydropyrimidin-1(2*H*)-yl)ethanone (S4). To a solution of S3 (0.112 g, 0.369 mmol) in CH₂Cl₂ (1.25 mL, 0.3 M) were added pyridine (0.06 mL, 0.7 mmol), and acetic anhydride (0.10 mL, 1.1 mmol). The reaction mixture was stirred at rt for 22 hours. At this time, TLC indicated the consumption of S3. The reaction mixture was concentrated. Purification by FCC (1:3 hexanes:EtOAc) to give S4 (0.119 g, 0.344 mmol, 93%) as a clear colorless oil.

Data for **S4**: R_f 0.46 (EtOAc); IR (thin film) 2945, 2812, 1646, 1433, 753 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 1.7:1 mixture of rotational isomers δ 7.85 (dd, J = 7.7, 1.4 Hz, 0.6 of 1 H), 7.81 (dd, J = 7.7, 1.4 Hz, 0.4 of 1 H), 7.47 (dd, J = 7.7, 2.1 Hz, 0.4 of 1 H), 7.41 (dd, J = 7.7, 1.4 Hz, 0.4 of 1 H), 7.33 (qd, J = 8.4, 1.4 Hz, 1 H), 6.98 (td, J = 7.7, 1.4 Hz, 0.6 of 1 H), 6.94 (td, J = 7.7, 1.4 Hz, 0.4 of 1 H), 4.33 (s, 0.7 of 2 H), 4.05 (s, 1.3 of 2 H), 3.63 (t, J = 5.6 Hz, 1.3 of 2 H), 3.59 (s, 2 H), 3.53 (t, J = 5.6 Hz, 0.7 of 2 H), 2.82 (t, J = 5.6 Hz, 0.7 of 2 H), 2.79 (t, J = 5.6 Hz, 1.3 of 2 H), 2.13 (s, 1.1 of 3 H), 1.95 (s, 1.9 of 3 H), 1.72-1.74 (m, 0.7 of 2 H), 1.68 (quintet, J = 5.6 Hz, 1.3 of 2 H), ; ¹³C (176 MHz, CDCl₃) δ 169.4 (0.6 of 1 C), 169.1 (0.4 of 1 C), 130.4 (0.4 of 1 C), 130.1 (0.6 of 1 C), 129.2 (0.6 of 1 C), 128.9 (0.4 of 1 C), 128.3 (0.4 of 1 C), 128.2 (0.4 of 1 C), 100.6 (0.4 of 1 C), 100.5 (0.6 of 1 C), 67.6 (0.6 of 1 C), 62.7 (0.4 of 1 C), 61.9 (0.6 of 1 C), 61.4 (0.4 of 1 C), 52.5 (0.6 of 1 C), 51.6 (0.4 of 1 C), 46.2 (0.4 of 1 C), 41.7 (0.4 of 1 C), 23.7 (0.4 of 1 C), 23.6 (0.6 of 1 C), 21.5 (0.4 of 1

C), 21.2 (0.6 of 1 C); HRMS (TOF MS ES+) calcd for C₁₃H₁₇IN₂O [M+]: 344.03860, found 344.03787.

methyl 3-(1-acetyl-3-benzylhexahydropyrimidin-2-yl)propanoate (**69**). To a solution of **S4** (0.172 g, 0.501 mmol) in benzene (3.0 mL, 0.17 M) were added methyl acrylate (0.22 mL, 2.4 mmol), 10% benzyl thiol in benzene (0.06 mL, 0.05 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.27 mL, 1.0 mmol), AIBN (0.0163 g, 0.0993 mmol), and benzene (2.0 mL, 0.50 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. The mixture was heated at reflux for an additional 10 hours. At this time, TLC indicated the consumption of **S4**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (1:4 hexanes:EtOAc) to give **69** (0.118 g, 0.386 mmol, 77%) as a colorless oil.

Data for **69**: $R_f 0.43$ (EtOAc); IR (thin film) 2949, 1736, 1641 cm⁻¹; ¹H NMR (700 MHz, DMSO D₆) δ 7.34-7.52 (m, 5 H), 3.91 (d, J = 4 Hz, 1 H), 3.69-3.79 (m, 4 H), 3.25-3.31 (m, 1 H), 2.90 (s, 3 H), 2.77-2.83 (m, 1 H), 2.65-2.67 (m, 2 H), 2.37-2.45 (m, 2 H), 2.03-2.12 (m, 4 H), 1.44-1.47 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 174.0 (0.5 of 1 C), 173.4 (0.5 of 1 C), 169.5, 139.1 (0.5 of 1 C), 138.7 (0.5 of 1 C), 129.0 (0.5 of 1 C), 128.7 (0.5 of 1 C), 128.5 (0.5 of 1 C), 128.3 (0.5 of 1 C), 127.5 (0.5 of 1 C), 127.1 (0.5 of 1 C), 70.4 (0.5 of 1 C), 67.3 (0.5 of 1 C), 57.2 (0.5 of 1 C), 56.8 (0.5 of 1 C), 51.6, 44.0 (0.5 of 1 C), 42.4 (0.5 of 1 C), 41.4 (0.5 of 1 C), 35.8 (0.5 of 1 C), 30.7 (0.5 of 1 C), 29.9 (0.5 of 1 C), 24.6 (0.5 of 1 C), 24.0 (0.5 of 1 C), 21.6 (0.5 of 1 C), 21.1 (0.5 of 1 C), 20.0 (0.5 of 1 C), 19.6 (0.5 of 1 C); HRMS (TOF MS ES+) calcd for C₁₇H₂₅N₂O₃ [M+H]: 305.1865, found 305.1876.

methyl 3-(1-acetyl-3-benzylhexahydropyrimidin-2-yl)propanoate (**69**)**.** To a solution of **S4** (0.188 g, 0.545 mmol) in benzene (5.4 mL, 0.1 M) were added methyl

acrylate (0.25 mL, 2.8 mmol), a 5% solution of benzyl thiol in benzene (0.13 mL, 0.055 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.34 mL, 1.1 mmol), and AIBN (0.0178 g, 0.108 mmol). The reaction mixture was heated to reflux for 18 hours. At this time, TLC indicated the consumption of **S4**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentred. Purification by FCC (1:4 hexanes:EtOAc) to give **69** (0.0471 g, 0.155 mmol, 28%) as a colorless oil.

2,2,2-trifluoro-1-(3-(2-iodobenzyl)tetrahydropyrimidin-1(2H)-yl)ethanone (S5). To a solution of S3 (0.126 g, 0.417 mmol) in dry Et_2O (1.5 mL, 0.3 M) were added triethylamine (0.07 mL, 0.5 mmol), and trifluoroacetic anhydride (0.07 mL, 0.5 mmol). The reaction mixture was stirred at rt for 10 minutes. At this time, TLC indicated the consumption of S3. The reaction mixture was concentrated. Purification by FCC (4:1 hexanes:EtOAc) to give S5 (0.126 g, 0.316 mmol, 76%) as a colorless oil.

Data for **S5**: $R_f 0.61$ (1:2 EtOAc:hexanes); IR (thin film) 2952, 1694, 752 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 1.2:1 mixture of rotational isomers δ 7.86 (ddd, J = 7.7, 3.5, 0.7 Hz, 1 H), 7.44 (dd, J = 7.7, 1.4 Hz, 0.6 of 1 H), 7.35-7.39 (m, 1.4 of 2 H), 7.00 (qd, J = 7.7, 1.4 Hz, 1 H), 4.46 (s, 1.2 of 2 H), 4.35 (s, 0.8 of 2 H), 3.76 (t, J = 5.6 Hz, 0.8 of 2 H), 3.74 (t, J = 5.6 Hz, 1.2 of 2 H), 3.72 (s, 1.2 of 2 H), 3.70 (s, 0.8 of 2 H), 2.96 (t, J = 5.6 Hz, 1.2 of 2 H), 2.85 (t, J = 5.6 Hz, 0.8 of 2 H), 1.82 (sextet, J = 5.6 Hz, 2 H); ¹³C (176 MHz, CDCl₃) δ 155.8 (q, J = 35.2 Hz, 0.6 of 1 C), 155.6 (q, J = 35.2 Hz, 0.4 of 1 C), 139.8 (0.4 of 1 C), 139.7 (0.6 of 1 C), 129.2 (0.4 of 1 C), 129.1 (0.6 of 1 C), 128.3 (0.6 of 1 C), 128.2 (0.4 of 1 C), 116.5 (q, J = 288.6 Hz, 0.6 of 1 C), 128.1 (0.6 of 1 C), 100.3 (0.4 of 1 C), 66.8 (q, J = 3.52 Hz, 0.4 of 1 C), 64.1 (0.6 of 1 C), 61.2 (0.4 of 1 C), 60.7 (0.6 of 1 C), 51.7 (0.6 of 1 C), 50.9 (0.4 of 1 C), 45.9 (0.4 of 1 C), 45.8 (0.6 of 1 C), 45.3 (1 C), 23.2

(0.6 of 1 C), 22.6 (0.4 of 1 C); HRMS (TOF MS ES+) calcd for C₁₃H₁₄F₃IN₂O [M+]: 398.01033, found 398.00872.

methyl 3-(1-benzyl-3-(2,2,2-trifluoroacetyl)hexahydropyrimidin-2-yl)propanoate (**70**). To a solution of **S5** (0.1902 g, 0.478 mmol) in benzene (2.8 mL, 0.17 M) were added methyl acrylate (0.43 mL, 4.8 mmol), 10% benzyl thiol in benzene (0.05 mL, 0.04 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.27 mL, 1.0 mmol), AIBN (0.0158 g, 0.0962 mmol), and benzene (2.0 mL, 0.50 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of **S5**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (7:1 hexanes:EtOAc) to give **70** (0.118 g, 0.329 mmol, 69%) as a colorless oil.

Data for **70**: $R_f 0.46$ (1:2 EtOAc:hexanes); IR (thin film) 2955, 1738, 1693, 1437, 756 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a mixture of rotational isomers δ 7.19-7.36 (m, 5 H), 6.22 (d, J = 2.1 Hz, 1 H), 5.62 (d, J = 2.1 Hz, 1 H), 4.27-4.64 (m, 2 H), 3.78 (s, 1.5 H), 3.70-3.68 (m, 2 H), 3.67 (m, 1.5 H) 3.02 (td, J = 13.3 4.2 Hz; 0.5 H), 2.32-2.84 (m, 3.5 H), 1.89-1.97 (m, 0.5 H), 1.28-1.78 (m, 0.5 H), 0.89-0.96 (m, 2 H); ¹³C (176 MHz, CDCl₃) δ 175.1, 173.9, 173.2, 167.0, 138.1, 137.5, 130.5, 129.5, 129.0, 128.5, 128.4, 128.4, 128.0, 127.4, 127.2, 129.3, 126.2, 64.3, 60.0, 56.2, 56.1, 55.5, 55.3, 52.0, 51.7, 51.6, 51.1, 50.9, 43.8, 43.4, 40.5, 35.5, 35.8, 34.7, 31.6, 30.6, 30.5, 29.1, 27.8, 27.6, 27.0, 26.6, 25.6, 24.7, 23.3, 23.0; HRMS (TOF MS ES+) calcd for C₁₇H₂₂F₃N₂O₃ [M+H]: 359.1583, found 359.1575.

methyl 3-(1-benzyl-3-(2,2,2-trifluoroacetyl)hexahydropyrimidin-2-yl)propanoate (**70**). To a solution of **S5** (0.2001 g, 0.504 mmol) in benzene (5.0 mL, 0.1 M) were added methyl acrylate (0.23 mL, 2.6 mmol), a 5% solution of benzyl thiol in benzene (0.12 mL, 0.051 mmol), 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (0.31 mL,

1.0 mmol), and AIBN (0.0168 g, 0.102 mmol). The reaction mixture was heated to reflux for 19 hours. At this time, TLC indicated the consumption of **S5**. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentrted. Purification by FCC (7:1 hexanes:EtOAc) to give **70** (0.0176 g, 0.0491 mmol, 10%) as a colorless oil.

tert-butyl (3-((2-iodobenzyl)amino)-3-oxopropyl)carbamate (S6). To a solution of known 3-((tert-butoxycarbonyl)amino)propanoic acid⁵⁸ (0.332 g, 1.75 mmol) in DCM (4.4 mL, 0.4 M) were added HOBt (2.66 g, 1.97 mmol), DCC (0.398 g, 1.93 mmol), and known (2-iodophenyl)methanamine (0.451 g, 1.94 mmol). The reaction mixture was stirred at rt for 7 hours. After filtration though celite to remove the solids, the reaction mixture was washed with 1 M aqueous citric acid, saturated aqueous NaHCO₃, and saturated aqueous NaCl. The organics were dried over MgSO₄ and concentrated. Purification by FCC (1:1 EtOAc:hexanes) to give **S7** (0.289 g, 0.715 mmol, 41%) as a white solid.

Data for **S6**: R_f 0.44 (2:1 EtOAc:Hexanes); mp = 147.8-149.0 °C; IR (thin film) 3308, 3062, 2975, 2930, 1693, 1651, 1525, 1169, 748 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.85 (d, *J* = 7.7 Hz, 1 H), 7.34-7.39 (m, 1 H), 7.01 (t, *J* = 7.7 Hz, 1 H), 6.13 (bs, 1 H), 5.18 (br s, 1 H), 4.49 (d, *J* = 5.6 Hz, 2 H), 3.45 (q, *J* = 6.3 Hz 2 H), 2.48 (t, *J* = 4.9 Hz 2 H), 1.44 (s, 9 H); ¹³C (176 MHz, CDCl₃) δ 171.3, 156.1, 140.2, 139.6, 129.8, 129.5, 128.7, 99.1, 79.4, 48.3, 36.7, 36.2, 28.4: HRMS (TOF MS ES+) calcd for C₁₀H₁₄IN₂O [M-Cl+H]: 305.0151, found 305.0155.

3-((2-iodobenzyl)amino)-3-oxopropan-1-aminium chloride (S7). To a solution of **S6** (0.156 g, 0.512 mmol) in MeOH (6 mL, 0.1 M) was added TMSCl (0.40 mL, 3.2 mmol). The reaction mixture was stirred at rt for 47 hours. At this time, TLC indicated the consumption of **S6**. The reaction mixture was concentrated to give **S7** (0.156 g, 0.512 mmol, 82%) as a white solid.

Data for **S7**: $R_f 0.58$ (10% NH₄OH in MeOH); mp = 161-163 °C; IR (thin film) 1627, 1108, 748 cm⁻¹; ¹H NMR (700 MHz, CD₄O) δ 7.89 (dd, J = 7.7, 0.7 Hz, 1 H), 7.36-7.41 (m, 2 H), 7.04 (td, J = 7.7, 2.1 Hz, 1 H), 4.44 (s, 2 H), 3.24 (t, J = 7.0 Hz, 2 H), 2.72 (t, J = 7.0 Hz, 2 H); ¹³C (176 MHz, CDCl₃) δ 170.7, 140.0, 139.3, 128.9, 128.5, 128.2, 97.8, 48.1, 35.7, 31.2; HRMS (TOF MS ES+) calcd for C₁₀H₁₄IN₂O [M+]: 305.0151, found 305.0155.

3-(2-iodobenzyl)tetrahydropyrimidin-4(1H)-one (**S8**). To a solution of 3-((2-iodobenzyl)amino)-3-oxopropan-1-aminium chloride (**S7**) (0.322 g, 0.946 mmol) in EtOH (3.2 mL, 0.3 M) were added 30% aqueous NaOH (0.20 mL, 1.5 mmol), and 36% aqueous formaldehyde (0.993 g, 1.19 mmol). This mixture was heated to reflux for 22 hours. After cooling to rt, the mixture was diluted with EtOAc and washed with saturated aqueous NaCl prior to drying with MgSO₄. Purification by FCC (19:1 EtOAc:10% NH₄OH in MeOH) to give **S8** (0.180g, 0.510 mmol, 54%) as a colorless oil.

Data for **S8**: $R_f 0.52$ (EtOAc:10% NH₄OH in MeOH); IR (thin film) 2924, 2855, 1634, 750 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (dd, J = 8.0, 1.2 Hz, 1 H), 7.34 (dt, J = 7.6, 1.2 Hz, 1 H), 7.24 (dd, J = 7.6, 1.2 Hz, 1 H), 6.96 (dt, J = 7.6, 1.6 Hz, 1 H), 4.66 (s, 2 H), 4.20 (s, 2 H), 3.20 (t, J = 6.4 Hz, 2 H), 2.52 (t, J = 6.4 Hz 2 H); ¹³C (176 MHz, CDCl₃) δ 168.2, 139.7, 138.7, 129.2, 128.7, 128.4, 99.0, 63.2, 52.0, 42.6, 33.4; HRMS (TOF MS ES+) calcd for C₁₁H₁₄N₂OI [M+H]: 317.0151, found 317.0138.

(*E*)-ethyl 6-(3-(2-iodobenzyl)-4-oxotetrahydropyrimidin-1(2*H*)-yl)hex-2-enoate (**S9**). To a solution of **S7** (0.426 g, 1.35 mmol) in DMF (4.0 mL, 0.3 M) were added K_2CO_3 (0.510 g, 3.69 mmol), tetrabutylammonium iodide (0.0894 g, 0.242 mmol), and known (*E*)-ethyl 6-bromohex-2-enoate⁵⁹ (0.827 g, 7.74 mmol). The reaction

mixture was heated to 80 °C 17 hours. At this time, TLC indicated the consumption of **S7**. The reaction mixture was cooled to rt, diluted with EtOAc, washed with saturated aqueous LiCl, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated. Purification by FCC (EtOAc) to give **S9** (0.3836 g, 0.0841 mmol, 62%) as a colorless oil.

Data for **S9**: $R_f 0.50$ (9:1 EtOAc:10% NH₄OH in MeOH); IR (thin film) 2951, 1733, 1666, 1492, 753 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.85 (dd, J = 7.7, 0.7 Hz, 1 H), 7.35 (td, J = 7.7, 0.7 Hz, 1 H), 7.25 (d, J = 7.0 Hz, 1 H), 7.00 (td, J = 7.7, 2.1 Hz, 1 H), 6.91 (dt, J = 15.4, 7.0 Hz, 1 H), 4.64 (s, 2 H), 4.20 (q, J = 7.0 Hz, 2 H), 3.94 (s, 2 H), 2.98 (t, J = 7.0 Hz, 2 H), 2.58 (t, J = 6.3 Hz, 2 H), 2.53 (t, J = 7.0 Hz, 2 H), 2.21 (qd, J = 8.4, 0.7 Hz, 2 H), 1.54 (quintet, J = 7.7 Hz, 2 H), 1.30 (t, J = 7.0 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 168.1, 166.5, 148.1, 139.6, 138.6, 129.2, 128.7, 128.4, 121.9, 98.9, 67.9. 60.3, 52.3, 51.7, 48.4, 29.7, 29.6, 25.8, 14.3 HRMS (TOF MS ES+) calcd for C₁₉H₂₆N₂O₃I [M+H]: 457.0988, found 457.0999.

ethyl 2-(1-benzyl-2-oxooctahydro-1*H***-pyrido[1,2-***a***]pyrimidin-9-yl)acetate** (**71).** To a solution of **S9** (0.1884 g, 0.413 mmol) in benzene (2.1 mL, 0.20 M) were added 10% benzyl thiol in benzene (0.05 mL, 0.04 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.22 mL, 0.82 mmol), AIBN (0.0133 g, 0.081 mmol), and benzene (2.0 mL, 0.41 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of **S9**. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (4:1 hexanes:EtOAc) to give **71** (0.0737 g, 0.223 mmol, 54%) as a colorless oil.

Data for **71**: $R_f 0.42$ (EtOAc); IR (thin film) 2938, 2812, 1729, 1654, 1447, 703 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.33-7.34 (m, 2 H), 7.26-7.28 (m, 3 H), 5.50 (d, J = 15.4 Hz, 1 H), 4.12 (q, J = 7.7 Hz, 2 H), 3.99 (d, J = 15.4, 1 H), 3.41 (d, J = 2.1 Hz, 1 H), 2.88 (dt, J = 11.2, 2.1 Hz, 1 H), 2.70-2.77 (m, 2 H), 2.64-2.66 (m, 1 H), 2.46-2.51 (m, 3 H), 2.33 (ddd, J = 16.8, 2.8, 1.4 Hz, 1 H), 2.19 (ddd, J = 23.8, 11.9, 2.8 Hz, 1 H), 1.72-1.79 (m, 2 H), 1.34-1.42 (m, 2 H), 1.28 (t, J = 7.7 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 173.3, 169.9, 136.8, 128.6, 128.1, 127.2, 60.4, 55.5, 49.7, 44.2, 33.2, 32.0, 30.6, 26.5, 19.8, 14.3; HRMS (TOF MS ES+) calcd for C₁₉H₂₇N₂O₃ [M+]: 331.2022, found 331.2006.

ethyl 2-(5-benzyl-11-oxo-5a,6,7,8,9,11-hexahydro-5*H*-pyrido[2,1-*b*]quinazolin-6yl)acetate (71). To a solution of S9 (0.155 g, 0.340 mmol) in benzene (3.4 mL, 0.1 M) were added 10% benzyl thiol in benzene (0.04 mL, 0.03 mmol), 1,1,1,3,3,3hexamethyl-2-(trimethylsilyl)trisilane (0.21 mL, 0.68 mmol), and AIBN (0.0120 g, 0.0730 mmol). The reaction mixture was heated to reflux for 2 hours. At this time, TLC indicated the consumption of S9. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (4:1 hexanes:EtOAc) to give **71** (0.0556 g, 0.168 mmol, 50%) as a colorless oil.

(*E*)-ethyl 6-(1-(2-iodobenzyl)-4-oxo-1,2-dihydroquinazolin-3(4*H*)-yl)hex-2-enoate (S10). To a solution of 60 (1.00 g, 2.75 mmol) in DMF (9.0 mL, 0.3 M) were added 57% NaH in mineral oil (0.234 g, 5.55 mmol) and known (*E*)-ethyl 6-bromohex-2-enoate (1.22 g, 5.50 mmol). The reaction mixture was heated to 80 °C 46 hours. The reaction mixture was cooled to rt, diluted with EtOAc, washed with saturated aqueous LiCl, washed with saturated aqueous NaCl, dried over MgSO₄, and concentrated. Purification by FCC (4:1 EtOAc:hexanes) to give S10 (0.2212 g, 0.439 mmol, 16%) as a colorless oil.

Data for **S10**: R_f 0.43 (1:1 EtOAc:Hexanes); IR (thin film) 2929, 1714, 1651, 1494, 751 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.05 (dd, J = 7.7, 1.4 Hz, 1 H), 7.93 (d, J = 8.4 Hz, 1 H), 7.34-7.37 (m, 3 H), 7.04-7.07 (m, 1 H), 6.92-6.96 (m, 2 H), 6.67 (d, J =

8.4 Hz, 1 H), 5.83 (dt, J = 15.4, 1.4 Hz, 1 H), 4.53 (s, 2 H), 4.44 (s, 2 H), 4.19 (q, J = 7.0 Hz, 2 H), 3.53 (t, J = 7.0 Hz, 2 H), 2.26 (qd, J = 8.4, 1.4 Hz, 2 H), 1.71 (quintet, J = 7.0 Hz, 2 H), 1.30 (t, J = 7.0 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 166.6, 136.7, 148.0, 147.8, 140.0, 138.1, 133.4, 129.6, 129.3, 128.7, 128.6, 121.9, 119.6, 118.3, 113.05, 98.4, 64.3, 60.3, 58.2, 44.7, 29.5, 26.2, 14.3; HRMS (TOF MS ES+) calcd for C₂₃H₂₆N₂O₃I [M+H]: 505.0988, found 505.0984.

ethyl 2-(5-benzyl-11-oxo-5a,6,7,8,9,11-hexahydro-5*H*-pyrido[2,1-*b*]quinazolin-6yl)acetate (72a and 72b). To a solution of S10 (0.0520 g, 0.103 mmol) in benzene (0.40 mL, 0.26 M) were added 5% benzyl thiol in benzene (0.03 mL, 0.01 mmol). This solution was heated to reflux. In a separate flask were combined tributyltin hydride (0.06 mL, 0.2 mmol), AIBN (0.0039 g, 0.024 mmol), and benzene (0.6 mL, 0.3 M). The tributyltin hydride solution was then added to the refluxing mixture via syringe pump over a period of 3 hours. At this time, TLC indicated the consumption of S10. After cooling to rt, the mixture was diluted with MeCN, washed with hexanes, and concentrated. Purification by FCC (3:1 hexanes:EtOAc) to give a 1:1.6 mixture of 72a (minor isomer) and 72b (major isomer) (0.0238 g, 0.0629 mmol, 61%) as a colorles oil.

Data for **72a**: $R_f 0.11$ (2:1 Hexanes:EtOAc); IR (thin film) 2935, 1728, 1647, 754 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.97 (dd, J = 8.4, 2.1 Hz, 1 H), 7.30-7.37 (m, 5 H), 7.20 (ddd, J = 8.4, 7.7, 2.1 Hz, 1 H), 6.73 (td, J = 8.4, 1.4 Hz, 1 H), 6.45 (d, J = 8.4 Hz, 1 H), 5.03 (d, J = 2.8 Hz, 1 H), 4.94-4.96 (m, 1 H), 4.68 (d, J = 17.5 Hz, 1 H), 4.40 (d, J = 16.8 Hz, 1 H), 4.00-4.04 (m, 1 H), 3.86-3.91 (m, 1 H), 2.63-2.65 (m, 1 H), 2.57-2.61 (m, 2 H), 2.33 (dd, J = 7.7 Hz, 1 H), 1.87-1.88 (m, 1 H), 1.75-1.77 (m, 1 H), 1.48-1.52 (m, 1 H), 1.11 (t, J = 7.7 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 171.7, 163.5, 145.9, 137.2, 133.5, 128.8, 128.7, 127.7, 127.6, 120.0, 118.6, 117.0, 78.9, 60.6,

57.7, 45.5, 38.7, 37.3, 31.4, 24.5, 14.1; HRMS (TOF MS ES+) calcd for C₂₃H₂₇N₂O₃ [M+H]: 379.2022, found 379.2015.

Data for **72b**: $R_f 0.11$ (2:1 Hexanes:EtOAc); IR (thin film) 2933, 1730, 1646, 750.3 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (dd, J = 7.6, 1.6 Hz, 1 H), 7.25-7.35 (m, 6 H), 6.92 (t, J = 7.2 Hz, 1 H), 6.78 (d, J = 8.4 Hz, 1 H), 4.80 (d, J = 15.6 Hz, 1 H), 4.69-4.74 (m, 1 H), 4.34-4.38 (m, 2 H), 3.97-4.15 (m, 2 H), 2.58 (td, J = 12.8, 3.2 Hz, 1 H), 2.38-2.50 (m, 2 H), 2.11 (dd, J = 6.0 Hz, 1 H), 1.95-2.01 (m, 1 H), 1.67-1.78 (m, 1 H), 1.60-1.63 (m, 1 H), 1.33-1.44 (m, 1 H), 1.15 (t, J = 7.2 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 172.5, 161.5, 145.8, 136.5, 133.8, 129.0, 128.9, 127.5, 126.6, 117.2, 113.8, 110.9, 77.3, 60.6, 50.6, 44.1, 36.2, 31.2, 31.4, 29.2, 19.9, 14.0; HRMS (TOF MS ES+) calcd for C₂₃H₂₇N₂O₃ [M+H]: 379.2022, found 379.2015.

ethyl 2-(5-benzyl-11-oxo-5a,6,7,8,9,11-hexahydro-5*H*-pyrido[2,1-*b*]quinazolin-6yl)acetate (72a and 72b). To a solution of S10 (0.0619 g, 0.123 mmol) in benzene (1.2 mL, 0.1 M) were added benzyl thiol (0.01 mL, 0.1 mmol), 1,1,1,3,3,3hexamethyl-2-(trimethylsilyl)trisilane (0.08 mL, 0.3 mmol), and AIBN (0.0059 g, 0.036 mmol). The reaction mixture was heated to reflux for 18 hours. At this time, TLC indicated the consumption of S10. The reaction mixture was cooled to rt, diluted with MeCN, washed with hexanes, and concentrted. Purification by FCC (3:2 hexanes:EtOAc) to give a 1:1.6 mixture of 72a and 72b (0.0227 g, 0.0600 mmol, 49%) as a colorless oil.

(S)-tert-butyl-2-((2-iodobenzyl)carbamoyl)piperidine-1-carboxylate (S11). To a solution of commercially available (S)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (700 mg, 3.06 mmol) in CH_2Cl_2 (6.1 mL) at 0 °C were added Et_3N (0.90 mL, 6.42 mmol) and isobutylchloroformate (0.44 mL, 3.36 mmol) dropwise. The mixture was stirred at 0 °C for one hour then 2-iodobenzylamine (783 mg, 3.36 mmol) was added. The solution was warmed to rt and stirred for 10 hours. The

mixture was washed with 1 M HCl, saturated sodium bicarbonate solution, and brine and dried over Na_2SO_4 . Purification by FCC (8:1 Hexanes:EtOAc) afforded **S11** (1.26 g, 2.83 mmol, 93%) as a white foam.

Data for **S11**: $R_f 0.24$ (6:1 Hexanes:EtOAc); IR (thin film) 3327, 2975, 2937, 1684, 1665, 1410, 1366, 1161 cm⁻¹; ¹H NMR (700 MHz, CDCl₃), δ 7.85 (d, J = 7.7 Hz, 1 H), 7.35 (m, 2 H), 7.01 (t, J = 7.35 Hz, 1 H), 6.56 (br s, 1 H), 4.80 (br s, 1 H), 4.50 (br s, 2 H), 4.08 (br s, 1 H), 2.80 (br s, 1 H), 2.36 (br s, 1 H), 1.60 (m, 5 H), 1.46 (s, 9 H); ¹³C NMR (176 MHz, CDCl₃) δ 171.1, 156.0, 140.4, 139.5, 129.6, 129.4, 128.6, 99.0, 80.7, 55.9, 54.0, 48.2, 42.6, 41.5, 28.4, 25.3, 24.9, 20.6; HRMS (TOF MS ES+) calcd for [M+Na]: C₁₈H₂₅IN₂O₃ 467.0802, found 467.0808; [α]_D²⁴ = -60.5 (*c* 1.0, CHCl₃).

(*S*)-*tert*-butyl 2-((2-iodobenzyl)carbamoyl)piperidine-1-carboxylate (S12). S11 (1.25 g, 2.82 mmol) was dissolved in 20% TFA in CH_2Cl_2 (5.9 mL, 0.48 M). The mixture was stirred at rt for 17 hours and diluted with 2 mL CH2Cl2. The mixture was made basic with 1 M NaOH until pH > 9. The aqueous layer was extracted with CH_2Cl_2 , dried over Na2SO4, and concentrated to give S12 (929 mg, 2.70 mmol, 96%) as a yellow oil.

Data for **S12**: R*f* 0.19 (EtOAc); IR (thin film) 3283 (br), 3058, 2934, 1662, 1552, 1523, 1013 cm-1; ¹H NMR (700 MHz, CDCl₃), δ 7.83 (d, *J* = 7.7 Hz, 1 H), 7.77 (s, 1 H), 7.31 (m, 2 H), 6.97 (m, 1 H), 4.48 (dd, *J* = 15.4, 6.3 Hz, 1 H), 4.37 (dd, *J* = 15.4, 5.6 Hz, 1 H), 3.62 (s, 1 H), 3.11 (d, *J* = 11.9 Hz, 1 H), 2.91 (t, *J* = 10.9 Hz, 1 H), 1.99 (d, *J* = 10.5 Hz, 1 H), 1.70 (m, 1 H), 1.62 (m, 1 H), 1.52 (m, 2 H), 1.35 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃) δ 172.4, 140.2, 139.4, 129.1, 128.8, 128.5, 98.5, 59.2, 48.0, 44.8, 29.3, 24.4, 23.0; HRMS (EI+) calcd for [M+]: C₁₃H₁₇IN₂O 344.0373, found 344.0386; [α]_D²⁴ = -27.0 (*c* 1.0, CHCl₃).

(S)-2-(2-iodobenzyl)hexahydroimidazo[1,5-*a*]pyridin-1(5*H*)-one (S13). To a solution of (S)-*N*-(2-iodobenzyl)piperidine-2-carboxamide (S12) (928 mg, 2.70 mmol) in formalin (36% in water, 11 mL, 0.668 M) was added K_2CO_3 (447 mg, 5.6 mmol) and stirred for 12 hours at rt. The mixture was diluted with EtOAc and washed with NaHSO₃ and brine and dried over sodium sulfate. Purification via FCC (10:1 EtOAc:MeOH) afforded S13 (1.39g, 4.06 mmol, 87%) as a yellow oil.

Data for **S13**: $R_f 0.58$ (10:1 EtOAc:MeOH); IR (thin film) 2936, 1707, 1438, 1012 cm⁻¹; ¹H NMR (700 MHz, CDCl₃), 7.84 (dd, J = 7.9, 1 Hz, 1 H), 7.34 (ddd, J = 8.4, 7.6, 1.1 Hz, 1 H), 7.29 (dd, J = 7.6, 1.4 Hz, 1 H), 7.00 (ddd, J = 9.1, 7.7, 1.7 Hz, 1 H), 4.59 (dd, J = 52.5, 15.4 Hz, 2 H), 4.11 (d, J = 5.4 Hz, 1 H), 3.84 (dd, J = 5.4, 2.1 Hz, 1 H), 2.85 (m, 2 H), 2.42 (m, 1 H), 2.01 (m, 1 H), 1.80 (m, 1 H), 1.70 (s, 1 H), 1.63 (m, 3 H), 1.40 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃) δ 173.0, 139.6, 138.5, 129.5, 129.3, 128.8, 98.9, 67.7, 63.2, 49.9, 49.6, 24.8, 24.3, 23.2; HRMS (TOF MS ES+) calcd for C₁₄H₁₇IN₂O [M+H]: 357.0458, found 357.0464; $[\alpha]_D^{24} = +13.9$ (*c* 1.0, CHCl₃).

Methyl-3-((8aS)-2-benzyl-1-oxooctahydroimidazo[1,5-a]pyridin-3-yl)-

propanoate (**73**). To a solution of **S13** (105 mg, 0.296 mmol) in PhH (1.5 mL, 0.2 M) were added methyl acrylate (0.13 mL, 1.478 mmol) and benzyl thiol (5% solution in PhH, 0.62 mL, 0.266 mmol) and heated to reflux. To the refluxing miture was added a solution of AIBN (9.7 mg, 0.059 mmol) and Bu₃SnH (0.16 mL, 0.591 mmol) in PhH (1.5 mL, 0.2 M) via syringe pump over 3 hours. After the addition was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC (3:2 Hex:EtOAc then EtOAc only) afforded **73** (64 mg, 0.201 mmol, 68% as a single diastereomer) as a yellow oil.

Data for **73**: $R_f 0.48$ (1:1 CH₂Cl₂:EtOAc); IR (thin film) 2924, 2849, 1735, 1553, 1440 cm⁻¹; ¹H NMR (400 MHz, CDCl₃), δ 7.36 (m, 2 H), 7.31 (m, 3 H), 5.06 (d, J =

15.4 Hz, 1 H), 4.08 (t, J = 8.4 Hz, 1 H), 3.88 (d, J = 14.7 Hz, 1 H), 3.68 (s, 3 H), 3.55 (m, 1 H), 2.68 (m, 1 H), 2.57 (m, 1 H), 2.38 (m, 1 H), 2.24 (m, 1 H), 1.93 (m, 2 H), 1.83 (m, 1 H), 1.66 (m, 2 H), 1.49 (m, 1 H), 1.39 (m, 2 H); ¹³C NMR (176 MHz, CDCl₃) δ 173.9, 173.8, 136.3, 128.8, 128.3, 127.8, 74.3, 58.5, 51.7, 46.6, 43.8, 27.9, 24.4, 24.0, 22.5, 22.2; HRMS (TOF MS ES+) calcd for C₁₈H₂₄N₂O₃ [M+H]: 317.1858, found 317.1865; [α]_D²⁴ = +13.6 (*c* 0.45, CHCl₃).

Methyl-3-((8aS)-2-benzyl-1-oxooctahydroimidazo[1,5-a]pyridin-3-yl)-

propanoate (73). To a solution of S13 (97 mg, 0.272 mmol) in PhH (2.7 mL, 0.1 M) were added AIBN (9 mg, 0.054 mmol), methyl acrylate (0.12 mL, 1.360 mmol) and benzyl thiol (5% solution in PhH, 0.57 mL, 0.245 mmol) and (TMS)₃SiH (0.17 mL, 0.544 mmol) and heated to reflux. After the reaction was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC (3:2 Hex:EtOAc then EtOAc only) afforded **73** (24 mg, 0.075 mmol, 28% as a single diastereomer) as a yellow oil.

3-((8aS)-2-benzyl-1-oxooctahydroimidazo[1,5-*a***]pyridin-3-yl)propanenitrile (74). To a solution of S13** (99 mg, 0.278 mmol) in PhH (1.3 mL, 0.21 M) were added acrylonitrile (0.09 mL, 1.391 mmol) and benzyl thiol (5% solution in PhH, 0.07 mL, 0.028 mmol) and heated to reflux. To the refluxing mixture was added a solution of AIBN (9 mg, 0.0556 mmol) and Bu₃SnH (0.15 mL, 0.556 mmol) in PhH (1.5 mL, 0.2 M) via syringe pump over 3 hours. After the addition was complete, the mixture was cooled to room temperature and the ! S23! solvent evaporated. Purification via FCC (1:1 EtOAc:CH₂Cl₂) afforded **74** (53 mg, 0.188 mmol, 68% as a single diastereomer) as a yellow oil.

Data for **74**: $R_f 0.52$ (1:1 CH₂Cl₂:EtOAc); IR (thin film) 2939, 2860, 2248, 1702, 1439 cm⁻¹; ₁H NMR (400 MHz, CDCl₃), δ 7.36 (m, 5 H), 4.94 (d, J = 15 Hz, 1 H), 4.19 (t, J = 3.4 Hz, 1 H), 4.0 (d, J = 15 Hz, 1 H), 3.59 (dd, J = 8.4, 4.9 Hz, 1 H), 2.8

(m, 1 H), 2.60 (m, 1 H), 2.41 (m, 1 H), 2.17 (m, 1 H), 1.87 (m, 2 H), 1.57 (m, 4 H), 1.40 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 174.0, 136.0, 129.0, 128.2, 128.1, 119.6, 73.3, 58.4, 46.1, 44.2, 24.9, 24.3, 22.2, 22.1, 10.8; HRMS (TOF MS ES+) calcd for C₁₇H₂₁N₃O [M+H]: 284.1763, found 284.1763; $[\alpha]_D^{24} = +5.4$ (*c* 0.5, CHCl₃).

3-((8aS)-2-benzyl-1-oxooctahydroimidazo[1,5-*a***]pyridin-3-yl)propanenitrile (74). To a solution of S13** (85 mg, 0.238 mmol) in PhH (2.4 mL, 0.1 M) were added, acrylonitrile (0.08 mL, 1.189 mmol), benzyl thiol (10% solution in PhH, 0.02 mL, 0.024 mmol), AIBN (8 mg, 0.048 mmol), and (TMS)₃SiH (0.15 mL, 0.476 mmol) and heated to reflux. After the reaction was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC (1:1 EtOAc:CH₂Cl₂) afforded **74** (11 mg, 0.039 mmol, 16%, dr not determined) as a yellow oil.

(S)-2-(2-iodobenzyl)hexahydro-1*H*-pyrrolo[1,2-*c*]imidazol-1-one (S14). To a solution of known (S)-*N*-(2-iodobenzyl)pyrrolidine-2-carboxamide (1.54 g, 4.67 mmol) in formalin (36% in water, 19 mL, 0.668 M) was added K_2CO_3 (774 mg, 5.6 mmol) and stirred for 12 hours at room temperature. The mixture was diluted with EtOAc and washed with NaHSO₃ and brine and dried over sodium sulfate. Purification via FCC (10:1 EtOAc:MeOH) afforded S14 (1.39g, 4.06 mmol, 87%) as a light yellow oil.

Data for **S14**: R_f 0.17 (10:1 EtOAc:MeOH); IR (thin film) 3464 (br), 2966, 2874, 1693, 1443, 1287 cm⁻¹; ¹H NMR (400 MHz, CDCl₃), δ 7.88 (dd, J = 7.9, 1.2 Hz, 1 H), 7.36 (ddd, J = 8.7, 7.6, 1.2 Hz, 1 H), 7.26 (dd, J = 7.7, 1.6 Hz, 1 H), 7.02 (ddd, J = 9.3, 7.7, 1.7, 1 H), 4.74 (d, J = 15.2 Hz, 1 H), 4.45 (d, J = 8.2 Hz, 1 H), 4.38 (d, J = 15.2 Hz, 1 H), 3.97 (d, J = 8.2 Hz, 1 H), 3.82 (dd, J = 8.8, 4.6 Hz, 1 H), 3.16 (m, 1 H), 2.56 (m, 1 H), 2.14 (m, 2 H), 1.82 (m, 2 H); ¹³C NMR (100 MHz, CDCl3) δ 175.0,

139.8, 138.3, 129.6, 129.2, 128.8, 98.9, 69.9, 65.2, 56.3, 50.0, 27.7, 25.3; HRMS (TOF MS ES+) calcd for $C_{13}H_{15}IN_2O$ [M+H]: 343.0315, found 343.0307; [α]_D ²⁴ = -14.3 (*c* 1.0, CHCl₃).

Methyl-3-((3R,7aS)-2-benzyl-1-oxohexahydro-1H-pyrrolo[1,2-c]imidazol-3-

yl)propanoate (75). To a solution of S14 (101 mg, 0.295 mmol) in PhH (1.5 mL, 0.2 M) were added methyl acrylate (0.13 mL, 1.48 mmol) and benzyl thiol (5% solution in PhH, 0.07 mL, 0.0295 mmol) and heated to reflux. To the refluxing mixture was added a solution of AIBN (9.7 mg, 0.059 mmol) and Bu₃SnH (0.16 mL, 0.591 mmol) in PhH (1.5 mL, 0.2 M) via syringe pump over 3 hours. After the addition was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC (10:1 EtOAc:MeOH) afforded 75 (41 mg, 0.135 mmol, 46% as a single diastereomer) as a yellow oil.

Data for **75**: $R_f 0.32$ (4:1 EtOAc:CH2Cl2); IR (thin film) 2944, 1735, 1694, 1438, 1259, 1166 cm⁻¹; ¹H NMR (700 MHz, CDCl₃), δ 7.36 (m, 2 H), 7.32 (m, 1H), 7.25 (m, 2 H), 5.04 (d, J = 14.7 Hz, 1 H), 3.90 (m, 1 H), 3.88 (d, J = 15.4 Hz, 1 H), 3.83 (dd, J = 9.1, 4.9 Hz, 1 H), 3.67 (s, 3 H), 3.03 (dd, J = 9.8, 5.6 Hz, 1 H), 2.42 (t, J = 7.4 Hz, 2 H), 2.40 (m, 1 H), 2.15 (m, 1 H), 2.02 (m, 2 H), 1.75 (m, 2 H), 1.68 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃) δ 174.6, 173.6, 136.1, 128.8, 128.1, 127.8, 78.8, 64.0, 56.2, 51.7, 44.0, 29.0, 29.0, 28.1, 25.1; HRMS (TOF MS ES+) calcd for C₁₇H₂₂N₂O₃ [M+H]: 303.1715, found 303.1709; $[\alpha]_D^{24} = +10.9$ (*c* 0.55, CHCl₃).

Methyl-3-((3R,7aS)-2-benzyl-1-oxohexahydro-1H-pyrrolo[1,2-c]imidazol-3-

yl)propanoate (75). To a solution of S14 (102 mg, 0.299 mmol) in PhH (1.5 mL, 0.1 M) were added AIBN (9 mg, 0.060 mmol), methyl acrylate (0.13 mL, 1.49 mmol) and benzyl thiol (5% solution in PhH, 0.07 mL, 0.030 mmol), and (TMS)₃SiH (0.18 mL, 0.60 mmol) and heated to reflux. After the reaction was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC

(10:1 EtOAc:MeOH) afforded **75** (13 mg, 0.041 mmol, 4%, dr not determined) as a yellow oil.

3-((7aS)-2-benzyl-1-oxohexahydro-1*H*-pyrrolo[1,2-*c*]imidazol-3-


yl)propanenitrile (76). To a solution of S14 (107 mg, 0.311 mmol) in PhH (1.5 mL, 0.2 M) were added acrylonitrile (0.10 mL, 1.56 mmol) and benzyl thiol (10% solution in PhH, 0.06 mL, 0.062 mmol) and heated to reflux. To the refluxing mixture was added a solution of AIBN (10 mg, 0.062 mmol) and Bu₃SnH (0.17 mL, 0.623 mmol) in PhH (1.6 mL, 0.2 M) via syringe pump over 3 hours. After the addition was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC (10:1 EtOAc:MeOH) afforded 76 (59 mg, 0.219 mmol, 50% as a single diastereomer) as a yellow oil.


Data for **76**: $R_f 0.29$ (1:1 CH₂Cl₂:EtOAc); IR (thin film) 2956, 2925, 2246, 1690, 1444 cm⁻¹; ¹H NMR (700 MHz, CDCl₃), δ 7.38 (m, 2 H), 7.34 (m, 1 H), 7.25 (d, J = 7.0 Hz, 2 H), 4.97 (d, J = 15.4 Hz, 1 H), 3.98 (m, 1 H), 3.97 (d, J = 15.4 Hz, 1 H), 3.83 (dd, J = 9.1, 4.9 Hz, 1 H), 3.09 (m, 1 H), 2.51 (m, 2 H), 2.43 (m, 1 H), 2.17 (m, 1 H), 2.08 (m, 1 H), 1.99 (m, 1 H), 1.78 (m, 1 H), 1.71 (m, 2 H); ¹³C NMR (176 MHz, CDCl₃) δ 174.4, 135.7, 129.0, 128.1, 128.0, 119.1, 78.3, 64.0, 56.4, 44.3, 29.9, 28.2, 25.1, 12.4; HRMS (TOF MS ES+) calcd for C₁₆H₁₉N₃O [M+H]: 270.1595, found 270.1606; $[\alpha]_D^{24} = +14.4$ (*c* 1.0, CHCl₃).


3-((7aS)-2-benzyl-1-oxohexahydro-1H-pyrrolo[1,2-c]imidazol-3-


yl)propanenitrile (76). To a solution of S14 (132 mg, 0.386 mmol) in PhH (3.9 mL, 0.1 M) were added acrylonitrile (0.13 mL, 1.93 mmol) and benzyl thiol (10% solution in PhH, 0.04 mL, 0.039 mmol), AIBN (13 mg, 0.077 mmol), and (TMS)₃SiH (0.24 mL, 0.772 mmol) and heated to reflux. After the reaction was complete, the mixture was cooled to room temperature and the solvent evaporated. Purification via FCC


(10:1 EtOAc:MeOH) afforded **76** (56 mg, 0.208 mmol, 45% as a 4:1 mixture of diastereomers) as a yellow oil.











































- - -















.


,















































- -












59 ___









MH MH


Hz Hz US K


Hz








| PPL1 SIPL1 S | NAME EXEMPT PROCEND PROCEND PROSEND FULTER SOLVENT NS SOLVENT SOLVENT NS SOLVENT |
|---|---|
| CHANNEL f1 14.00 400.1428010 MH 400.1428010 MH 400.1400000 MH 400.1400000 MH 0.00 1.00 | JKV3095 8 20120910 10.50 70binson 5 mm PABBO BB- 37768 CDC13 10 7183.908 Hz 0.219235 Hz 2.2807028 set 6.500 us 6.500 us 6.500 us 6.500 us 2.98.2 K 2.9.00000000 set 1 |

















40 Hesse, M. Alkaloid Chemistry, WILEY, New York, 1981, pp. 175–200.

41 Wuts, P. G. M.; Greene, T. W. Protective Groups in Organic Synthesis, 4th Ed. WILEY, Hoboken, NJ, **6807**, pp. 696–926.

42 For example: (a) Nicolaou, K. C.; Chakraborty, T. K.; Piscopio, A. D.; Minowa, N.; Bertinato, P. *J. Am. Chem. Soc.* **1993**, *115*, 4419–4420; (b) Ge, H. M.; Zhang, L.– D.; Tan, R. X.; Yao, Z.–J. *J. Am. Chem. Soc.* **6860**, *134*, 12323–12325.

43 Tennant, G. in *Comp. Org. Synth.*, Vol. 2 (Eds: D. Barton, W. D. Oates), Pergamon Press, Oxford, **1979**, pp. 383-590.

44 Ono, N. The Nitro Group in Organic Synthesis, WILEY-VCH, New York, 6801.

45 For selected recent examples of radical reactions as key steps in alkaloid synthesis, see: (a) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; Gallagher, J. D. J. Am. Chem. Soc. **6806**, 128, 8678–8693. (b) Movassaghi, M.; Schmidt, M. A. Angew. Chem. Int. Ed. **6807**, 46, 3725–3728. (c) Zhang, H.; Curran, D. P. J. Am. Chem. Soc. **6811**, 133, 10376–10378. (d) Palframan, M. J.; Parsons, A. F.; Johnson, P. Tetrahedron Lett. **6811**, 52, 1154–1156.

46 For review, see: (a) Köck, M.; Grube, A.; Seiple, I. B.; Baran, P. S. Angew. Chem. Int. Ed. 2007, 46, 6586 – 6594; (b) Heasley, B. Eur. J. Org. Chem. 2009, 1477–1489; (c) Zhang, D.; Song, H.; Qin, Y. Acc. Chem. Res., 2011, 44, 447-457.

47 (a) Bhonde, V. R.; Looper, R. E. J. Am. Chem. Soc. **6811**, 133, 20172–20174; (b) Iwamoto, O.; Shinohara, R.; Nagasawa, K. Chem. Asian J. **6809**, 4, 277–285; (c) Fleming, J. J.; McReynolds, M. D.; Du Bois, J. J. Am. Chem. Soc. **6807**, 129, 9964–9975; (d) Jacobi, P. A.; Martinelli, M. J.; Polanc, S. J. Am. Chem. Soc. **1984**, 106, 5594–5598; (e) Tanino, H.; Nakata, T.; Kaneko, T.; Kishi, Y. J. Am. Chem. Soc. **1977**, 99, 2818–2819; (f) Jessen, H. J.; Gademann, K. Angew. Chem. Int. Ed. **6810**, 49, 2972–2974; (g) Seiple, I. B.; Su, S.; Young, I. S.; Lewis, C. A.; Yamaguchi, J.; Baran, P. S. Angew. Chem. Int. Ed. **6810**, 49, 1095–1098; (h) Zuo, Z.; Xie, W.; Ma, D. J. Am. Chem. Soc. **6807**, 129, 13794–13795; (j) Liu, P.; Seo, J. H.; Weinreb, S. M. Angew. Chem. Int. Ed. **6810**, 49, 2000.

48 N–H bonds, O–H bonds, and lone pairs are known to be spectators in radical reactions. For example, see: (a) Urry, W. H.; Juveland, O. O.; Stacey, F. W. J. Am. Chem. Soc. **1952**, 74, 6155; (b) Bongini, A.; Cardillo, G.; Orena, M.; Sandri, S.; Tomasini, C. J. Org. Chem. **1986**, 51, 4905–4910; (c) Sibi, M. P.; Ji, J.; Wu, J. H.; Gürtler, S.; Porter, N. A. J. Am. Chem. Soc. **1996**, 118, 9200–9201.

49 (a) Yao, C.; Cuadrado–Peinado, M. L.; Polášek, M.; Tureček, F. Angew. Chem. Int. Ed. 6805, 44, 6708–6711; (b) Novais, H. M.; Steenken, S. J. Am. Chem. Soc. 1986, 108, 1–6.

50 Fragementation and protonation reactions of aminal radicals have been reported. See: (a) Cabrera–Rivera, F. A.; Ortíz–Nava, C.; Escalante, J.; Hernández–Pérez, J. M.; Hô, M. *Synlett* **6860**, *23*, 1057–1063; (b) Steenken, S.; Telo, J. P.; Novais, H. M.; Candeias, L. P. J. Am. Chem. Soc. **1992**, *114*, 4701–4709.

51 For review, see: (a) Aurrecoechea, J. M.; Suero, R. *Arkivoc* **6804**, *14*, 10–35; (b) Renaud, P.; Giraud, L. *Synthesis* **1996**, *8*, 913–926

52 Williams, L.; Booth, S. E.; Undheim, K. Tetrahedron 1994, 50, 13697–13708.

53 Song, K.-S.; Liu, L.; Guo, Q.-X. Tetrahedron 6804, 60, 9909–9923.

54 Leroy, G.; Dewispelaere, J.-P.; Benkadour, H.; Riffi Temsamani, D.; Wilante, C. Bull. Soc. Chim. Belg. **1994**, *103*, 367–378.

55 Roberts, B. P. *Chem. Soc. Rev.* **1999**, *28*, 25–35. 56 Note that Scheme 3.3 updates and corrects the stereochemical model given in the original manuscript.

57 J. M. Khurana, G. Khkreja, J. Heterocyclic Chem. 6803, 40, 677-679.

58 J.-W. Shen, D.-G. Qin, H.-W. Zhang, Z.-J. Yao, J. Org. Chem. 6803, 68, 7479-7484.

59 K. Somekawa, H. Okuhira, M. Sendayama, T. Suishu, T. Shimo, J. Org. Chem. **1992**, *57*, 5708-5712.

Chapter 3: Reductive Synthesis of Aminal Radicals for Carbon– Carbon Bond Formation

David A. Schiedler, Yi Lu, and Christopher M. Beaudry

Organic Letters

http://pubs.acs.org/doi/abs/10.1021/ol500024q

Issue 4


3.1 Introduction

Biologically active molecules commonly contain one or more nitrogen atoms. As a result, nitrogenous molecules, such as alkaloids, make compelling targets for synthesis.⁶⁰ However, synthesis of molecules containing Lewis basic nitrogen atoms or Bronsted acidic nitrogenous functional groups is not trivial. For example, the Lewis basic reactivity of amines, the weakly acidic N–H hydrogens, and the ability of amines to quaternize represent considerable challenges for the synthetic chemist.

Single electron processes (i.e. radical reactions) can be used to circumvent the acidbase reactivity of nitrogen.⁶¹ Carbon-centered radicals are generally tolerant of heteroatom lone pairs and N–H bonds. Thus, chemoselective reactions of nitrogenrich functional groups would enjoy useful application in synthesis. The aminal functional group was identified as a particularly attractive substrate for radical-based bond forming reactions.

Aminals are conveniently prepared from condensation reactions of readily available starting materials. Furthermore, calculations suggested that carbon-centered aminal radicals could be prepared in the presence of other nitrogen-containing carbon atoms.⁶²

We recently reported the first use of aminal radical intermediates in synthetic reactions (Scheme 3.1).⁶³ Iodobenzyl-substituted aminals (**60**) undergo radical translocation⁶⁴ (i.e. hydrogen atom abstraction) to give aminal radical intermediates such as **77**. The aminal radicals add to electron poor alkenes to give products of carbon-carbon bond formation (**67**). Radical translocation selectively activates the aminal position in the presence of carbons bearing only one nitrogen atom. Intermolecular and intramolecular reactions are possible, and diastereoselectivities can be quite high.



Scheme 3.1. Formation of C–C bonds with aminal radicals

Despite the potential of the aminal radical reaction in synthesis, a complementary approach for the formation of the aminal radical intermediates was desired. Such a reaction would avoid the use of toxic or foul-smelling reagents. Starting materials that are convenient to prepare and do not require an iodobenzyl group would be particularly useful. An amidine reduction reaction (Scheme 3.1; $78 \rightarrow 67$) satisfies these criteria and was selected for further study.

3.2 Results and Discussion

The success of substrate **60** in the translocation reaction indicated that if presumptive intermediate radical **77** was produced under different conditions, then the desired product **67** could be formed. Amidine **78** was prepared and subjected to reductive conditions in the presence of acrylonitrile (Table 3.1). Reductions with Zn and LiDBB⁶⁵ did not give the desired product (entries 1-4). Gratifyingly, treatment of **78** with the single-electron reducing agent SmI₂,⁶⁶ camphor sulfonic acid (CSA), and acrylonitrile as a radical acceptor gave product **67** (entry 5). The reaction is operationally easy, requires no noxious reagents, is high yielding, and occurs rapidly at rt. The reaction yield decreased if an acid was not present (entry 6). After a screen

of several acids, ammonium chloride was identified as a convenient and effective proton source that generally gives higher yields than CSA (entry 7).⁶⁷





Table 3.1. Development of the Amidine Reduction Reaction


The amidine reduction reaction was examined with various substrates and acceptors (Scheme 3.2). Quinazolinones have important medicinal properties,⁶⁸ are easy to prepare,⁶⁹ and have an acyl amidine substructure. Substrate **78** reacted with acrylates to form products **66** and **68**, respectively. In the amidine reduction reaction a benzyl group is not required. Thus, phenyl substitution is tolerated, and **79** reacts with acrylonitrile, methyl acrylate, and *tert*-butyl acrylate to give **80**, **81**, and **82**, respectively. Unsubstituted quinazolinone **83** reacted to give **84**, **85**, and **86** in good yield. The presumptive aminal radical intermediate does not add to unactivated alkenes. Thus, substrate **87** preferentially undergoes bimolecular addition to acrylonitrile and acrylates giving **88**, **89**, and **90** rather than unimolecular 5-*exo*-trig cyclizations of the pendent alkene.

Gratifyingly, substituted amidines also participate in the reaction in good yields. Substrate **91** gave products **92–94** which contain fully-substitued carbon stereocenters. Benzyl-substituted amidine **95** reacted to give fully-substituted aminals **96–98**. Even the *tert*-butyl substituted amidine **99** (Scheme 3.3) reacts to give product **100**, which contains vicinal fully-substituted carbon atoms. Cyclopropyl groups are tolerated in the substrate (101), provided they are distant from the carbon-centered radicals, to give product 102. A sterically hindered amidine appended with a cyclohexyl group (103) participated giving product 104. Electron rich arenes are tolerated in the reaction, and 105 reacts to form 106 in high yield.




Scheme 3.2. Scope of the amidine reduction reaction. ^a Reaction was preformed with CSA.

Disubstituted alkenes are reactive acceptors, and **78** added to ethyl crotonate to give **107** in good yield, but the diastereoselectivity was modest.⁷⁰ However, intramolecular reactions proceeded in good yield and high diastereocontrol. Substrate **108** reacted to form a six-membered ring product **109**. This reaction also demonstrates that the amidine can be substituted at either nitrogen atom. Compound **110** contains a trisubstituted alkene acceptor, and it reacts smoothly in high yield and high diastereoselectivity to give **111**, which contains a quaternary carbon stereocenter. The relative stereochemistry was confirmed by NOE methods.




Scheme 3.3. Scope of the amidine reduction reaction (continued).

Acyl amidines that are not quinazolinones are suprisingly rare in the literature. Nevertheless, we found that they also participate in the reaction (Scheme 4). Spiro-fused amidine **112** reacted to produce **113**. Substituted amidine substrate **114** reacted under the conditions to give **115**. Bicyclic amidine **116** gave **117**, which contains a fully-substituted stereocenter. The acyl substitutent may be present as an acetyl group on the amidine, and substrate **118** reacted with acrylonitrile to give **119**. Pyrimidinone **120** underwent dearomatizative reductive bond formation to give substituted product **121**.



Scheme 3.4. Scope of amidine substrates


The mechanism of the amidine reduction reaction may involve initial protonation of the amidine to form an amidinium ion, followed by single-electron reduction to give the aminal radical. If this is the case, then amidinium ions should participate in the reaction. Various amidinium ions were formed using standard transformations of the corresponding amidine.¹⁰ Subjection of the amidinium ions to SmI₂, acid, and a radical acceptor led to carbon-carbon bond formation in good yields (Scheme 3.5).⁷¹ Quinazolinone-derived amidinium ion **122** participated in the reaction with standard radical acceptors to give **123–125**. Substituted amidinium ion **126** also participated in the reduction, giving a product (**127**) with a fully substituted carbon stereocenter. The monocyclic amidinium substrate **128** also participated in the reaction giving good yield of the desired product (**129**). Aliphatic amidinium ions also participated in the reduction. Known amidinium **130** underwent reductive bond formation with acryonitrile to form product **131**. Phenyl-substituted amidinium **132** reacted to form **133**.



Scheme 3.5. Amidinum reduction.^a Reaction was preformed with CSA.

Mechanistically, amidine **78** may receive a proton and an electron to form neutral aminal radical **77** (Scheme 3.6, eq. 1). The aminal radical could react with the electron poor acceptor to give radical **134**. This radical would be further reduced and

protonated to give the product (67). Alternatively, the acrylate may be reduced to radical 135 (eq. 2). Addition to the amidine would give intermediate 136. This intermediate could be reduced and protonated to give the product (67). Related radical mechanisms have been proposed in the literature.⁷²




Scheme 3.6. Mechanistic investigation


To distinguish between these mechanistic possibilities, amidine substrate **137** was prepared, which contains a cyclopropyl group attached directly to the amidine. Reduction of **137** by SmI₂ in the absence of a radical acceptor leads to fragmentation of the cyclopropane and formation of **138** (Scheme 3.7, eq. 1). Reduction of **137** in the presence of an acceptor gave addition product **139** and formation of ring-fragmentation product **140** (eq. 2).⁷³ This product may arise by the mechanism given in Scheme 3.8 wherein the cyclopropane ring fragmented to give a primary radical which could then undergo tautomerization followed by radical cyclization to give an aminal radical. After addition to acrylonitrile, the product **140** was obtained.

Cyclopropyl-containing radical acceptors were also investigated. Amidine **78** reacted with cyclopropyl acrylate **141** to form addition product **142** (Scheme 3.7, eq. 3). The balance of the material was the reduction product **143** and unreacted starting material. Control experiments indicated the acrylate acceptors (acrylonitrile, methyl acyrlate, *tert*-butyl acrylate, and **141**) did not react under the reaction conditions in the absence

of the amidine. This suggests that the amidine is reduced prior to reactions with the alkene acceptor. Reduction of the aminal radical such as 77 to carbanion intermediates is unlikely in the presence of strong acids (CSA and NH₄Cl). On the basis of these experiments, we believe the first mechanism is operative (i.e. $78 \rightarrow 77 \rightarrow 134 \rightarrow 67$, Scheme 3.6, eq. 1).



Scheme 3.7. Mechanistic investigation (continued)



Scheme 3.8. A possible mechanism for the formation of the product 140

3.3 Conclusion

In conclusion, aminal radicals are formed via reduction of the corresponding amidine and amidinium ions in the presence of a proton source. The putative radical intermediates react with radical acceptors in C–C bond-forming reactions in good yields without the use of heavy metal hydrides or thiols. The reaction can be performed in inter- and intramolecular contexts in high yield. Furthermore, fully substituted aminal stereocenters are formed in good yields with this chemistry. We believe this reactivity will be useful in the synthesis of nitrogen-rich alkaloids, and efforts to apply this chemistry in synthesis are underway in our laboratory.

3.4 Experimental Section

General Experimental Details:

All reactions were carried out under an inert Ar atmosphere in oven-dried glassware. Flash column chromatography was carried out with SiliaFlash P60, 60 Å silica gel. Reactions and column chromatography were monitored with EMD silica gel 60 F254 plates and visualized with potassium permanganate, iodine, or vanillin stains. Toluene (PhMe) and methylene chloride (DCM) were dried by passage through activated alumina columns. Tetrahydrofuran (THF) was distilled from sodium and benzophenone and stored under an atmosphere of Ar. Methyl acrylate and *tert*-butyl acrylate were purified by washing with aqueous NaOH, drying over MgSO₄, and calcium hydride. These reagents were then distilled under vacuum prior to use. Acrylonitrile was distilled from sodium and benzophenone and were stored under an atmosphere of argon with vigorous stirring.⁷⁴ The concentrations of the samarium iodide solutions were determined by iodometirc titration. All other reagents and solvents were used without further purification from commercial sources.

Instrumentation: FT-IR spectra were obtained on NaCl plates with a PerkinElmer Spectrum Vision spectrometer. Proton and carbon NMR spectra (¹H NMR and ¹³C NMR) were recorded in deuterated chloroform (CDCl₃) unless otherwise noted on a Bruker 700 MHz Avance III Spectrometer with carbon-optimized cryoprobe and Bruker 400 MHz DPX-400 spectrometer and calibrated to residual solvent peaks. Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sept = septet, br = broad, m = multiplet. Melting points were determined with a Cole–Parmer instrument and are uncorrected.

3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (67) (general reductive alkylation procedure). To a solution of 3-benzylquinazolin-4(3H)-one⁷⁵ (0.0327 g, 0.1390 mmol), NH₄Cl (0.0089g, 0.166 mmol), and acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) was added a THF solution of SmI₂ (3.7 mL, 0.35 mmol) via syringe pump over a period of 1 hour. At this time, TLC indicated the consumption of 3-benzylquinazolin-4(3H)-one. The reaction mixture was diluted with half-saturated aqueous Rochelle salt. This biphasic mixture was extracted with ethyl acetate. The combined extracts were dried over MgSO₄ and concentrated to give known adduct **67** (0.0403 g, 0.1383 mmol, 99%) as a colorless oil.

methyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (66). *Following the general reductive alkylation procedure,* 3-benzylquinazolin-4(3H)-one (0.0332 g, 0.141 mmol), CSA (0.0358g, 0.154 mmol), methyl acrylate (0.065 mL, 0.70 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.45 mL, 0.35 mmol) to give known adduct **66** (0.0261 g, 0.080 mmol, 57%) as a colorless oil after purification by FCC (4:1 hexanes:EtOAc).

3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (80). *Following the general reductive alkylation procedure*, 3-phenylquinazolin-4(3H)- one⁷⁶ (0.0320 g, 0.144 mmol), NH₄Cl (0.0086g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI_2 (4.4 mL, 0.36 mmol) to give **80** (0.0375 g, 0.135 mmol, 94%) as a colorless oil.

Data for **80**: $R_f 0.40$ (1:1 hexanes:EtOAc); mp = 155–156 °C; IR (thin film) 2929, 2246, 1638, 1496, 1154, 757 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, J = 7.7, 1.2 Hz, 1 H), 7.41 (m, 5 H), 7.33 (t, J = 7.7 Hz, 1 H), 7.01 (t, J = 7.7 Hz, 1 H), 6.84 (d, J = 8.1 Hz, 1 H), 5.20 (dt, J = 9.0, 4.5 Hz, 1 H), 4.72 (d, J = 4.5 Hz, 1 H), 2.36 (m, 2 H), 2.10 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 161.8, 143.6, 140.1, 118.5, 118.2; *C*H 134.0, 128.9, 129.5, 129.2, 127.4, 127.0, 121.0, 117.0; *C*H₂ 28.5, 13.7; HRMS (EI) calcd for C₁₇H₁₅N₃O [M+]: 277.1215, found 277.1227.

methyl 3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (81). *Following the general reductive alkylation procedure*, 3-phenylquinazolin-4(3H)-one (0.0312 g, 0.140 mmol), CSA (0.0358 g, 0.154 mmol), methyl acrylate (0.07 mL, 0.70 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI_2 (4.6 mL, 0.35 mmol) to give **81** (0.0195 g, 0.0629 mmol, 45%) as a colorless oil after purification by FCC (4:1 hexanes:EtOAc).

Data for **81**: $R_f 0.44$ (1:1 hexanes:EtOAc); mp = 79–80 °C; IR (thin film) 2951, 1732, 1634, 1496, 1169, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, J = 7.8 Hz, 1 H), 7.42 (m, 4 H), 7.34 (t, J = 7.6 Hz, 1 H), 7.29 (m, 1 H), 6.91 (t, J = 7.6 Hz, 1 H), 6.72 (d, J = 8.1 Hz, 1 H), 5.19 (dd, J = 8.5, 3.8 Hz, 1 H), 3.60 (s, 3 H), 2.35 (m, 2 H), 2.22 (m, 1 H), 2.13 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.3, 162.3, 144.8, 140.4, 117.4; *C*H 133.7, 129.3, 129.1, 127.1, 127.0, 119.8, 115.7, 71.3; *C*H₂ 29.7, 28.5; *C*H₃ 51.8; HRMS (ESI) calcd for C₁₈H₁₈N₂O₃ [M+H]: 310.1318, found 310.1304.

tert-butyl 3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (82). Following the general reductive alkylation procedure, 3-phenylquinazolin-4(3H)-one (0.0313 g, 0.141 mmol), NH₄Cl (0.0083 g, 0.155 mmol), *tert*-butyl acrylate (0.11 mL, 0.71 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.3 mL, 0.35 mmol) to give **10** (0.0367 g, 0.104 mmol, 74%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **82**: $R_f 0.65$ (1:1 hexanes:EtOAc); IR (thin film) 2977, 1724, 1685, 1495, 1152, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, J = 7.7, 1.6 Hz, 1 H), 7.42 (m, 4 H), 7.34 (ddd, J = 8.1, 7.6, 1.6 Hz, 1 H), 7.29 (tt, J = 6.6, 2.1 Hz, 1 H), 6.91 (t, J = 7.8 Hz, 1 H), 6.73 (d, J = 8.1 Hz, 1 H), 5.18 (dd, J = 8.4, 4.2 Hz, 1 H), 2.28 (m, 2 H), 2.14 (m, 2 H), 1.37 (s, 3 H),; ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 172.1, 162.3, 145.0, 140.5, 117.2, 81.0; *C*H 133.7, 129.3, 129.1, 127.2, 127.0, 119.7, 115.5, 71.4; *C*H₂ 31.1, 28.5; *C*H₃ 28.0; HRMS (ESI) calcd for C₂₁H₂₄N₂O₃Na[M+Na]: 375.1685, found 375.1674.

3-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (84). Following the general reductive alkylation procedure, 3-phenylquinazolin-4(3H)-one⁷⁷ (0.0191 g, 0.131 mmol), NH₄Cl (0.0079 g, 0.144 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.0 mL, 0.33 mmol) to give known⁷⁸ adduct **84** (0.0169 g, 0.0832 mmol, 63%) as a colorless oil.

methyl 3-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (85). *Following the general reductive alkylation procedure*, quinazolin-4(3H)-one (0.0218 g, 0.149 mmol), CSA (0.0381g, 0.164 mmol), methyl acrylate (0.08 mL, 0.89 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.8 mL, 0.37 mmol) to give **85** (0.0195 g, 0.083 mmol, 56%) as a colorless oil.

Data for **85**: $R_f 0.25$ (1:4 hexanes:EtOAc); IR (thin film) 2951, 1725, 1653, 1438, 1382, 1155, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (dd, J = 7.7, 1.4 Hz, 1 H), 7.30 (ddd, J = 8.1, 7.3, 1.5 Hz, 1 H), 6.85 (td, J = 7.5 1.0 Hz, 1 H), 6.66 (d, J = 8.0 Hz, 1 H), 6.46 (s, 1 H), 5.05 (t, J = 4.6 Hz, 1 H), 3.71 (s, 3 H), 2.64 (dt, J = 17.1, 6.6 Hz, 1 H), 2.57 (dt, J = 17.1, 6.6, Hz, 1 H), 2.12 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.9, 165.3, 147.2, 115.6, 81.1; CH 133.9, 128.5, 119.4, 114.8, 64.7; CH₂ 29.9, 28.1, CH₃ 52.1; HRMS (EI) calcd for C₁₂H₁₄N₂O₃ [M+]: 234.1005, found 234.1016.

tert-butyl 3-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (86). Following the general reductive alkylation procedure, quinazolin-4(3H)-one (0.0238 g, 0.162 mmol), NH₄Cl (0.0096 g, 0.178 mmol), *tert*-butyl acrylate (0.12 mL, 0.81 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (5.0 mL, 0.41 mmol) to give **86** (0.0289 g, 0.105 mmol, 65%) as a colorless oil after purification by FCC (1:3 hexanes:EtOAc).

Data for **86**: $R_f 0.48$ (1:2 hexanes:EtOAc); mp = 114–115 °C; IR (thin film) 2978, 2830, 1728, 1677, 1469, 1367, 1154, 757 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (dd, J = 7.7, 1.4 Hz, 1 H), 7.28 (td, J = 7.6, 1.6 Hz, 1 H), 6.96 (s, 1 H), 6.82 (td, J = 7.5 1.0 Hz, 1 H), 6.64 (d, J = 8.0 Hz, 1 H), 5.01 (t, J = 4.6 Hz, 1 H), 4.56 (s, 1 H), 2.55 (dt, J = 17.0, 7.0 Hz, 1 H), 2.45 (dt, J = 17.0, 6.7, Hz, 1 H), 2.01–2.13 (m, 2 H), 1.44 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 172.8, 165.5, 147.4, 115.5, 81.1; *C*H 133.8, 128.4, 119.1, 114.7, 64.8; *C*H₂ 29.9, 29.6, *C*H₃ 28.3; HRMS (EI) calcd for C₁₅H₂₀N₂O₃Na [M+Na]: 299.1372, found 299.1379.

3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (**88**). *Following the general reductive alkylation procedure,* 3-(but-3-en-1-yl)quinazolin-4(3H)-one⁷⁹ (0.0276 g, 0.138 mmol), NH₄Cl (0.0086 g, 0.160 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) were reacted with a THF solution of

 SmI_2 (3.7 mL, 0.35 mmol) to give **88** (0.0307 g, 0.120 mmol, 87%) as a colorless oil after purification by FCC (1:1 hexanes:EtOAc).

Data for **88**: R_f 0.31 (1:1 hexanes:EtOAc); IR (thin film) 2916, 2246, 1632, 1469, 1394, 759 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (dd, J = 7.7, 1.4 Hz, 1 H), 7.32 (td, J = 7.6, 1.5 Hz, 1 H), 6.93 (t, J = 7.5, 1.0 Hz, 1 H), 6.77 (d, J = 8.1 Hz, 1 H), 5.84 (ddt, J = 17.0, 10.2, 6.8 Hz, 1 H), 5.12 (dd, J = 17.1, 1.6 Hz, 1 H), 5.07 (d, J = 10.3 Hz, 1 H), 4.75 (dd, J = 9.2, 3.6 Hz, 1 H), 4.20 (dt, J = 13.7, 6.9 Hz, 1 H), 2.92 (dt, J = 14.0, 7.1 Hz, 1 H), 2.50–2.36 (m, 1 H), 2.15 (m, 1 H), 1.94 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 162.0, 143.2, 118.5; *C*H 134.8, 133.5, 128.6, 120.9, 117.1; *C*H₂ 117.5, 44.9, 32.9, 28.5, 13.6; HRMS (ESI) calcd for C₁₅H₁₈ N₃O [M+H]: 256.1450, found 256.1446.

methyl 3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (89). *Following the general reductive alkylation procedure,* 3-(but-3-en-1-yl)quinazolin-4(3H)-one (0.0295 g, 0.147 mmol), CSA (0.0375 g, 0.162 mmol), methyl acrylate (0.07 mL, 0.78 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.6 mL, 0.37 mmol) to give **17** (0.0264 g, 0.0916 mmol, 62%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **89**: $R_f 0.42$ (2:1 hexanes:EtOAc); IR (thin film) 2976, 2926, 1733, 1632, 1468, 1370, 1168, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (dd, J = 7.8, 1.4 Hz, 1 H), 7.28 (td, J = 7.6, 1.5 Hz, 1 H), 6.87 (t, J = 7.5, 1.0 Hz, 1 H), 6.65 (d, J = 8.1 Hz, 1 H), 5.84 (ddt, J = 17.1, 10.2, 6.9 Hz, 1 H), 5.12 (dd, J = 17.2, 1.6 Hz, 1 H), 5.05 (d, J = 10.1 Hz, 1 H), 4.72 (dd, J = 8.9, 3.8 Hz, 1 H), 4.54 (brs, 1 H), 4.19 (dt, J = 13.9, 7.0 Hz, 1 H), 3.67 (s, 3 H), 2.92 (dt, J = 13.7, 7.1 Hz, 1 H), 2.40 (m, 4 H), 2.40 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.3, 162.2, 144.3, 117.5; *C*H 135.1, 133.2, 128.5, 119.6, 115.7, 68.4; *C*H₂ 117.0, 44.8, 32.7, 29.6, 28.5; *C*H₃ 51.8; HRMS (ESI) calcd for C₁₆H₂₁N₂O₃ [M+H]: 289.1541, found 289.1552.

tert-butyl 3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-

yl)propanoate (90). Following the general reductive alkylation procedure, 3-(but-3en-1-yl)quinazolin-4(3H)-one (0.0289 g, 0.144 mmol), CSA (0.0368 g, 0.158 mmol), *tert*-butyl acrylate (0.11 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.5 mL, 0.36 mmol) to give **90** (0.0364 g, 0.110 mmol, 77%) as a colorless oil after purification by FCC (3:2 hexanes:EtOAc).

Data for **90**: R_f 0.68 (1:1 hexanes:EtOAc); IR (thin film) 2977, 2930, 1726, 1631, 1470, 1367, 1152, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (dd, J = 7.8, 1.3 Hz, 1 H), 7.27 (td, J = 7.7, 1.4 Hz, 1 H), 6.85 (t, J = 7.7 Hz, 1 H), 6.65 (d, J = 7.9 Hz, 1 H), 5.84 (ddt, J = 17.1, 10.2, 6.9 Hz, 1 H), 5.11 (dd, J = 17.1, 1.5 Hz, 1 H), 5.05 (d, J = 10.7 Hz, 1 H), 4.70 (dd, J = 8.8, 3.9 Hz, 1 H), 4.59 (brs, 1 H), 4.20 (dt, J = 13.9, 7.0 Hz, 1 H), 2.90 (dt, J = 14.1, 7.2 Hz, 1 H), 2.41 (q, J = 7.4 Hz, 1 H), 2.28 (t, J = 6.9 Hz, 1 H), 2.09–1.91 (m, 2 H), 1.44 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 172.0, 162.2, 144.5, 117.3, 81.0; *C*H 135.1, 133.2, 128.4, 119.4, 115.4; *C*H₂ 117.0, 44.7, 32.7, 31.0, 28.6; *C*H₃ 28.0; HRMS (ESI) calcd for C₁₉H₂₇N₂O₃ [M+H]: 331.2022, found 331.2015.

3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (92).

Following the general reductive alkylation procedure, 2-methylquinazolin-4(3H)one⁸⁰ (0.0229 g, 0.141 mmol), NH₄Cl (0.0085 g, 0.155 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.6 mL, 0.35 mmol) to give **92** (0.0247 g, 0.115 mmol, 81%) as a white solid.

Data for **92**: $R_f 0.26$ (1:2 hexanes:EtOAc); mp = 113–114 °C; IR (thin film) 2927, 2249, 1655, 1486, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (dd, J = 7.8, 1.4 Hz, 1 H), 7.66 (s, 1 H), 7.33 (td, J = 7.6, 1.5 Hz, 1 H), 6.85 (t, J = 7.5 Hz, 1 H), 6.66 (d, J = 8.0 Hz, 1 H), 4.22 (s, 1 H), 2.67 (ddd, J = 17.4, 8.7, 6.3 Hz, 1 H), 2.55 (ddd, J = 17.3, 8.7, 6.5 Hz, 1 H), 2.20 (ddd, J = 14.5, 8.7, 6.5 Hz, 1 H), 2.09 (ddd, J = 14.5, 8.7,

6.3 Hz, 1 H), 1.60 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 164.8, 145.4, 119.6, 113.9, 69.4; *C*H 134.4, 128.2, 119.3, 114.9; *C*H₂ 37.3, 12.3; *C*H₃ 28.5; HRMS (ESI) calcd for C₁₂H₁₄N₃O [M+H]: 216.1137, found 216.1129.

methyl 3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (93). Following the general reductive alkylation procedure, 2-methylquinazolin-4(3H)-one (0.0211 g, 0.130 mmol), CSA (0.0333 g, 0.143 mmol), methyl acrylate (0.04 mL, 0.65 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI_2 (4.9 mL, 0.33 mmol) to give know adduct **93** (0.0179 g, 0.115 mmol, 55%).

tert-butyl 3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (94). *Following the general reductive alkylation procedure*, 2-methylquinazolin-4(3H)-one (0.0220 g, 0.136 mmol), CSA (0.0348 g, 0.150 mmol), *tert*-butyl acrylate (0.10 mL, 0.68 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.3 mL, 0.34 mmol) to give **94** (0.0227 g, 0.0782 mmol, 58%) as a white solid after purification by FCC (1:1 hexanes:EtOAc).

Data for **94**: $R_f 0.53$ (1:2 hexanes:EtOAc); mp = 116–117 °C; IR (thin film) 2976, 2929, 1709, 1656, 1486, 1368, 1155, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (dd, J = 7.9, 1.2 Hz, 1 H), 7.27 (td, J = 7.7, 1.4 Hz, 1 H), 6.79 (t, J = 7.6 Hz, 1 H), 6.57 (d, J = 8.0 Hz, 1 H), 6.30 (s, 1 H), 4.23 (s, 1 H), 2.55 (dt, J = 16.9, 7.1 Hz, 1 H), 2.44 (dt, , J = 16.9, 6.8 Hz, 1 H), 2.11 (dt, J = 14.7, 6.9 Hz, 1 H), 1.99 (dt, J = 14.8, 6.9 Hz, 1 H), 1.53 (s, 3 H), 1.42 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.2, 164.4, 145.9, 114.0, 80.9, 70.0; *CH* 134.0, 128.3, 118.5, 114.5; *CH*₂ 36.4, 30.0; *CH*₃ 29.1, 28.0; HRMS (ESI) calcd for C₁₆H₂₃N₂O₃ [M+H]: 291.1709, found 291.1697.

3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile

(96). Following the general reductive alkylation procedure, 3-benzyl-2methylquinazolin-4(3H)-one^{s1} (0.0356 g, 0.142 mmol), NH₄Cl (0.0093 g, 0.174 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.7 mL, 0.36 mmol) to give 96 (0.0416 g, 0.136 mmol, 96%) as a white solid.

Data for **96**: $R_f 0.45$ (1:1 hexanes:EtOAc); mp = 148–149 °C; IR (thin film) 3013, 2249, 1625, 1489, 1397, 1158, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98 (dd, J = 8.0, 1.2 Hz, 1 H), 7.36–7.25 (m, 6 H), 6.91 (dt, J = 7.6, 1.0 Hz, 1 H), 6.68 (d, J = 8.0 Hz, 1 H), 4.85 (d, J = 16.0 Hz, 1 H), 4.35 (d, J = 16.0 Hz, 1 H), 4.35 (s, 1 H), 2.36 (m, 2 H), 2.12 (m, 1 H), 1.86 (m, 1 H), 1.55 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 163.9, 143.8, 138.7, 119.2, 115.5, 73.4; CH 134.0, 128.9, 128.8, 127.4, 127.3, 119.8, 115.1; CH₂ 45.4, 34.5, 12.3; CH₃ 25.6; HRMS (ESI) calcd for C₁₉H₁₉N₃ONa [M+Na]: 328.1426, found 328.1415.

methyl 3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (97). *Following the general reductive alkylation procedure*, 3-benzyl-2-methylquinazolin-4(3H)-one (0.0321 g, 0.128 mmol), CSA (0.0328 g, 0.141 mmol), methyl acrylate (0.06 mL, 0.92 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.2 mL, 0.32 mmol) to give 97 (0.0199 g, 0.0588 mmol, 46%) as a white solid after purification by FCC (5:1 hexanes:EtOAc).

Data for **97**: $R_f 0.66$ (1:1 hexanes:EtOAc); mp = 136–137 °C; IR (thin film) 2950, 1734, 1624, 1489, 1397, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 7.7 Hz, 1 H), 7.35–7.20 (m, 6 H), 6.85 (t, J = 7.7 Hz, 1 H), 6.57 (d, J = 8.1 Hz, 1 H), 4.96 (d, J = 15.8 Hz, 1 H), 4.60 (d, J = 15.8 Hz, 1 H), 4.27 (s, 1 H), 3.59 (s, 3 H), 2.34 (m, 2 H), 2.12 (dt, J = 14.7, 5.2 Hz, 1 H), 2.02 (td, J = 10.0, 5.1 Hz, 1 H), 1.46 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.8, 164.2, 144.5, 139.1, 115.2, 74.1; *C*H

133.6, 128.9, 128.5, 127.4, 127.0, 119.0, 114.4; CH₂ 45.3, 34.0, 28.9; CH₃ 51.8, 26.4; HRMS (ESI) calcd for C₂₀H₂₃N₂O₃ [M+H]: 339.1709, found 339.1693.

tert-butyl 3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2yl)propanoate (98). Following the general reductive alkylation procedure, 3-benzyl-2-methylquinazolin-4(3H)-one (0.0331 g, 0.132 mmol), NH₄Cl (0.0080 g, 0.145 mmol), *tert*-butyl acrylate (0.10 mL, 0.66 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.4 mL, 0.33 mmol) to give **98** (0.0322 g, 0.0847 mmol, 64%) as a white solid.

Data for **98**: R_f 0.40 (3:1 hexanes:EtOAc); mp = 142–143 °C; IR (thin film) 2977, 2930, 1726, 1625, 1489, 1394, 1154, 754 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.96 (d, *J* = 7.7 Hz, 1 H), 7.33–7.20 (m, 5 H), 7.22 (t, *J* = 7.3 Hz, 1 H), 6.83 (t, *J* = 7.5 Hz, 1 H), 6.56 (d, *J* = 7.7 Hz, 1 H), 5.00 (d, *J* = 15.8 Hz, 1 H), 4.54 (d, *J* = 15.9 Hz, 1 H), 4.40 (s, 1 H), 2.27 (m, 2 H), 2.10–1.99 (m, 1 H), 1.42 (s, 3 H), 1.38 (s, 9 H); ¹³C NMR (175 MHz, CDCl₃, DEPT) δ *C* 172.7, 164.2, 144.6, 139.0, 115.0, 80.8, 74.1; *C*H 133.6, 128.8, 128.5, 127.3, 126.9, 118.7, 114.2; *C*H₂ 45.2, 33.8, 30.2; *C*H₃ 27.9, 26.4; HRMS (ESI) calcd for C₂₀H₂₃N₂O₃ [M+H]: 339.1709, found 339.1693.

3-(2-(*tert***-butyl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile** (100). Following the general reductive alkylation procedure, 2-(*tert*-butyl)quinazolin-4(3H)one^{s2} (0.0280 g, 0.138 mmol), CSA (0.0366 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.7 mL, 0.35 mmol) to give **100** (0.0124 g, 0.0482 mmol, 35%) as a white solid along with 0.0099g of 2-(*tert*-butyl)quinazolin-4(3H)-one after purification by FCC (1:1 hexanes:EtOAc). Data for **100**: R_f 0.65 (1:2 EtOAc: Hexanes); IR (thin film) 3356, 2921, 2246, 1655 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.79 (dd, J = 8.4, 1.4 Hz, 1 H), 6.73 (t, J = 7.7 Hz, 1 H), 6.55 (d, J = 8.4 Hz, 1 H), 6.10 (s, 1 H), 4.09 (s, 1 H), 2.61-2.66 (m, 1 H), 2.53-2.58 (m, 1 H), 2.03-2.11 (m, 2 H), 1.03 (s, 9 H); ¹³C (176 MHz, CDCl₃) δ 164.1, 146.5, 134.9, 128.3, 120.0, 118.2, 12.8, 111.6, 43.2, 33.5, 29.9, 24.6, 12.8; HRMS (TOF MS ES+) calcd for C₁₅H₂₀N₃O [M+H]: 258.1606, found 258.1599.

3-(3-cyclopropyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (102). Following the general reductive alkylation procedure, 3-cyclopropylquinazolin-4(3H)-one⁸³ (0.0261 g, 0.140 mmol), NH₄Cl (0.0086 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.7 mL, 0.35 mmol) to give **102** (0.0340 g, 0.140 mmol, 99%) as a colorless oil.

Data for **102**: R_f 0.24 (1:1 EtOAc: Hexanes); IR (thin film) 3294, 2929, 2246, 1636 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (dd, J = 8.0, 1.6 Hz, 1 H), 7.32 (td, J = 8.0, 1.6 Hz, 1 H), 6.90 (ddd, J = 8.0, 8.0, 0.8 Hz, 1 H), 6.73 (d, J = 8.0 Hz, 1 H), 4.81 (dd, J = 9.6, 4.0 Hz, 1 H), 2.69 (ddd, J = 9.6, 6.8, 4.0 Hz, 1 H), 2.46 (ddd, J = 8.0, 6.4, 4.4 Hz, 2 H), 2.15-2.24 (m, 1 H) 2.01-2.10 (m, 1 H), 1.09-1.17 (m, 1 H), 0.79-0.89 (m, 2 H), 0.61-0.68 (m, 2 H); ¹³C (100 MHz, CDCl₃) δ 164.4, 143.4, 134.0, 128.6, 120.3, 118.9, 117.4, 116.4, 68.9, 28.5, 27.9, 13.8, 10.2, 6.0; HRMS (EI+) calcd for C₁₄H₁₅N₃O [M+]: 241.12152, found 241.12128.

3-(3-cyclohexyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (104). Following the general reductive alkylation procedure, 3-cyclohexylquinazolin-4(3H)one⁸⁴ (0.0338 g, 0.148 mmol), NH₄Cl (0.0089 g, 0.166 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.49 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.9 mL, 0.37 mmol) to give **104** (0.0409 g, 0.144 mmol, 97%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc). Data for **104**: R_f 0.38 (1:1 EtOAc: Hexanes); IR (thin film) 3284, 2932, 2856, 2245, 1622 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.94 (dd, J = 7.7, 1.4 Hz, 1 H), 7.32 (td, J = 8.4, 1.4 Hz, 1 H), 6.95 (ddd, J = 8.4, 8.4, 1.4 Hz, 1 H), 6.77 (d, J = 7.7 Hz, 1 H), 4.82 (dd, J = 10.5, 2.8 Hz,1 H), 4.46 (tt, J = 11.9, 3.5 Hz, 1 H), 2.34-2.44 (m, 2 H), 2.23-2.29 (m, 1 H) 1.78-1.92 (m, 6 H), 1.69 (d, J = 13.3 Hz, 1 H), 1.54 (qd, J = 11.9, 3.5 Hz, 1 H), 1.37-1.45 (m, 3 H), 1.14 (qt, J = 9.1, 4.2 Hz, 1 H); ¹³C (176 MHz, CDCl₃) δ 161.8, 142.9, 133.4, 128.9, 120.8, 119.6, 118.9, 117.1, 63.2, 53.4, 31.8, 31.6, 30.2, 26.1, 25.9, 25.5, 14.0; HRMS (EI+) calcd for C₁₇H₂₁N₃O [M+]: 283.16847, found 283.16723.

3-(3-benzyl-6,7-dimethoxy-4-oxo-1,2,3,4-tetrahydroquinazolin-2-

yl)propanenitrile (106). Following the general reductive alkylation procedure, 3benzyl-6,7-dimethoxyquinazolin-4(3H)-one⁸⁵ (0.0425 g, 0.143 mmol), NH₄Cl (0.0092 g, 0.172 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.48 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.7 mL, 0.36 mmol) to give **106** (0.0481 g, 0.137 mmol, 95%) as a white foam after purification by FCC (1:2 hexanes:EtOAc).

Data for **106**: R_f 0.36 (4:1 EtOAc: Hexanes); IR (thin film) 3326, 2930, 2247, 1674, 1613, 1502 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 1 H), 7.28-7.34 (m, 5 H), 6.30 (s, 1 H), 5.32 (d, 14.8 Hz, 1 H), 4.62 (dd, *J* = 17.5, 5.6 Hz, 1 H), 4.13 (d, *J* = 14.8 Hz, 1 H), 3.88 (s, 3 H), 3.85 (s, 3 H), 2.28-2.43 (m, 2 H), 2.09-2.18 (m, 1 H), 1.74-1.82 (m, 1 H); ¹³C (100 MHz, CDCl₃) δ 162.1, 154.2, 144.7, 138.1, 137.2, 129.0, 128.2, 128.0, 119.0, 111.3, 110.1, 101.5, 67.0, 56.4, 56.2, 47.9, 27.7, 13.8; HRMS (TOF MS ES+) calcd for C₂₀H₂₁N₃O₃ [M+H]: 352.1661, found 352.1660.

(±)-ethyl 3-((**R**)-3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)butanoate (107) Following the general reductive alkylation procedure, 3-benzylquinazolin-4(3H)-one (0.0327 g, 0.139 mmol), NH₄Cl (0.0085g, 0.159 mmol), ethyl crotylate (0.86 mL, 6.9 mmol) in THF (0.46 mL, 0.3 M) were reacted with a THF solution of SmI_2 (4.8 mL, 0.35 mmol) to give adduct **107** (0.0369 g, 0.105 mmol, 76%) as a light yellow oil.

Data for **107**: $R_f 0.51$ (1:1 hexanes:EtOAc); IR (thin film) 2919, 1730, 1630 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.93 (dd, J = 7.7, 0.7 Hz, 1 H), 7.27-7.33 (m, 6 H), 6.84 (td, J = 7.7, 0.7 Hz, 1 H), 6.59 (dd, J = 0.7, 8.4 Hz, 1 H), 5.74 (d, J = 15.4 Hz, 1 H), 4.55 (d, J = 6.3 Hz, 1 H), 4.05-4.10 (m, 2 H), 3.96 (d, J = 15.4 Hz, 1 H), 2.58-2.63 (m, 1 H), 2.38 (dd, J = 15.4, 4.9 Hz, 1 H), 2.15 (dd, J = 15.4, 8.4 Hz, 1 H), 1.19 (t, J = 7.0 Hz, 3 H), 1.05 (d, J = 7.0 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 172.4, 162.8, 145.3, 137.1, 133.7, 129.0, 128.9, 127.9, 127.7, 119.2, 116.6, 114.5, 71.6, 60.8, 49.0, 37.1, 35.5, 16.5, 14.3; HRMS (ES+) calcd for C₂₁H₂₅N₂O₃ [M+H]: 353.1865, found 353.1870.

ethyl (E)-6-((2-carbamoylphenyl)amino)hex-2-enoate (S15). To a DMF (5.4 mL, 0.3 M) solution of 2-aminobenzamide (0.6663 g, 4.89 mmol) was added K_2CO_3 (0.4556 g, 3.30 mmol), tetrabutylammonium iodide (0.1808g, 0.490mmol), and the known^{s6} bromo ester (0.3608 g, 1.63 mmol). This mixture was heated to 50 °C with stirring for a period of 16 hours. After cooling, the reaction mixture was diluted with ethyl acetate and washed with half-saturated aqueous LiCl. The organics were dried over MgSO₄, concentrated, and purified by FCC (2:1 hexanes:EtOAc) to give S15 (0.2425 g, 0.878 mmol, 54%) as a colorless oil.

Data for **S15**: R_f 0.57 (2:1 EtOAc: Hexanes); IR (thin film) 3345, 2936, 1711, 1648 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.38 (dd, J = 7.6, 1.2 Hz, 1 H), 7.30 (ddd, J = 8.4, 8.4, 1.2 Hz, 1 H), 6.96 (dt, J = 15.6, 6.8 Hz, 1 H), 6.66 (d, J = 8.4 Hz, 1 H), 6.56 (t, J = 7.6 Hz, 1 H), 5.92 (bs, 2 H), 5.85 (d, J = 15.6 Hz, 1 H), 4.17 (q, J = 7.2 Hz, 2 H), 3.19 (t, J = 6.8 Hz, 2 H), 2.32 (q, J = 6.8 Hz, 2 H), 1.82 (quin. J = 7.2 Hz, 2 H), 1.27 (t, J = 7.2 Hz, 3 H); ¹³C (100 MHz, CDCl₃) δ 172.4, 166.7, 150.3, 148.2, 133.6,

128.5, 122.1, 114.6, 113.0, 111.8, 60.3, 42.2, 29.8, 27.6, 14.4; HRMS (EI+) calcd for C₁₅H₂₀N₂O₃ [M+]: 276.14740, found 276.14666.

ethyl (E)-6-(4-oxoquinazolin-1(4H)-yl)hex-2-enoate (108). To a THF (0.75 mL, 0.3 M) solution of S15 (0.0621 g, 0.255 mmol) were added trimethyl orthoformate (0.12 mL, 1.097 mmol), and one drop of trifluoroacetic acid. The mixture was heated to reflux for 65 minutes. At this time, TLC indicated the consumption of S15. After cooling, the reaction mixture was concentrated and purified by FCC (19:1 hexanes:EtOAc) to give 108 (0.0559g, 0.195 mmol, 86%) as a colorless oil.

Data for **108**: R_f 0.75 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 2981, 1713, 1648, 1606, 1546 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (dd, J = 8.0, 0.8 Hz, 1 H), 8.32 (bs, 1 H), 7.77 (td, J = 7.2, 1.6 Hz, 1 H), 7.52 (td, J = 7.6, 0.4 Hz, 1 H), 7.33 (d, J = 8.4 Hz, 1 H), 7.92 (dt, J = 15.6, 6.8 Hz, 1 H), 5.90 (dt, J = 15.6, 1.6 Hz, 1 H), 4.18 (quin, J = 7.2 Hz, 2 H), 2.35 (q, J = 6.8 Hz, 2 H), 2.07 (quin, J = 7.2 Hz, 2 H), 1.28 (t, J = 6.8 Hz, 3 H); ¹³C (100 MHz, CDCl₃) δ 169.0, 166.0, 153.0, 145.5, 138.8, 134.0, 129.5, 126.7, 123.4, 12.09, 114.4, 60.5, 49.6, 28.8, 27.0, 14.2; HRMS (TOF MS ES+) calcd for C₁₆H₁₉N₂O₃ [M+H]: 287.1396, found 287.1392.

ethyl 2-((4R,4aR)-6-oxo-2,3,4,4a,5,6-hexahydro-1H-pyrido[1,2-a]quinazolin-4yl)acetate (109). To a solution of 108 (0.0458 g, 0.1594 mmol) and CSA (0.0412g, 0.177 mmol) in THF (0.53 mL, 0.3 M) was added a THF solution of SmI_2 (4.3 mL, 0.40 mmol) via syringe pump over a period of 1 hour. At this time, TLC indicated the consumption of 108. The reaction mixture was diluted with half-saturated aqueous Rochelle salt. This biphasic mixture was extracted with ethyl acetate. The combined extracts were dried over MgSO₄ and concentrated. Purification by FCC (1:1 hexanes:EtOAc) gave 109 (0.0343 g, 0.119 mmol, 75%) as a white solid. Data for **109**: R_f 0.71 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 3201, 2939, 1730, 1675 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.96 (dd, J = 7.7 1.4 Hz, 1 H), 7.39 (ddd, J = 8.4, 7.0, 1.4 Hz, 1 H), 6.91 (t, J = 7.0 Hz, 1 H), 6.85 (d, J = 8.4 Hz, 1 H), 4.67 (d, J = 3.5 Hz, 1 H), 4.14-4.21 (m, 2 H), 3.74 (d, J = 10.5 Hz, 1 H), 3.05 (dd, J = 7.0, 17.5 Hz, 1 H), 2.59 (td, J = 3.5, 11.9 Hz, 1 H), 2.53 (sept. J = 3.5 Hz, 1 H), 2.36 (dd, J = 16.8, 2.8 Hz, 1 H), 1.75-1.82 (m, 2 H), 1.66-1.73 (m, 2 H), 1.26 (t, J = 7.0 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 174.1, 164.2, 149.9, 134.1, 128.9, 119.9, 117.6, 113.2, 71.0, 61.2, 46.0, 34.0, 33.0, 27.5, 20.1, 14.3; HRMS (TOF MS ES+) calcd for C₁₆H₂₁N₂O₃ [M+H]: 289.1552, found 289.1556.

ethyl (E)-5-(2-aminobenzamido)-3-methylpent-2-enoate (S16). To a DCM (4.1 mL, 0.5M) solution of the known^{s7} ester (0.5275 g, 2.05 mmol) was added trifluoroacetic acid (0.80 mL, 10.4 mmol). The solution was stirred at room temperature for 18 hours. At this time, TLC indicated the consumption of the ester. The reaction was quenched with excess solid K₂CO₃, filtered, and concentrated to give the free aminoester. The aminoester was dissolved in THF (7 mL, 0.3M). To this solution were added Isatoic anhydride (0.2787 g, 1.71 mmol) along with DMAP (0.0420 g, 0.342 mmol) and the mixture was heated to reflux for 24 hours. At this time, TLC indicated the consumption of the isatoic anhydride. The reaction mixture was diluted with EtOAc, washed with brine, the organics were dried over MgSO₄, and concentrated. Purification by FCC (3:1 hexanes:EtOAc) gave **S16** (0.4703 g, 1.70 mmol, 99%) as a colorless oil.

Data for **S16**: R_f 0.44 (4:1 EtOAc : Hexanes); IR (thin film) 3461, 3353, 2981, 1707, 1693 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.28 (dd, J = 7.6, 1.2 Hz, 1 H), 7.23 (dd, J = 7.6, 1.2 Hz, 1 H), 7.74 (d, J = 8.0 Hz, 1 H), 6.68 (t, J = 7.2 Hz, 1 H), 6.10 (bs, 1 H), 5.74 (d, J = 1.2 Hz, 1 H), 4.16 (q, J = 7.2 Hz, 2 H), 2.45 (t, J = 6.8 Hz, 2 H), 2.22 (d, J = 1.2 Hz, 3 H), 1.28 (t, J = 7.2 Hz, 3 H); ¹³C (100 MHz, CDCl₃) δ 169.3, 133.5,

156.1, 148.0, 132.5, 127.2, 118.0, 117.9, 117.4, 116.6, 59.9, 40.7, 37.4, 18.8, 14.4; HRMS (TOF MS ES+) calcd for C₁₅H₂₁N₂O₃ [M+H]: 277.1552, found 277.1547.

ethyl (E)-3-methyl-5-(4-oxoquinazolin-3(4H)-yl)pent-2-enoate (110). To a THF (2.0 mL, 0.3 M) solution of S16 (0.1613 g, 0.584 mmol) was added one drop of trifluoroacetic acid and trimethyl orthoformate (0.32 mL, 2.92 mmol). This mixture was heated to reflux for 30 hours. The reaction mixture was concentrated and purified by FCC (1:1 hexanes:EtOAc) to give 110 (0.0384 g, 0.134 mmol, 23%) along with 0.0904 g of recovered S16.

Data for **110**: R_f 0.42 (1:1 EtOAc : Hexanes); IR (thin film) 2981, 1714, 1676 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.31 (dd, J = 7.7, 0.7 Hz, 1 H), 7.96 (s, 1 H), 7.77 (ddd, J = 8.4, 8.4, 1.4 Hz, 1 H), 7.71 (d, J = 8.4 Hz, 1 H), 7.52 (ddd, J = 7.7, 7.7, 0.7Hz, 1 H), 5.67 (d, J = 0.7 Hz, 1 H), 4.13 (quin, J = 7.7 Hz, 4 H), 2.62 (t, J = 7.7 Hz, 2 H), 2.26 (d, J = 0.7 Hz, 3 H), 1.24 (t, J = 7.0 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 166.2, 161.1, 154.2, 148.2, 146.2, 134.5, 127.7, 127.6, 126.8, 122.2, 118.8, 59.9, 45.3, 40.1, 18.9, 14.4; HRMS (TOF MS ES+) calcd for C₁₆H₁₉N₂O₃ [M+H]: 287.1396, found 287.1387.

ethyl 2-((3R,3aR)-3-methyl-9-oxo-1,2,3,3a,4,9-hexahydropyrrolo[2,1b]quinazolin-3-yl)acetate (111). To a solution of 110 (0.0390 g, 0.136 mmol) and NH₄Cl (0.0080g, 0.150 mmol) in THF (0.45 mL, 0.3 M) was added a THF solution of SmI₂ (4.5 mL, 0.34 mmol) via syringe pump over a period of 1 hour. At this time, TLC indicated the consumption of 110. The reaction mixture was diluted with halfsaturated aqueous Rochelle salt. This biphasic mixture was extracted with ethyl acetate. The combined extracts were dried over MgSO₄ and concentrated. Purification by FCC (2:1 hexanes:EtOAc) gave 111 (0.0308 g, 0.107 mmol, 78%, 9.5:1 dr) as a white solid. Data for **111** (major diastereomer): R_f 0.29 (1:1 EtOAc: Hexanes); IR (thin film) 3284, 2976, 1726, 1637 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.88 (dd, J = 7.7, 1.4 Hz, 1 H), 7.28 (d, J = 1.4 Hz, 1 H), 7.27-7.27 (m, 2 H), 6.86 (td, J = 7.7, 0.7 Hz, 1 H), 6.68 (dd, J = 7.7, 0.7 Hz, 1 H), 4.84 (bs, 1 H), 4.76 (s, 1 H), 4.16 (qd, J = 7.0, 1.4 Hz, 2 H), 3.76 (dt, J = 11.9, 8.4 Hz, 1 H), 3.64 (dd, J = 12.6, 9.1, 4.2 Hz, 1 H), 2.73 (d, J = 15.4 Hz, 1 H), 2.43 (d, J = 15.4 Hz, 1 H), 2.06 (ddd, J = 13.3, 7.7, 4.2 Hz, 1 H), 1.73 (dt, J = 12.6, 1.4 Hz, 1 H), 1.31 (s, 3 H), 1.27 (t, J = 7.0 Hz, 3 H); ¹³C (176 MHz, CDCl₃) δ 172.7, 162.6, 147.4, 133.2, 128.3, 119.8, 117.3, 115.0, 77.7, 60.9, 44.3, 42.2, 38.7, 35.6, 22.4, 14.4; HRMS (EI+) calcd for C₁₆H₂₁N₂O₃ [M+H]: 289.1552, found 289.1539.

3-(3-benzyl-4-oxo-1,3-diazaspiro[4.4]nonan-2-yl)propanenitrile (**113**). Following the general reductive alkylation procedure, 3-benzyl-1,3-diazaspiro[4.4]non-1-en-4-one^{ss} (0.0294 g, 0.129 mmol), NH₄Cl (0.0078 g, 0.146 mmol), acrylonitrile (0.04 mL, 0.61 mmol) in THF (0.43 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.2 mL, 0.32 mmol) to give **113** (0.0319 g, 0.113 mmol, 87%) as a yellow oil after purification by FCC (3:2 hexanes:EtOAc).

Data for **113**: R_f 0.68 (EtOAc); IR (thin film) 3326, 2947, 2246, 1689 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 4.87 (d, J = 15.4 Hz, 1 H), 4.36 (dd, J = 8.4, 2.8 Hz, 1 H), 4.09 (d, J = 15.4 Hz, 1 H), 2.41-2.46 (m, 1 H) 2.34-2.39 (m, 1 H), 2.07-2.14 (m, 2 H), 2.01 (dddd, J = 16.8, 14.0, 8.4, 2.8 Hz, 1 H), 1.82-1.84 (m, 2 H) 1.74-1.80 (m, 2 H), 1.67-1.71 (m, 1 H), 1.60-1.65 (m, 1 H), 1.55-1.59 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 177.9, 136.1, 129.1, 128.2, 128.0, 128.0, 119.2, 69.5, 68.8, 44.7, 39.3, 38.5, 37.4, 29.9, 25.5, 25.3, 12.2; HRMS (TOF MS ES+) calcd for C₁₇H₂₂N₃O [M+H]: 284.1763, found 284.1767.

(±) *tert*-butyl (1S,2S,5R,6R)-4-oxo-3-azatricyclo[4.2.1.02,5]nonane-3-carboxylate (S17). To a THF (5.0 mL, 0.3 M) solution of known⁸⁹ (1S,2S,5R,6R)-3-

azatricyclo[4.2.1.02,5]nonan-4-one was added Boc_2O (0.35 mL, 1.52 mmol) and DMAP (0.0180 g, 0.147 mmol). This mixture was stirred at rt for 20 hours. At this time, TLC indicated the consumption of the (1S,2S,5R,6R)-3-azatricyclo[4.2.1.02,5]nonan-4-one. The mixture was diluted with EtOAc, washed with brine, dried over MgSO₄, and concentrated. Purification by FCC (9:1 hexanes:EtOAc) gave **S17** (0.0874 g, 0.368 mmol, 26%) as a white solid.

Data for **S17**: R_f 0.34 (1:1 EtOAc: Hexanes); IR (thin film) 2973, 2877, 1796, 1720 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.70 (d, *J* = 7.7 Hz, 1 H), 2.92 (d, *J* = 7.7 Hz, 1 H), 2.67 (d, *J* = 6.3 Hz, 1 H), 2.48 (d, *J* = 4.2 Hz, 1 H), 1.53-1.68 (m, 3 H), 1.50 (s, 9 H), 1.24-1.28 (m, 1 H), 1.07-1.13 (m, 2 H); ¹³C (100 MHz, CDCl₃) δ 166.5, 147.8, 83.0, 56.6, 56.5, 37.1, 34.8, 31.2, 28.2, 27.2, 24.5; HRMS (TOF MS ES+) calcd for C₁₃H₁₉NO₃ [M+Na]: 260.1263, found 260.1255.

(±) *tert*-butyl ((1S,2S,3R,4R)-3-(benzylcarbamoyl)bicyclo[2.2.1]heptan-2yl)carbamate (S18). To a THF (0.40 mL, 0.3 M) solution of S17 (0.0297 g, 0.125 mmol) was added benzylamine (0.02 mL, 0.183 mmol). The mixture was stirred at rt for 22 hours. At this time, TLC indicated the consumption of S17. The mixture was concentrated to give S18 (0.0430 g, 0.125 mmol, 99%) as a white solid.

Data for **S18**: R_f 0.28 (3:1 Hexanes : EtOAc); IR (thin film) 3292, 2952, 1643, 1555 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.32 (t, J = 7.7 Hz, 2 H), 7.25–7.27 (m, 3 H), 5.94 (bs, 1 H), 5.36 (d, J = 9.1 Hz, 1 H), 4.53 (dd, J = 14.7, 6.3 Hz, 1 H), 4.23 (dd, J = 14.7, 4.9 Hz, 1 H), 3.88 (t, J = 8.4 Hz, 1 H), 2.46 (d, J = 2.1 Hz, 1 H), 2.39 (d, J = 8.4 Hz, 1 H), 2.15 (d, J = 4.2 Hz, 1 H), 1.98 (d, J = 10.5 Hz, 1 H), 1.57 (dddd, J = 16.1, 12.6, 4.2, 4.2 Hz, 1 H), 1.45–1.51 (m, 1 H), 1.42, (s, 9 H), 1.22–1.26 (m, 2 H), 1.12 (dddd, J = 14.0, 8.4, 2.8, 2.8); ¹³C (176 MHz, CDCl₃) δ 172.5, 156.0, 138.3, 128.8, 127.9, 127.6, 79.4, 56.4, 53.9, 43.7, 42.6, 40.7, 35.3, 28.8, 28.6, 26.7; HRMS (TOF MS ES+) calcd for C₂₀H₂₉N₂O₃ [M+H]: 345.2178, found 345.2164.

(±) (4aR,5R,8S,8aS)-3-benzyl-4a,5,6,7,8,8a-hexahydro-5,8-methanoquinazolin-4(3H)-one (114). Gaseous HCl was bubbled through a DCM (7.0 mL, 0.1 M) solution of S4 (0.2404 g, 0.698 mmol) while stirring at rt for a period of 1 hour. At this time, TLC indicated the consumption of S18. The reaction mixture was concentrated to give the HCl salt of the Boc-deprotected S18 (0.2006 g, 0.714 mmol, 99%). This salt (0.0846 g, 0.301 mmol) was dissolved in triethyl orthoformate (3.0 mL, 0.1 M) and heated to reflux for 19 hours. The reaction mixture was concentrated and purified by FCC (1:1 hexanes:EtOAc to give 114 (0.0270 g, 0.0762 mmol, 35%) as a white solid.

Data for **114**: R_f 0.38 (2:1 EtOAc: Hexanes); IR (thin film) 3377, 2959, 2873, 1671 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.23-7.36 (m, 6 H), 4.80 (d, J = 26.6 Hz, 1 H), 4.62 (d, J = 26.6 Hz, 1 H), 3.84 (d, J = 15.4 Hz, 1 H), 2.74 (s,1 H), 2.62 (d, J = 15.4 Hz, 1 H), 2.51 (s, 1 H), 1.58-1.69 (m, 2 H) 1.22-1.46 (m, 4 H); ¹³C (176 MHz, CDCl₃) δ 168.4, 144.0, 136.4, 129.1, 128.1, 127.8, 65.0, 48.7, 48.1, 46.1, 43.7, 34.6, 29.9, 26.4; HRMS (TOF MS ES+) calcd for C₁₆H₁₉N₂O [M+H]: 255.1497, found 255.1493.

(±) **3-((2R,4aR,5R,8S,8aS)-3-benzyl-4-oxodecahydro-5,8-methanoquinazolin-2-yl)propanenitrile (115)**. *Following the general reductive alkylation procedure*, **114** (.0234 g, 0.0920 mmol), NH₄Cl (0.0056 g, 0.105 mmol), acrylonitrile (0.03 mL, 0.46 mmol) in THF (0.31 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.0 mL, 0.23 mmol) to give **115** (0.0283 g, 0.0915 mmol, 99%, single diastereomer) as a yellow oil.

Data for **115**: R_f 0.50 (2:1 EtOAc: Hexanes); IR (thin film) 3317, 2953, 2246, 1633 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.36 (m, 5 H), 5.00 (bs, 1 H), 4.17 (bs, 2 H), 3.24 (d, 7.6 Hz, 1 H), 3.09 (s, 1 H), 2.41-2.45 (m, 2 H), 2.19 (d, *J* = 6.8 Hz, 2 H), 1.98-2.07 (m, 1 H), 1.77-1.86 (m, 1 H), 1.59-1.70 (m, 2 H), 1.47 (d, *J* = 10.4 Hz, 1 H), 1.21-1.34 (m, 4 H); ¹³C (176 MHz, CDCl₃) δ 169.4, 137.3, 129.1, 128.2, 127.9,

119.0, 68.6, 57.2, 49.4, 48.2, 42.6, 41.1, 34.2, 28.4, 27.7, 27.2, 14.3; HRMS (TOF MS ES+) calcd for C₁₉H₂₄N₃O [M+H]: 310.1919, found 310.1933.

3-(6-oxohexahydropyrrolo[1,2-a]pyrimidin-8a(6H)-yl)propanenitrile (117). Following the general reductive alkylation procedure, known⁹⁰ 3,4,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-6(2H)-one (.0187 g, 0.135 mmol), CSA (0.0343 g, 0.148 mmol), acrylonitrile (0.04 mL, 0.61 mmol) in THF (0.45 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.5 mL, 0.34 mmol) to give **117** (0.0044 g, 0.0228 mmol, 17%) as a colorless oil after purification by FCC (6:1 EtOAc:10% NH₄OH in MeOH).

Data for **117**: R_f 0.40 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 3358, 2933, 2247, 1674 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 4.17 (dd, J = 14.0, 4.2 Hz, 1 H), 2.92-3.04 (m, 3 H), 2.34-2.50 (m, 5 H), 2.25 (t, J = 12.6 Hz, 1 H), 1.87 (bs, 1 H), 1.53-1.69 (m, 4 H); ¹³C (176 MHz, CDCl₃) δ 171.8, 119.5, 75.0, 40.0, 36.1, 31.9, 28.9, 28.1, 25.5, 12.5; HRMS (TOF MS ES+) calcd for C₁₀H₁₆N₃O [M+H]: 194.1293, found 194.1294.

3-(3-acetyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (**119**). Following the general reductive alkylation procedure, known⁹¹ 1-(quinazolin-3(4H)-yl)ethan-1-one (.0248 g, 0.142 mmol), NH₄Cl (0.0087 g, 0.16 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.7 mL, 0.36 mmol) to give **119** (0.0116 g, 0.0506 mmol, 36%) as a colorless oil after purification by FCC (3:2 EtOAc:hexanes).

Data for **119**: R_f 0.14 (2:1 EtOAc: Hexanes); IR (thin film) 3346, 2930, 2245, 1639 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 3:1 mixture of rotational isomers δ 7.13 (t, *J* = 7.7 Hz, 1 H), 7.03 (d, *J* = 7.7 Hz, 1 H), 6.85 (t, *J* = 7.7 Hz, 1 H), 6.71 (d, *J* = 7.7 Hz, 1 H), 5.90 (t, *J* = 7.7 Hz, 1 H), 4.66 (d, *J* = 16.1 Hz, 1 H), 4.57 (d, *J* = 16.1 Hz, 1 H),

2.39-2.52 (m, 2 H), 2.00 (s, 3 H), 1.96-2.06 (m, 2 H); 13 C (176 MHz, CDCl₃) δ 169.9, 140.1, 128.5, 126.6, 120.1, 119.4, 118.7, 117.8, 59.4, 43.5, 29.0, 22.2, 13.7; HRMS (EI+) calcd for C₁₃H₁₅N₃O [M+]: 229.12152, found 229.12141.

tert-butyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydropyrimidin-2-yl)propanoate (121). *Following the general reductive alkylation procedure*, known⁹² 3-benzylpyrimidin-4(3H)-one (.0293 g, 0.157 mmol), CSA (0.0419 g, 0.180 mmol), *tert*-butyl acrylate (0.11 mL, 0.75 mmol) in THF (0.52 mL, 0.3 M) were reacted with a THF solution of SmI₂ (5.0 mL, 0.39 mmol) to give **121** (0.0195 g, 0.0616 mmol, 39%) as a colorless oil along with 0.0046g of recovered starting material after purification by FCC (2:1 hexanes:EtOAc).

Data for **121**: R_f 0.45 (EtOAc); IR (thin film) 3283, 2977, 2920, 1726, 1616 cm⁻¹; ¹H NMR (700 MHz, D₃COD) δ 7.32-7.35 (m, 4 H), 7.26-7.29 (m, 1 H), 6.92 (dd, *J* = 7.0, 0.7 Hz, 1 H), 5.20 (d, *J* = 15.4 Hz, 1 H), 4.75 (d, *J* = 7.0 Hz, 1 H), 4.72-4.74 (m, 1 H), 4.06 (d, *J* = 15.4 Hz, 1 H), 2.23-2.29 (m, 3 H), 1.77-1.81 (m, 1 H), 1.44 (s, 9 H); ¹³C (176 MHz, CDCl₃) δ 172.4, 166.0, 143.9, 137.7, 128.2, 127.9, 127.1, 90.1, 80.4, 66.9, 46.5, 29.8, 26.9, 25.7; HRMS (TOF MS ES+) calcd for C₁₈H₂₄N₂O₃Na [M+Na]: 339.1685, found 339.1688.

3-(1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (123). *Following the general reductive alkylation procedure,* known⁹³ 1,3-dimethyl-4-oxo-3,4-dihydroquinazolin-1-ium iodide (.0430 g, 0.142 mmol), NH₄Cl (0.0085 g, 0.156 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.4 mL, 0.36 mmol) to give **123** (0.0335 g, 0.138 mmol, 97%) as a colorless oil.

Data for **123**: $R_f 0.18$ (1:2 hexanes:EtOAc); IR (thin film) 2938, 2245, 1646, 1495, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (dd, J = 8.0, 1.3 Hz, 1 H), 7.40 (td, J =

8.0, 1.6 Hz, 1 H), 6.93 (t, J = 7.7 Hz, 1 H), 6.75 (d, J = 7.7 Hz, 1 H), 4.61 (t, J = 6.5 Hz, 1 H), 3.16 (s, 3 H), 3.06 (s, 3 H), 2.36 (t, J = 7.2 Hz, 2 H), 2.02 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 162.2, 146.1, 118.5, 118.2; *C*H 133.7, 128.5, 120.0, 115.3, 76.6; *C*H₂ 27.2, 13.4; *C*H₃ 39.4, 33.7; HRMS (ESI) calcd for C₁₃H₁₅N₃O [M+H]: 229.1215, found 229.1220.

methyl 3-(1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (124). Following the general reductive alkylation procedure, known 1,3-dimethyl-4-oxo-3,4-dihydroquinazolin-1-ium iodide (.0412 g, 0.136 mmol), NH₄Cl (0.0089 g, 0.166 mmol), methyl acrylate (0.06 mL, 0.68 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.5 mL, 0.34 mmol) to give **124** (0.0331 g, 0.120 mmol, 88%) as a colorless oil.

Data for **124**: $R_f 0.27$ (1:2 hexanes:EtOAc); IR (thin film) 2950, 1735, 1648, 1494, 1162, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (dd, J = 7.8, 1.5 Hz, 1 H), 7.36 (td, J = 7.8, 1.5 Hz, 1 H), 6.85 (t, J = 7.5 Hz, 1 H), 6.63 (d, J = 8.1 Hz, 1 H), 4.62 (t, J = 5.9 Hz, 1 H), 3.64 (s, 3 H), 3.13 (s, 3 H), 2.99 (s, 3 H), 2.33 (t, J = 7.5 Hz, 2 H), 2.02 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 173.0, 162.5, 146.5, 117.4; CH 133.5, 128.5, 118.7, 113.3, 77.3; CH₂ 29.2, 26.5; CH₃ 51.8, 37.9, 33.8; HRMS (ESI) calcd for C₁₄H₁₈N₂O₃ [M+H]: 262.1318, found 262.1323.

tert-butyl 3-(1,3-dimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (125). *Following the general reductive alkylation procedure,* known 1,3-dimethyl-4-oxo-3,4-dihydroquinazolin-1-ium iodide (.0442 g, 0.146 mmol), NH₄Cl (0.0088 g, 0.161 mmol), *tert*-butyl acrylate (0.11 mL, 0.73 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.5 mL, 0.37 mmol) to give **125** (0.0434 g, 0.136 mmol, 93%) as a colorless oil.

Data for **125**: $R_f 0.51$ (1:2 hexanes:EtOAc); IR (thin film) 2975, 1726, 1649, 1494, 1152, 754 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.93 (dd, J = 7.6, 1.2 Hz, 1 H), 7.36 (td, J = 7.7, 1.6 Hz, 1 H), 6.85 (t, J = 7.8 Hz, 1 H), 6.64 (d, J = 8.1 Hz, 1 H), 4.63 (t, J = 6.0 Hz, 1 H), 3.14 (s, 3 H), 3.00 (s, 3 H), 2.45 (t, J = 7.4 Hz, 2 H), 1.97 (m, 2 H), 1.43 (s, 9 H); ¹³C NMR (100 MHz, CDCl₃, DEPT) δ *C* 171.9, 162.6, 146.5, 117.4, 80.9; *C*H 133.5, 128.5, 118.5, 113.1, 77.2; *C*H₂ 30.6, 26.5; *C*H₃ 37.7, 33.9, 28.1; HRMS (ESI) calcd for C₁₇H₂₄N₂O₃ [M+H]: 304.1787, found 304.1796.

3-(1,2,3-trimethyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (127). *Following the general reductive alkylation procedure,* known⁹⁴ 1,2,3-trimethyl-4-oxo-3,4-dihydroquinazolin-1-ium iodide (.0450 g, 0.142 mmol), NH₄Cl (0.0089 g, 0.166 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.7 mL, 0.36 mmol) to give **127** (0.0334 g, 0.137 mmol, 97%) as a colorless oil.

Data for **127**: R_f 0.77 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 2952, 2247, 1644 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (dd, J = 7.6, 1.2 Hz, 1 H), 7.40 (ddd, J = 8.4, 7.2, 1.6 Hz, 1 H), 6.92 (ddd, J = 8.4, 8.4, 0.8 Hz, 1 H), 6.79 (d, J = 8.4 Hz, 1 H), 3.10 (s, 3 H), 2.86 (s, 3 H) 2.35-2.50 (m, 2 H), 2.22-2.34 (m, 2 H), 1.58 (s, 3 H); ¹³C (176 MHz, CDCl₃) δ 163.3, 146.9, 134.1, 128.7, 119.9, 119.1, 117.0, 114.6, 33.7, 33.0, 28.6, 20.8, 12.1; HRMS (EI+) calcd for C₁₄H₁₇N₃O [M+]: 243.13717, found 243.13734.

3-(1,3-dimethyl-4-oxo-1,2,3,4-tetrahydropyrimidin-2-yl)propanenitrile (129). Following the general reductive alkylation procedure, known⁹⁵ 1,3-dimethyl-4-oxo-3,4-dihydropyrimidin-1-ium iodide (.0343 g, 0.144 mmol), CSA (0.0376 g, 0.162 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.48 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.9 mL, 0.36 mmol) to give **129** (0.0173 g, 0.0965 mmol, 67%) as a yellow oil after purification by FCC (9:1 EtOAc:10% NH₄OH in MeOH).

Data for **129**: R_f 0.45 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 2927, 2246, 1627 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 6.53 (dd, J = 7.7, 1.4 Hz, 1 H), 4.82 (d, J = 7.7 Hz, 1 H), 4.66 (td, J = 6.3, 1.4 Hz, 1 H), 3.05 (s, 3 H), 2.99 (s, 3 H), 2.43-2.53 (m, 2 H), 2.16-2.21 (m, 1 H), 2.10-2.14 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 163.6, 145.7, 118.9, 93.9, 75.3, 40.9, 33.2, 25.6, 13.0; HRMS (EI+) calcd for C₉H₁₃N₃O [M+]: 179.10587, found 179.10647.

3-(1,3-dimesityl-5,5-dimethyl-4-oxohexahydropyrimidin-2-yl)propanenitrile

(131). Following the general reductive alkylation procedure, known⁹⁶ 1,3-dimesityl-5,5-dimethyl-4-oxo-3,4,5,6-tetrahydropyrimidin-1-ium chloride (.0569 g, 0.143 mmol), CSA (0.0401 g, 0.173 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.48 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.8 mL, 0.36 mmol) to give **131** (0.0301 g, 0.0721 mmol, 50%) as a white solid after purification by FCC (9:1 EtOAc:10% NH₄OH in MeOH).

Data for **131**: R_f 0.65 (1:1 EtOAc:hexanes); IR (thin film) 2959, 2244, 1651 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.00 (s, 1 H), 6.99 (s, 1 H), 6.93 (s, 1 H), 6.89 (s, 1 H), 5.29 (t, *J* = 5.6 Hz, 1 H), 3.60 (d, *J* = 12.6 Hz, 1 H), 3.23 (d, *J* = 12.6 Hz, 1 H), 2.48 (s, 3 H), 2.45 (s, 3 H) 2.34 (s, 3 H), 2.29 (s, 3 H), 2.25 (s, 3 H), 2.19 (s, 3 H), 1.95-2.00 (m, 1 H), 1.78-1.83 (m, 1 H), 1.54-1.62 (m, 2 H), 1.48 (s, 3 H), 1.26 (s, 3 H); ¹³C (176 MHz, CDCl₃) δ 177.7, 142.7, 139.4, 138.6, 138.5, 137.9, 137.7, 136.1, 135.6, 132.1, 131.3, 131.1, 130.6, 119.9, 76.7, 61.0, 49.4, 49.2, 49.1, 49.0, 48.9, 48.8, 48.6, 42.0, 28.7, 26.5, 24.8, 21.0, 20.9, 20.7, 20.5, 19.0, 18.9, 14.7; HRMS (EI+) calcd for C₂₇H₃₆N₃O [M+H]: 418.2858, found 418.2842.

5,5-dimethyl-4-oxo-1,3-diphenyl-3,4,5,6-tetrahydropyrimidin-1-ium chloride (132). To a DCM (4 mL, 0.5 M) solution of known⁹⁷ chloropivalic acid (0.2537 g, 1.86 mmol) and 1 drop of DMF was added oxalyl chloride (0.17 mL, 1.98 mmol). This solution was stirred at rt for 2 h. At this time, the solution of the acid chloride was added dropwise to a DCM (3.7 mL, 0.2 M) solution of known⁹⁸ (E)-*N*,*N'*-diphenylformimidamide (0.3004 g, 1.53 mmol) and triethylamine (0.28 mL, 2.00 mmol). After stirring at rt for 0.5 hours, the mixture was concentrated and extracted with PhMe. The PhMe extracts were filtered through celite and then refluxed for 28 hours. Filtration of the white precipitate gave **132** (0.2815 g, 0.08941 58%) as a white solid.

Data for **132**: R_f 0.64 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 2972, 2873, 1671, 1594 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.44 (s, 1 H), 7.71-7.30 (m, 2 H), 7.59-7.68 (m, 6 H), 7.51-7.54 (m, 2 H), 4.54 (s, 2 H), 1.57 (s, 6 H); ¹³C (100 MHz, CDCl₃) δ 170.0, 156.1, 140.8, 135.3, 130.4, 130.4, 130.3, 128.2, 123.5, 60.4, 38.1, 22.8; HRMS (TOF MS ES+) calcd for C₁₈H₁₉N₂O [M+]: 279.1497, found 279.1487.

3-(5,5-dimethyl-4-oxo-1,3-diphenylhexahydropyrimidin-2-yl)propanenitrile

(133). Following the general reductive alkylation procedure, 132 (.0418 g, 0.133 mmol), NH₄Cl (0.0081 g, 0.151 mmol), acrylonitrile (0.04 mL, 0.61 mmol) in THF (0.44 mL, 0.3 M) were reacted with a THF solution of SmI_2 (4.4 mL, 0.33 mmol) to give **61** (0.0247 g, 0.0741 mmol, 56%) as a colorless oil after purification by FCC (2:1 hexanes:EtOAc).

Data for **133**: R_f 0.37 (4:1 EtOAc: 10% NH₄OH in MeOH); IR (thin film) 3364, 2926, 2245, 1651 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (t, *J* = 7.6 Hz, 2 H), 7.32-7.38 (m, 5 H), 7.15 (d, *J* = 8.0 Hz, 2 H), 6.97 (t, *J* = 7.6 Hz, 1 H), 5.43-5.46 (m, 1 H), 3.73 (dd, *J* = 14.4, 1.2 Hz, 1 H), 3.58 (d, *J* = 14.4 Hz, 1 H), 2.16-2.29 (m,4 H), 1.28

(s, 3 H), 1.11 (s, 3 H); 13 C (176 MHz, CDCl₃) δ 174.8, 149.6, 140.2, 130.0, 129.9, 128.0, 127.9, 121.5, 118.8, 117.6, 74.7, 54.5, 40.6, 28.3, 27.4, 25.0, 13.5; HRMS (TOF MS ES+) calcd for C₂₁H₂₃N₃O [M+H]: 334.1919, found 334.1904.

3-benzyl-2-propylquinazolin-4(3H)-one (138). To a stirring THF (0.48 mL, 0.3M) solution of known⁹⁹ amidine **137** (0.0396 g, 0.143 mmol) and NH₄Cl (0.0091 g, 0.170 mmol) was added a THF solution of SmI₂ (4.7 mL, 0.36 mmol) via syringe pump over 1 hour. The reaction mixture was then diluted with half-saturated aqueous Rochelle salt. This biphasic mixture was extracted with ethyl acetate. The combined extracts were dried over MgSO₄ and concentrated to give known¹⁰⁰ amidine **138** (0.0114 g, 0.041 mmol, 23%) as a white solid along with 0.0179 g of recovered **137**.

3-(3-benzyl-2-cyclopropyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-

yl)propanenitrile (139) and 3-(4-benzyl-5-oxo-2,3,4,5-tetrahydropyrrolo[1,2a]quinazolin-3a(1H)-yl)propanenitrile (140). Following the general reductive alkylation procedure, known¹⁰¹ amidine 137 (.0391 g, 0.141 mmol), CSA (0.0371 g, 0.160 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI₂ (3.8 mL, 0.36 mmol) to give 139 (0.0074 g, 0.0224 mmol, 16%) as a colorless oil and 140 (0.0069 g, 0.0208 mmol, 15%) as a colorless oil after purification by FCC (2:1 hexanes:EtOAc) along with 0.0136 g of 137.

Data for **139**: R_f 0.52 (1:1 Hexanes: EtOAc); IR (thin film) 3330, 2929, 2247, 1625 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.96 (dd, J = 7.7, 1.4 Hz, 1 H), 7.35 (d, J = 7.0 Hz, 1 H), 7.31 (td, J = 7.7, 2.1 Hz, 2 H), 7.24-7.25 (m,3 H), 6.87 (td, J = 7.7, 0.7 Hz, 1 H), 6.62 (dd, J = 7.7, 0.7 Hz, 1 H), 5.10 (d, J = 15.4 Hz, 1 H), 4.79 (d, J = 15.4 Hz, 1 H), 3.90 (s, 1 H), 2.32-2.37 (m, 2 H), 2.09-2.14 (m, 1 H), 1.69-1.73 (m, 1 H), 1.30 (dddd, J = 10.5, 8.4, 5.6, 5.6 Hz, 1 H), 0.69-.73 (m, 1 H), 0.60-.64 (m, 1 H), 0.50-.54 (m, 1 H), .37-.41 (m, 1 H); ¹³C (176 MHz, CDCl₃) δ 163.9, 144.3, 139.2, 134.2,

129.0, 128.8, 127.8, 127.5, 119.6, 119.5, 114.4, 114.3, 75.8, 45.5, 34.2, 19.7, 12.5, 4.0, 1.9; HRMS (TOF MS ES+) calcd for $C_{21}H_{22}N_3O$ [M+H]: 332.1763, found 332.1773.

Data for **140**: R_f 0.42 (1:1 Hexanes: EtOAc); IR (thin film) 3356, 2963, 2247, 1660 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.99 (dd, J = 7.7, 1.4 Hz, 1 H), 7.41 (ddd, J = 8.4, 7.7, 2.1 Hz, 1 H), 7.23-7.32 (m, 5 H), 7.88 (td, J = 8.4, 1.4 Hz, 1 H), 6.68 (d, J = 8.4 Hz, 1 H), 5.21 (d, J = 16.1 Hz, 1 H), 4.34 (d, J = 16.1 Hz, 1 H), 3.73 (td, J = 9.1, 3.5 Hz, 1 H), 3.47 (q, J = 7.7 Hz, 1 H), 2.35 (ddd, J = 11.2, 8.4, 4.2 Hz, 1 H), 2.29 (ddd, J = 8.4, 7.7, 2.1 Hz, 2 H), 2.22 (ddd, J = 12.6, 7.0, 2.8 Hz, 1 H), 2.11 (ddd, J = 14.7, 8.4, 8.4, 2.11 Hz, 1 H), 1.95-2.06 (m, 3 H); ¹³C (176 MHz, CDCl₃) δ 163.6, 144.7, 138.6, 134.4, 129.3, 128.9, 127.4, 127.2, 119.0, 118.9, 115.4, 114.4, 81.4, 49.0, 47.1, 37.2, 34.4, 21.9, 12.9; HRMS (TOF MS ES+) calcd for C₂₁H₂₁N₃NaO [M+Na]: 354.1582, found 354.1587.

tert-butyl 2-cyclopropylacrylate (141). To a dry THF (10.2 mL, 0.4 M) solution of $(iPr)_2NH$ (0.06 mL, 0.43 mmol) and methyltriphenylphosphonium bromide (1.6034 g, 4.49 mmol) stirring at -78 °C, was added a solution of *n*-butyl lithium in hexanes (2.8 mL, 4.11 mmol). The mixture was allowed to warm to rt. Once the solution had stirred at rt for 1 h, the solution was again cooled to -78 °C and the known¹⁰² *tert*-butyl 2-cyclopropyl-2-oxoacetate (0.6970 g, 4.10 mmol) was added in a dropwise fashion. The solution was allowed to warm to rt over 16 hours. At this time, TLC indicated the consumption of the ketoester and the reaction was quenched with the addition of 5% aqueous H₂SO₄. The mixture was then diluted with brine, extracted with EtOAc, and the organic extracts were dried over MgSO₄. After concentration, the oil was purified by FCC (19:1 hexanes:EtOAc) to give **141** (0.4426 g, 2.65 mmol, 64%) as a colorless oil.

Data for **141**: R_f 0.80 (1:1 hexanes: EtOAc); IR (thin film) 2926, 1716, 1629 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 5.19 (d, J = 0.7 Hz, 1 H), 5.21 (t, J = 1.4 Hz, 1 H), 1.69-1.73 (m, 1 H), 1.51 (s, 9 H), 0.76 (ddd, J = 6.3, 4.2, 4.2 Hz, 2 H), 5.21 (ddd, J = 5.63,


4.2, 4.2 Hz, 2 H); ¹³C (176 MHz, CDCl₃) δ 166.7, 144.2, 119.5, 80.7, 28.2, 12.0, 7.5; HRMS (EI+) calcd for C₆H₈O₂ [M-*t*Bu]: 112.05243, found 112.05274.


tert-butyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)-2cyclopropylpropanoate (142) and 3-benzyl-2,3-dihydroquinazolin-4(1H)-one (143). Following the general reductive alkylation procedure, **78** (.0347 g, 0.148 mmol), NH₄Cl (0.0088 g, 0.164 mmol), **141** (0.1242 g, 0.7382 mmol) in THF (0.49 mL, 0.3 M) were reacted with a THF solution of SmI₂ (4.9 mL, 0.37 mmol) to give **142** (0.0291 g, 0.0716 mmol, 49%, 1.4:1 dr) as a colorless oil, **143**¹⁰³ (0.0109 g, 0.0460 mmol, 31%) as a colorless oil, and 0.0055 g of recovered **78** after purification by FCC (4:1 hexanes:EtOAc).

Data for **142a**: R_f 0.81 (1:1 EtOAc:hexanes); IR (thin film) 3301, 2926, 2246, 1718, 1629 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.4 Hz, 1 H), 7.25-7.36 (m, 6 H), 6.88 (td, J = 8.4, 1.4 Hz, 1 H), 6.60 (dd, J = 7.7, 0.7 Hz, 1 H), 5.58 (d, J = 15.4 Hz, 1 H), 4.52 (dd, J = 10.5, 2.8 Hz, 1 H), 3.95 (d, J = 15.4 Hz, 1 H), 2.19 (ddd, J = 14.7, 11.2, 4.2 Hz, 1 H), 1.98 (ddd, J = 14.0, 11.2, 2.1 Hz, 1 H) 1.50 (ddd, J = 11.2, 9.8, 4.2 Hz, 1 H), 1.38 (s, 9 H), 0.81-0.86 (m, 1 H), 0.46-0.50 (m, 1 H), 0.42-0.46 (m, 1 H), 0.26 (sextet, J = 4.2 Hz, 1 H), -0.08 (sextet, J = 4.9 Hz, 1 H); ¹³C (176 MHz, CDCl₃) δ 174.3, 162.6, 144.6, 137.2, 133.6, 129.0, 128.8, 128.2, 127.7, 119.6, 117.0, 115.4, 81.4, 66.2, 48.1, 47.1, 34.4, 28.2, 13.7, 4.3, 4.0; TOF MS ES+) calcd for C₂₅H₃₀N₂O₃Na [M+H]: 407.2335, found 407.2339.


Data for **142b**: R_f 0.77 (1:1 EtOAc:hexanes); IR (thin film) 3320, 2917, 2248, 1722, 1630 m⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.4 Hz, 1 H), 7.27-7.35 (m, 6 H), 6.89 (td, J = 8.4, 1.4 Hz, 1 H), 6.61 (dd, J = 8.4, 0.7 Hz, 1 H), 5.49 (d, J = 15.4 Hz, 1 H), 4.69 (dd, J = 8.4, 3.5 Hz, 1 H), 4.05 (d, J = 15.4 Hz, 1 H), 2.27 (dt, J = 14.7, 7.7 Hz, 1 H), 1.94 (ddd, J = 9.8, 6.3, 4.2 Hz, 1 H) 1.46 (ddd, J = 9.8, 7.7, 5.6 Hz, 1 H), 1.41 (s, 9 H), 0.86-0.90 (m, 1 H), 0.74-0.79 (m, 1 H), 0.43-0.52 (m, 2 H),


0.28 (sextet, J = 4.9 Hz, 1 H), 0.00 (sextet, J = 4.9 Hz, 1 H); ¹³C (176 MHz, CDCl₃) δ 174.3, 162.6, 144.9, 137.3, 133.5, 128.9, 128.9, 128.2, 127.8, 119.6, 117.0, 115.8, 81.2, 67.2, 48.4, 47.9, 35.9, 28.3, 14.2, 4.9, 3.5; (TOF MS ES+) calcd for C₂₅H₃₀N₂O₃Na [M+Na]: 429.2154, found 429.2134.








| | ==== RG2 2 | | E D | NO ROG ENT |
|--|------------------|---|--|---|
| 16.16 dB 17.00 dH 400.141C00 MHz 32768 MHz 100.6152841 MHz 0 3.00 Hz 1.40 | N II | CHANNEL f1 ====== 13C 9.00 use -2.00 dB 100.6253446 MHz | 23980.814 Hz 0.365918 Hz 1.366756 sec 32768 c 20.850 use 6.50 use 300.3 K 1.0000000 sec 0.0300000 sec 1 | LU1043 3 20130413 x robinson 5 mm PABBO BB- ZEUP30 65536 65536 4000 |











































HZ HZ USE K SEC SEC





Ηz

dB MH: Hz Hz us K












| P1 P1 P1 P1 P1 SF01 SF01 SF01 SF01 SF01 SF01 SF01 SF0 | RES |
|--|---|
| EL £1 ==== EL £1 ==== 14.00 0.1428010 0.1428010 0.1428010 0.1428010 0.1428010 0.1428010 0.1428010 0.1428010 0.12000 0.30 0.30 0.30 0.30 0.30 0.30 0.30 | LUI1035 20130411 20130411 1 20130411 1 20130411 2 153 1 5 mm PABB0 BB- 3 2768 3 2768 3 27183 908 0 21935 1 0 21935 1 2 .2807028 5 114 6 5.001 6.50 2.000000000 5 2.000000000 5 2.0000000000 5 2.000000000 5 2.000000000 5 2.000000000 5 2.000000000 5 2.000000000 5 2.0000000000000 5 2.000000000000000000000000000000000000 |


HOOOMONOOM








| 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | AME ACCINO ACCNO A |
|--|---|
| CHANNEL fl =====: 14.00 14.00 400.1428010 MH: 400.1428010 MH: 2768 400.1400071 MH: EM 0.30 Hz 0.30 Hz 1.00 | LU1036 1 20130410 2.2.20 Fobinson 2.2.20 3.7768 3.7768 3.7768 3.7768 3.7768 3.7768 3.7768 3.7768 3.2768 3.2768 3.2768 3.2 6.21028 sei 6.5.00 usi 6.5.00 usi 6.5.00 usi 6.5.00 usi 1.28 5.00000000 sei 1.28 5.00000000 sei 1.28 5.00000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.200000000 sei 1.2000000000 sei 1.20000000000 sei 1.2000000000000000000000000000000000000 |

































DAS50361














DAS41



























DAS50601








DAS














































20130407 20.31 robinson n PABBO BB-zg30 32768 CDC13

se us e Hz


LU1040




| ====== CPDPRG2 PC2DPRG2 PL12 PL12 PL13 SFO2 SF SF SF SF SF SF SF SF SF SF SF SF SF | ====== NUC1 P1 PL1 SF01 | DATE DATE Time Trime TROSHUM PROBHD PROBHD PROBHD PROBHD SULVENT NS SULVENT NS SULVENT NS SULVENT SUH FIDRES AQ RG DM TE D1 D1 D1 D1 TD0 |
|---|---|---|
| CHANNEL £2 ===== waltz16 90.00 16.16 17.00 400.1416066 32768 100.6152900 3.00 1.00 1.00 | CHANNEL fl ===== 13C 9.00 t -2.00 d 100.6253446 h | 5 mm PABO BD 20130407 rc5L1.59 rc5L1.59 rc5L1.59 rc5L1.59 cc513 cc |
| Hz MHz | use MHz | Sec sec |



| UUC1 PDW SBB CC | JAME VIATE VIATE VIATE VIATE VIATE VIATENT VIA |
|--|---|
| CHANNEL £1 ======: 14.00 us 10.00 dB 400.1428010 MH: 32768 400.1400070 MH: 0 0.00 Hz 0.10 Hz 1.00 | LU1041 1 20130407 22355 Frobinson 32768 CDC13 22260 32768 CDC13 32768 CDC13 32 2.2807028 set 6.500 ust 6.500 ust 6.50 ust 2.28.5 K 2.00000000 set |






 H_{Z}


dB MH


i


HZ HZ K Se




| | BR | 13 02 | ===== DPRG2 C2 PD2 2 | 01 f | | 10 | H DRES | LVENT | ME PNO OCNO te_ STRUM OBHD |
|-----|---------------|--|----------------------------------|---|-------------------|-----------------------------|---|-----------------------|---|
| .40 | ω ίλ 00 ΜΠ | 16.16 dB 17.00 dB 400.1416006 MHz 32768 | ==== z16 1H .00 | 9.00 use -2.00 dB 100.6253446 MHz | CHANNEL fl ====== | 6.50 300.0 00000 1 | 23980.814 Hz 0.365918 Hz 1.3664756 sec 18390.4 20.850 use | 29293 65536 500 | 4 0/00114 |











DAS53041

















































60 Hesse, M. Alkaloid Chemistry; Wiley: New York, 1981; pp 175-200.

61 Selected recent examples of radical reactions in alkaloid synthesis: (a) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; Gallagher, J. D. J. Am. Chem. Soc. 2006, 128, 8678–8693. (b) Movassaghi, M.; Schmidt, M. A. Angew. Chem. Int. Ed. 2007, 46, 3725–3728. (c) Zhang, H.; Curran, D. P. J. Am. Chem. Soc. 2011, 133, 10376–10378. (d) Palframan, M. J.; Parsons, A. F.; Johnson, P. Tetrahedron Lett. 2011, 52, 1154–1156.

62 The aminal radical is predicted to be 1-2 kcal/mol more stable than the \Box -amino radical. See: Song, K.–S.; Liu, L.; Guo, Q.–X. *Tetrahedron* **2004**, *60*, 9909–9923.

63 Schiedler, D. A.; Vellucci, J. K.; Beaudry, C. M. Org. Lett. 2012, 14, 6092-6095.

64 (a) Rowlands, G. J. *Tetrahedron* **2010**, *66*, 1593–1636. (b) Aurrecoechea, J. M.; Suero, R. ARKIVOC **2004**, *14*, 10–35. (c) Renaud, P.; Giraud, L. *Synthesis* **1996**, *8*, 913–926. (d) Snieckus, V.; Cuevas, J.-C.; Sloan, C. P.; Liu, H.; Curran, D. J. Am. Chem. Soc. **1990**, *112*, 896–898.

65 (a) Freeman, P. K. Hutchinson, L. L. *Tetrahedron Lett.* **1976**, *17*, 1849–1852. (b) Donohoe, T. J.; House, D. J. Org. Chem. **2002**, *67*, 5015–5018.

66 (a) Gopalaiah, K.; Kagan, H. B. *Chem. Rec.* **2013**, *13*, 187–208. (b) Kagan, H. B. *Tetrahedron* **2003**, *59*, 10351–10372.

67 The reaction stoichiometry requires 2 equivalents of acid, but our optimized conditions use 1.1 equivalent of H^+ . We speculate that upon aqueous work up an anionic intermediate (e.g. an enolate) is protonated.

68 (a) Chawla, A.; Batra, C. *Int. Res. J. Pharm.* **2013**, *4*, 49–58. (b) Rajput, R.; Mishra, A. P. *Int. J. Pharm. Pharma. Sci.* **2012**, *4*, 66–70. (c) Rajput, C. S.; Bora, P. S. *Int. J. Pharma. Bio. Sci.* **2012**, *3*, 119–132.


69 See Expermintal Section.

70 The configuration of the major diastereomer was not determined.

71 The amidinium reduction stoichiometry requires one equivalent of acid, and the reaction yield drops substantially if acid is omitted.

72 Ishida, T.; Tsukano, C.; Takemoto, Y. Chem. Lett. 2012, 41, 44-46.

73 SmI₂ is known to induce fragmentation of strained rings with incorporation of iodide, likely giving intermediate **144**, which would undergo intramolecular substitution to give **68**. See: (a) Kwon, D. W.; Kim, Y. H. *J. Org. Chem.* **2002**, *67*, 9488–9491. (b) Park, H. S.; Kwon, D. W.; Lee, K.; Kim. Y. H. *Tetrahedron Lett.* **2008**, *49*, 1616–1618.



74 Szostak, M.; Spain, M.; Procter, D. J. J. Org. Chem. 2012, 77, 3049–3059.

75 Wang, S.-L.; Wang, X.-S.; Yang, K.; Yao, C.-S. Synth. Comm. 2012, 42, 341–349.

76 Wang, M.; Zhang, T.-T.; Song, Z.-G. Org. Prep. Proc. 2010, 42, 169–163.

77 Stevenson, T. M.; Kazmierczak, F.; Leonard, N. J. J. Org. Chem. 1986, 51, 616–620.

78 Bell, Stanley C.; Conklin, George T. 3,3a-Dihydropyrrolo[1,2-a]quinazoline-1,5(2H,4H)-diones and related intermediates, US Patent 3,707,468, December 26, 1972; *SciFinder Scholar* 1973:72188.

79 Kaneko, C.; Kasai, K.; Katagiri, N.; Chiba, T. *Chem. Pharm. Bull.* **1986**, *34*, 3672–3681.

80 Fu, H.; Fu, Y.; Huang, C.; Jiang, Y.; Zhao, Y.; Huang, C.; Jiang, Y. Chem. Commun. 2008, 47, 6333–6335.

81 Baghbanzadeh, M.; Dabiri, M.; Mohammadi, A. A.; Salehi, P.; Dabiri, M. *Synth. Commun.* **2005**, *35*, 279–287.

82 Le Fur, N.; Mojovic, L.; Ple, N.; Queguiner, G.; Turck, A.; Metzner, P.; Perrio, S.; Reboul, V. *Tetrahedron* **2004**, *60*, 7983–7994.

83 De Meijere, A.; Lygin, A. V. Org. Lett. 2009, 11, 389–392.

84 Xu, L.; Jiang, Y.; Ma, D. Org. Lett. 2012, 14, 1150-1153.

85 Jacobi, A.; Schul, M. Process for Preparing Quinazolinone Derivatives, US Patent 319,194, December 25, 2008.

86 Somekawa, K.; Okuhira, H.; Sendayama, M.; Suishu, T.; Shimo, T. J. Org. Chem. **1992**, *57*, 5708–5712.

87 Qin, D.-G.; Shen, J.-W.; Yao, Z.-J.; Zhang, H.-W. J. Org. Chem. 2003, 68, 7479–7484.

88 Dias, H.V. R.; Du, H.; He, Y.; Lovely, C. J. Org. Lett. 2004, 6, 735-738.

89 Dener, J. M.; Fantauzzi, P. P.; Kelly, D. E.; Kshirsagar, T. A.; Wolfe, A. B. Org. Proc. Res. Dev. 2001, 5, 445–449.

90 Matsuyama, H.; Robinson, R. P.; Wasserman, H. H. *Tetrahedron* **2002**, *58*, 7177–7190.

91 Burdick, B. A.; Benkovic, P. A.; Benkovic, S. J. J. Am. Chem. Soc. 1977, 99, 5716–5725.

92 Khan, F. R. N.; Roopan, S. M.; Mandal, B. K. Tetrahedron Lett. 2010, 51, 2309–2311.

93 Bogert, M. T.; Geiger, G. A. J. Am. Chem. Soc. 1912, 34, 683-693.

94 Bogert, M. T.; Geiger, G. A. J. Am. Chem. Soc. 1912, 34, 683-693.

95 Tee, O. S.; Banerjee, S. J. Org. Chem. 1979, 44, 3256-3261.

96 Bielawski, C. W.; Blake, G. A.; Moerdyk, J. P. Organometallics 2012, 31, 3373–3378.

97 Kharasch, M. S.; Brown, H. C. J. Am. Chem. Soc. 1940, 62, 925–929.

98 Glorius, F., Hirano, K.; Urban, S.; Wang, C. Org. Lett. 2009, 11, 1019–1022.

99 Somasekhara et al. Indian J. Pharm. 1972, 3, 121.

100 Rani et al. J. Indian Chem. Soc. 1953, 30, 331-333.

101 Somasekhara et al. Indian J. Pharm. 1972, 3, 121.

102 Wu, M.; Begley, T. P. Org. Lett. 2000, 2, 1345-1348.

103 Cabrera-Rivera, F. A.; Ortiz-Nava, C.; Roman-Bravo, P.; Escalante, J.; Leyva, M. A. *Heterocycles* **2012**, *85*, 2173–2195.

Chapter 4: Application of Aminal Radicals in Total Synthesis: Progress Towards the Total Synthesis of Leuconoxine

4.1 Isolation and Previous Syntheses

(–)-Leuconoxine (**1**), a monoterpene indole alkaloid, was isolated from the stems of *Leuconotis eugenifolius*, a leafy plant indigenous to Malaysia and Indonesia.¹⁰⁴ While there have been no reports on the biological activity of **1**, the latex of *L. eugenifolius* has been used in traditional medicine for the treatment of yaws. A number of structurally related natural products **145–147** (Figure 4.1) have been found to exhibit cytotoxicity toward human cancer cell lines.¹⁰⁵





Figure 4.1. Leuconoxine and its biological active congeners

The structure of **1** features a pentacyclic [5.5.6.6]diazafenestrane skeleton which contains three contiguous stereogenic centers including an all-carbon quaternary stereocenter and a fully substituted aminal stereocenter. The structural complexity of **1** has garnered the interest of the synthetic community resulting in two recent total syntheses from the groups of Zhu and Tokuyama.¹⁰⁶

Zhu's enantioselective synthesis of **1** is outlined in Scheme 4.1. The sequence begins from the substituted cyclohexanone **148** which can be prepared in three steps from commercially available 1,7-heptanedioic acid.¹⁰⁷ Using a procedure developed by Stoltz, **148** was converted to the enantioenriched ketone **149** bearing the necessary all-carbon quaternary stereocenter.¹⁰⁸ Functional group manipulation of **149** yielded


the vinyl iodide **150** in 4 steps. Suzuki cross coupling of **150** with 2-nitrophenyl boronic acid (**151**) followed by oxidative cleavage gave the 1,2-dione **152**. Hydrogenation of the nitro group in the presence of acetic anhydride followed by oxidation with molecular oxygen and subsequent treatment with KOH in ethanol resulted in the formation of the *N*,*O*-ketal **153**. The fully substituted aminal stereocenter present in **1** was then constructed in an intramolecular iminium ion trapping event by treatment of **153** with acidic conditions to give the aminal **154**. The pyrrolidinone ring was closed by an intramolecular aldolization reaction to give **155**. Mesylation of the resulting tertiary alcohol followed by elimination and hydrogenation gave (–)-leuconoxine (**1**) in 16 steps (longest linear sequence) and 4.2% overall yield.



Scheme 4.1. Zhu's enantioselective total synthesis of (-)-leuconoxine


Tokuyama's synthesis of (±)-1 is outlined in Scheme 4.2. The carboxylic acid **156** was prepared in five steps. The acid was coupled with the known iodoindole **157** to give the Mizoroki–Heck substrate **158**.¹⁰⁹ Intramolecular Heck reaction of **158** formed the necessary all–carbon quaternary stereocenter yielding the annulated product **159**. Functional group manipulation gave the hydroxyindolenine **160** in eight steps. Treatment of **160** with TMSOTf and 2,6-lutidine induced an intramolecular aminal

formation to provide **161**. Formation of the δ -lactam ring was accomplished under basic conditions to give the divinylallyl compound **162**. Diastereoselective ring closing metathesis gave **163**. Hydrogenation of the alkene and Barton–McCombie deoxygenaiton completed the synthesis of (±)-leuconoxine in 21 steps (longest linear sequence) and 5.7% overall yield.



Scheme 4.2. Tokuyama's synthesis of (±)-1


4.2 Retrosynthetic Analysis



Scheme 4.3. Retrosynthetic analysis of 1 with an aminal radical disconnection

While the previously reported routes to 1 all involved the late-stage installation of the aminal functional group by way of an intramolecular condensation reaction, we

envisioned the early installation of the aminal functionality and. In a retrosynthetic sense, the opening of the pyrrolidinone ring gives the amino ester **164** (Scheme 4.3). The structure of **164** exhibits all of the features found in the product of an aminal radical reaction. Specifically, the aminal is acylated and bears an electron withdrawing substituent located three carbon atoms away from the aminal stereocenter. We envisioned that **164** could be easily prepared by the 5-*exo*-trig radical cyclization of the aminal radical intermediate **165** with the appended cinnamate. The necessary aminal radical **165** could be accessed by the reaction of SmI₂ with the bicyclic *N*-acyl amidine **166** under the conditions previously developed in our laboratory. Enticed by the simplifying nature of this synthetic strategy, we chose to pursue the total synthesis of **1** as a means to demonstrate the utility of aminal radicals in the synthesis of complex alkaloid synthesis.




Scheme 4.4. Known methods for the preparation of bicyclo[4.4.0]amidines

We next turned our attention to the retrosynthetic analysis of the key intermediate 166. A search of the literature revealed there have been no reports of bicyclo[4.4.0]-N-aryl-amidines. However, methods for the preparation of unsubstituted amidines of known. The three methods for the preparation this type were of bicyclo[4.4.0] amidines are detailed in Scheme 4.4. Amidines of the type reported by Leffek (eq. 1, 167) were prepared by the double alkylation of propionitrile (168) with an allyl bromide (169) to give the all-carbon quaternary stereocenter containing nitrile prodouct 170.110 Subsequent addition of sodium amide to the nitrile produced the amidine 171. Heating 171 in the presence of gaseous HCl resulted in the formation of **167.** While this method allowed for the preparation of a bicyclo[4.4.0]amidine bearing a quaternary stereocenter at the bridgehead position as is present in structure of 166, the method does not appear to be general. The cyclization was carried out under harsh reaction conditions and would likely be unsuccessful for a substrate that did not contain a functional group capable of forming a tertiary carbocation intermediate.

Smissman reported the synthesis of bicyclo[4.4.0]amidines such as **172** (eq. 2).¹¹¹ These amidines contain both the desired quaternary stereocenter and the acyl substitution found in **166**. The first step in the synthesis of **172** was the alkylation of phenyl acetonitrile **173** with the THP protected alcohol **174** to give the bis-nitrile **175**. Selective alkylation of **175** at the benzylic position with acrylonitrile produced the quaternary stereocenter containing product **176**. Deprotection of the alcohol followed by formation of the tosylate and displacement with ammonia gave the amine **177**. Treatment of **177** with ethanolic HCl yielded the bicyclic amidine **172**. This method relies on the phenyl substituent to provide selectivity in the second alkylation reaction, and an analogous sequence using butyronitrile as the substrate would likely be unsuccessful.


The third method was reported by Wamhoff to give amidines such as **178** (eq. 3).¹¹² The synthesis of **178** began from the known δ -lactam **179**, which was prepared in two steps from diethylmalonate.¹¹³ Imidate formation followed by addition of ammonia gave the ketene aminal **180**. Treatment of **180** with methyl acrylate yielded the amidine **178**. While this amidine bears the desired acyl substitution and the necessary quaternary stereocenter, the method of its preparation likely relied upon the presence of the electron-withdrawing ethyl ester functionality in order to successfully prepare the ketene aminal **180**. An analogous reaction sequence beginning from 3-ethylpiperidin-2-one would likely fail to produce the necessary ketene aminal functionality

Having found no suitable procedure among the known methods for the synthesis of bicyclo[4.4.0]amidines, a new synthetic strategy was devised. We envisioned that **166** might be accessible from the intramolecular condensation of the amino imide **181** (Scheme 4.5). The amine could then be obtained from the thioester **182** by way of Fukkuyama reduction and reductive amination.¹¹⁴ The thioester **182** could then be prepared from the known tri-carboxylic acid **183** and the known ester **184**.¹¹⁵



Scheme 4.5. The first generation retrosynthetic analysis of 166


The thioester **182** was rapidly constructed using a one-pot sequence starting from the known tri-acid **183**. Treatment of the acid with thionyl chloride resulted in the formation of the anhydride **185** (Scheme 4.6, not isolated).¹¹⁶ The solvent was exchanged for THF and AcOH was added in addition to the aniline **184**. After refluxing the mixture for several hours, excess acetic anhydride and triethylamne were added and heating was continued to give a mixed acyl carbonate intermediate. Finally, the addition of ethane thiol gave the desired thioester **182** in 39% yield.



Scheme 4.6. Attempted synthesis of the amine 181


Reduction of the thioester proceeded cleanly in the presence of stoichiometric palladium to give the aldehyde **186**. However, attempts to synthesize the amine **181** by reductive amination using NaCNBH₄ / NH₄OAc resulted in decomposition, presumably by reduction of the imide. Reductive amination of **186** with *tert*-butyl carbamate and triethyl silane as described by Dubé also failed to install the desired nitrogen functionality (**187**).¹¹⁷

Unable to prepare the amine **181**, we modified our retrosynthetic analysis (Scheme 4.7). We envisioned that **166** could be prepared by the aza-Wittig reaction of the imido azide **188**.¹¹⁸ Intramolecular aza-Wittig reactions of imides were well precedented, and the necessary azido imide **188** might be easily prepared from the alcohol **189**.¹¹⁹ The alcohol could likely be prepared from the tri-acid **183** and the ester **184**.




Scheme 4.7. Second-Generation retrosynthetic analysis of the key intermediate 166

Preparation of the desired alcohol commenced with an analogous one-pot sequence from the known tri-acid **183** to give the carboxylic acid **190** (Scheme 4.8). Selective reduction of the carboxylic acid in the presence of the imide was accomplished by treatment with BH₃•SMe₂ furnishing the alcohol **189** in 99% yield. While attempts to convert the alcohol directly to the azide **188** with DPPA were unsuccessful, the azide was readily obtained from a one-pot mesylation / displacement sequence.




Scheme 4.8. Synthesis of the amido lactam 191

With the azide in hand, we attempted the key intramolecular aza-Wittig reaction (Scheme 4.8). Unexpectedly, treatment of **188** with triphenylphosphine in anhydrous THF resulted in the formation of the amido lactam **191** as the sole isolable product. The same result was obtained upon treatment of the azide with zinc metal in methanol. We speculate that the amido lactam may form by the mechanism shown in Scheme 4.9. Staudinger reduction of the azide **188** with triphenylphospine gave the aza-ylide **192**. Upon intramolecular addition of the aza-ylide to the imide carbonyl, the tetrahedral intermediate **193** was formed. Collapse of the tetrahedral intermediate to eject an aryl-amide anion followed by hydrolysis upon aqueous workup resulted in the formation of the amido lactam **191**.



Scheme 4.9. Plausible mechanism for the formation of the amido lactam 191

A wide variety of conditions were examined in order to induce an intramolecular condensation reaction between the δ -lactam and the aryl amide (Scheme 4.10). Treatment with dehydrating reagents including Martin's sulfurane, phosphoryl chloride, phosphorus pentachloride, diphosphorus pentoxide, oxalyl chloride, thionyl chloride, mesyl chloride, and triflic anhydride¹²⁰ all failed to produce the desired bicyclo[4.4.0]amidine. Heating **191** under acidic (AcOH or *p*-TsOH) or basic¹²¹ (K₂CO₃) conditions also failed to yield any of the amidine. Heating **191** at 230 °C and 0.2 torr, for an extended period gave no reaction. It is likely that both the poor nucleophilicity of the electron-poor aryl amide and the sterically hindered nature of the neopentylic lactam carbonyl conspire against this transformation.




Scheme 4.10. The attempted dehydration of the amido lactam 191

An expanded literature search indicated that it might be possible to induce the desired condensation reaction under Lewis-acidic conditions. In 2007, Zhou reported the total


synthesis of the alkaloid isoshizogamine wherein the amido lactam **194** was dehydrated to form an *N*-aryl-*N*-acyl bicyclo[4.3.0]amidine (**195**) by way of the imidate **196** (Scheme 4.11, eq. 1).¹²² Following this precedent, the lactam was selectively converted to the imidate **197** (eq.2). However, upon treatment with Me₂AlCl, the substrate decomposed yielding none of the desired amidine. Reasoning that the methyl ester may be the source of the observed decomposition, the analogous 2-iodo aryl compound **198** was prepared (eq. 3, see the Experimental Section for details). After selective imidate formation, the cyclization substrate **199** was obtained. Unfortunately, none of the desired amidine **200** was observed upon treatment of **199** with Zhou's conditions.

It was envisioned that the desired amidine **166** might accessible from the intramolecular condensation reaction of an amine onto a dithioimide (**201**, Scheme 4.12). While dithioimides are relatively rare in the literature and only a few reactions for the formation of an *N*-thioacyl amidine from a dithioimide were known, the condensation reactions of thioamides with amines have been well studied.¹²³



Scheme 4.11. Lewis-acid catalyzed amidine formation


In order to probe this possibility, the model imido ester **202** was prepared from glutarimide and the aniline **184**. Upon treatment of the dithioimide **202** with benzyl amine as a generic primary amine nucleophile, the cyclized product **203** was formed as a single diastereomer (relative stereochemistry not determined). Reasoning that removal of the unsaturated ester would prevent the intramolecular trapping of the presumed thiolate anion intermediate, the analogous iodo compound **204** was prepared (eq. 3). However, treatment of **204** with benzyl amine also resulted in the formation of a sulfur containing addition product (**205**). Reaction conditions with mercuric chloride or NBS also failed to produce the desired addition products. Based on these results, this line of research has suspended.



Scheme 4.12. Reactions of the dithioimide model systems


Having been unsuccessful in achieving the synthesis of 166, an alternate retrosynthetic analysis was performed. Disconnection of the *N*-acyl bond of the amidine through an intramolecular *N*-acylation reaction of an *N*-aryl amidine gave **206** (Scheme 4.13). It was envisioned that the amidine could be prepared from a

bimolecular condensation reaction of the aniline **184** and a δ -lactam derivative (**207**). The δ -lactam derivative could then be prepared from the known δ -lactam **208**.¹²⁴



Scheme 4.13. An alternate retrosynthetic analysis of 166

Starting from the known alkenyl lactam **208**, the carboxylic acid **209** was synthesized by oxidative cleavage (Scheme 4.14).¹²⁵ It was envisioned that **166** might be prepared by the treatment of **209** with oxalyl chloride to first give the chloroiminium ion **210** followed by the addition of the aniline **184**. This reaction failed to produce the desired amidine, instead giving adducts of oxalyl chloride. Treatment of **209** with phosphoryl chloride gave only the amido lactam **191**.




Scheme 4.14. Attempts to form the desired amidine from 209

In order to prevent the amide formation previously observed, the carboxylic acid **209** was protected as the ester **211** by methylation with TMSCHN_2 (Scheme 4.15, eq. 1). Subsequent treatment of **211** with phosphoryl chloride followed by addition of the aniline **184** gave no reaction. Treatment of **211** with a variety of other reagents known


to give chloroiminium ions by their reactions with amides also failed to give amidine formation.

In order to activate the carbonyl carbon toward nucleophilic addition, the imidate **211** was prepared (eq. 2). Heating a 1:1 mixture of the imidate **211** and the aniline **184** to reflux in toluene resulted in no reaction. Analogous reaction conditions using AcOH resulted in decomposition. The thiolactam **212** was prepared by treatment of **207** with Lawesson's reagent (L.R.) (eq. 3).¹²⁶ Treatment of the thiolactam **212** with mercuric chloride or NBS in the presence of **184** resulted in decomposition of **212** and no reaction respectively. The corresponding thioimidate **213** was prepared and treated with the aniline **184**. However, its reactions also failed to produce the desired amidine **206** (eq. 4).



Scheme 4.15. Attempted addition of anilines to activated lactams


It was postulated that poor the nucleophilicity of **184** coupled with the steric hindrance provided by the quaternary stereocenter on the lactam, thiolactam, imidate, and thioimidate substrates were responsible for the of the lack of desired reactivity. Dimethylaluminium amides are known to have enhanced nucleophilic character when compared with their amine counterparts.¹²⁷ While dimethylaluminium amides were known to react with esters, there had been no reports on their addition to imidates. However, other amine nucleophiles were known to react with imidates in the presence methyl esters. The dimethylaluminium amide of 2-iodoaniline (**214**) was generated *in situ* by the method reported by Weinreb in 1977 (eq. 5).¹²⁸ Addition of a solution of **214** to the imidate **211** gave only the imidate **199** resulting from the selective addition to the methyl ester. The addition of a solution of **214** to mixture of the thiolactam **212** and mercuric chloride (not shown) gave no reaction.



Scheme 4.16. Retrosynthetic analysis of 166 from Wamhoff's amidine 178

Concluding that the bimolecular amidine formation strategy would be unsuccessful, we again revised our retrosynthetic analysis of **166** (Scheme 4.16). It was envisioned that the *N*-aryl bond could be forged by the coupling of the amidine previously reported by Wamhoff (**178**) and an aryl iodide, such as the known acyrlate **215** using cross coupling conditions.¹²⁹ This strategy required the conversion of the undesired ethyl ester to the required ethyl substituent.

Preliminary investigations of this chemistry are currently under way and are detailed in Scheme 4.17. Attempts to selectively reduce the ester to the alcohol **216** in the presence of the amidine by treatment with diisobutylaluminium hydride or with lithium aluminum hydride have resulted in no reaction (eq. 1). Using **178** as a model substrate, investigations on the reductive alkylation with samarium iodide have been carried out (eq. 2). Using ammonium chloride as the proton source and methyl acrylate or *trans*-methyl cinnamate as the radical acceptor, only starting material was recovered. Using CSA as the proton source in the presence of *tert*-butyl acrylate gave none of the desired addition product **217**, instead yielding the corresponding aminal.



Scheme 4.17. Reactions of Wamhoff's amidine 178

Examining the *N*-arylation reaction, **178** was treated with Ullman coupling conditions using a variety of aryl iodides (eq. 3).¹³⁰ The reactions with 2-iodophenyl methyl acrylate, 2-iodobenzaldehyde, and 2-iodostyrene all resulted in partial decomposition of the starting materials and no coupling products were detected. However, the reaction of iodobenzene gave the coupling product **218** in 35% yield.

4.4 Experimental Section

General Experimental Details:

All reactions were carried out under an inert Ar atmosphere in oven-dried glassware. Flash column chromatography (FCC) was carried out with SiliaFlash P60, 60 Å silica gel. Reactions and column chromatography were monitored with EMD silica gel 60 F254 plates and visualized with potassium permanganate, iodine, ninhydrin, or vanillin stains. Tetrahydrofuran (THF), methylene chloride (DCM), benzene (PhH), and toluene (PhMe) were dried by passage through an activated alumina column. 1,4-dioxanne and 1,2-dichloroethane (1,2-DCE) were dried over calcium hydride and distilled under argon prior to use. *N*,*N*-dimethylfomamide (DMF) was dried over 3 Å molecular sieves prior to use. Methyl acrylate was purified by washing with aqueous NaOH, drying over MgSO₄, and calcium hydride. It was then distilled under vacuum prior to use. *tert*-Butyl acrylate was distilled prior to use. All other reagents and solvents were used without further purification from commercial sources. FT-IR spectra were measured using NaCl plates. Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, br = broad, m = multiplet. Melting points are uncorrected.

methyl (E)-3-(2-(3-ethyl-3-(3-(ethylthio)-3-oxopropyl)-2,6-dioxopiperidin-1yl)phenyl)acrylate (182). To a solution of the known acid 183 (0.1185 g, 0.510 mmol) suspended in 1,2-dichloroethane (1.0 mL, 0.5 M) stirring at room temperature was added thionyl chloride (0.04 mL, 0.55 mmol). The mixture was heated to reflux. After 11 hours, the solvent was removed under vacuum and the resulting anhydride was dissolved in THF. To this solution were added 2-iodoaniline (0.0747 g, 0.422 mmol) and AcOH (0.03 mL, 0.52 mmol). This mixture was heated to reflux. After 8 hours, the mixture was cooled to room temperature and Ac₂O (0.16 mL, 1.70 mmol) and Et_3N (0.26 mL, 1.9 mmol) were added. The mixture was heated to reflux again. After 12.5 hours, the mixture was again cooled to room temperature and ethane thiol (0.12 mL, 1.7 mmol) was added prior to heating to reflux. After an additional 2 hours, the mixture was cooled to room temperature, concentrated, diluted with EtOAc, washed with saturated sodium chloride solution, dried over MgSO₄, filtered, and concentrated. The resulting mixture was purified by flash column chromatography (1:2 EtOAc : hexanes) to give 182 (0.0679g, 0.163 mmol, 39%) as a light yellow oil.

Data for **182**: $R_f 0.35$ (1:1 EtOAc : hexanes); IR (thin film) 2950, 1716, 1668, 1639 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 1:1 mixture of rotational isomers δ 7.70 (d, J = 7.7 Hz, 1 H), 7.45–7.49 (m, 1 H), 7.42–7.44 (m, 1 H), 7.39 (dd, J = 16.1, 4.2 Hz, 1 H), 7.09 (dd, J = 7.0, 1.4 Hz, 0.5 H), 7.02 (dd, J = 7.7, 0.7 Hz, 0.5 H), 6.39 (dd, J = 15.4, 6.3 Hz, 1 H), 3.77 (d, J = 14.0 Hz, 3 H), 2.84–2.98 (m, 4 H), 2.56–2.68 (m, 2 H), 1.96–2.22 (m, 4 H), 1.86–1.92 (m, 0.5 H), 1.75–1.85 (m, 1.5 H), 1.24 (t, J = 7.0 Hz, 3 H), 0.98 (t, J = 7.0 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) as a 1:1 mixture of rotational isomers δ 199.1, 198.9, 176.2, 176.1, 171.89, 171.85, 167.0, 166.8, 138.9, 138.8, 135.44, 135.36, 132.46, 132.42, 131.2, 131.1, 129.7, 129.5, 129.38, 129.36, 127.3, 127.2, 121.0, 120.7, 52.0, 51.9, 45.2, 45.1, 38.7, 30.4, 30.3, 29.32, 29.30, 28.48, 48.45, 25.7, 25.3, 23.6, 23.5, 14.8, 8.13, 8.10; HRMS (TOF MS ES+) calcd for C₂₂H₂₇NO₅NaS [M+Na]: 440.1508, found 440.1492.

methyl (E)-3-(2-(3-ethyl-2,6-dioxo-3-(3-oxopropyl)piperidin-1-yl)phenyl)acrylate (186). To a solution of 182 (0.0369 g, 0.0884 mmol) dissolved in DCM (0.9 mL, 0.1 M) stirring at room temperature were added triethylsilane (0.10 mL, 0.63 mmol) and 10% Pd / C (0.0911 g, 0.086 mmol). The mixture was stirred at room temperature. After 0.5 hours, the reaction mixture was filtered through celite 535 and concentrated. The resulting mixture was purified by flash column chromatography (1:1 EtOAc : hexanes) to give 186 (0.03115 g, 0.087 mmol, 99%) as a colorless oil.

Data for **186**: $R_f 0.37$ (2:1 EtOAc : hexanes); IR (thin film) 295, 1717, 1687 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 1:1 mixture of rotational isomers δ 9.77 (d, J = 14.7 Hz, 1 H), 7.71 (ddd, J = 9.8, 8.4, 1.4 Hz, 1 H), 7.48 (td, J = 7.0, 0.7 Hz, 1 H), 7.43–7.45 (m, 1 H), 7.38 (dd, J = 16.1, 10.5 Hz, 1 H), 7.05 (ddd, J = 26.6, 7.7, 1.4 Hz, 1 H), 6.40 (dd, J = 16.1, 13.3 Hz, 1 H), 3.76 (d, J = 1.4 Hz, 3 H), 2.88–3.00 (m, 2 H), 2.50–2.69 (m, 2 H), 2.08–2.18 (m, 1.5 H), 2.03–2.08 (m, 2 H), 1.89–2.01 (m, 1.5 H), 1.74–1.87 (m, 2 H), 0.97 (q, J = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) as a 1:1

mixture of rotational isomers δ 201.3, 176.3, 171.9, 167.01, 166.95, 138.8, 135.4, 132.3, 132.2, 131.2, 129.6, 129.5, 129.42, 129.40, 127.2, 127.1, 120.71, 120.66, 52.0, 51.9, 44.9, 38.9, 38.7, 29.3, 28.7, 28.4, 27.0, 26.9, 25.9, 25.6, 8.09, 8.05; HRMS (TOF MS ES+) calcd for C₂₀H₂₄NO₅ [M+H]: 358.1654, found 358.1659.

(E)-3-(3-ethyl-1-(2-(3-methoxy-3-oxoprop-1-en-1-yl)phenyl)-2,6-dioxopiperidin-

3-yl)propanoic acid (190). To a suspension of the known tri-acid **183** (3.1230 g, 13.4 mmol) in 1,2-dichloroethane (27 mL, 0.5 M) stirring at room temperature was added thionyl chloride (1.10 mL, 15.1 mmol). The mixture was heated to reflux. After 22 hours, an additional portion of thionyl chloride (0.10 mL, 1.4 mmol) was added. After an additional 2 hours, thionyl chloride (0.10 mL, 1.4 mmol) was added. After an additional 12 hours, the reaction mixture was cooled and concentrated to give a white solid. This material was dissolved in THF (45 mL, 0.25 M) and 2-iodoaniline (1.9890 g, 11.2 mmol) along with AcOH (0.77 mL, 13.5 mmol) were added prior to heating at reflux. After 17 hours, the reaction mixture was cooled to room temperature and Ac₂O (3.2 mL, 33.9 mmol) along with Et₃N (4.7 mL, 33.7 mmol) were added. The mixture was again heated to reflux for one additional hour prior to cooling to room temperature and concentrating the mixture. Purification by flash column chromatography (1:1 hexanes:EtOAc with 2% AcOH) gave **190** (3.9317 g, 10.5 mmol, 94%) as a colorless oil.

Data for **190**: R_f 0.60 (1:2 hexanes:EtOAc); IR (thin film) 3201, 2971, 1715, 1686 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) as a mixture of rotational isomers δ 7.71 (ddd, J = 9.2, 5.6, 2.0 Hz, 1 H), 7.37–7.49 (m,3 H), 7.03 (ddd, J = 12.8, 7.2, 0.8 Hz, 1 H), 6.40 (dd, J = 16.0, 10.0 Hz, 1 H), 3.76 (d, J = 0.4 Hz, 3 H), 2.84–3.03 (m, 2 H), 2.37–2.53 (m, 2 H), 1.93–2.18 (m, 4 H), 1.71–1.91 (m, 2 H), 0.97 (ddd, J = 7.6, 7.6, 0.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) as a mixture of rotational isomers δ 178.4, 177.5, 176.3, 176.1, 172.1, 172.0, 167.6, 167.0, 139.3, 138.9, 135.5, 135.4, 132.42, 132.38, 131.24. 131.15, 129.6, 129.5, 129.4, 127.17, 127.15, 120.7, 120.6, 52.2, 51.9, 45.1,

45.0, 30.0, 29.6, 29.3, 29.2, 29.04, 28.96, 28.7, 28.4, 25.7, 25.5, 8.11, 8.05; HRMS (TOF MS ES+) calcd for C₂₀H₂₃NO₆Na [M+Na]: 396.1423, found 396.1415.

methyl (E)-3-(2-(3-ethyl-3-(3-hydroxypropyl)-2,6-dioxopiperidin-1yl)phenyl)acrylate (189). To a solution of the acid 190 (0.2743 g, 0.735 mmol) dissolved in THF (2.5 mL, 0.3 M) stirring at room temperature was added borane dimethyl sulfide complex (2 M in THF 0.74 mL, 1.48 mmol). After 0.5 hours, the reaction mixture was diluted with EtOAc, washed with saturated aqueous sodium chloride, dried over MgSO₄, filtered, and concentrated. The resulting mixture was purified by flash column chromatography (2:1 EtOAc : hexanes) to give 189 (0.2483g, 0.691 mmol, 94%) as a colorless oil.

Data for **189**: $R_f 0.31$ (4:1 EtOAc : hexanes); IR (thin film) 2951, 1716, 1683 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a 1:1 mixture of rotational isomers δ 7.72 (ddd, J = 7.7, 1.4 Hz, 1 H), 7.39–7.49 (m, 3 H), 7.04 (ddd, J = 7.7, 4.2, 1.4 Hz, 1 H), 6.42 (dd, J = 29.4, 16.1 Hz, 1 H), 3.76 (d, J = 6.3 Hz, 3 H), 3.73 (quintet, J = 5.6 Hz, 0.5 H), 3.62– 3.66 (m, 1 H), 3.58–3.61 (m, 0.5 H), 2.86–3.03 (m, 2 H), 2.00–2.11 (m, 2 H), 1.93– 1.98 (m, 0.5 H), 1.81–1.89 (m, 2.5 H), 1.72–1.77 (m, 1 H), 1.59–1.65 (m, 2 H), 1.52–1.57 (m, 0.5 H), 0.95 (dt, J = 14.7, 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) as a 1:1 mixture of rotational isomers δ 176.9, 176.7, 172.4, 172.2, 167.8, 167.0, 139.6, 138.9, 135.8, 135.5, 132.4, 132.2, 131.4, 131.2, 129.5, 129.33, 129.29, 127.2, 127.0, 120.6, 120.1, 62.8, 62.7, 52.2, 51.9, 45.3, 31.9, 31.2, 29.43, 29.35, 28.6, 28.5, 27.5, 27.1, 25.5, 25.3, 8.3, 8.2; HRMS (TOF MS ES+) calcd for C₂₀H₂₅NO₅Na [M+Na]: 382.1630, found 382.1638.

methyl (*E*)-3-(2-(3-(3-azidopropyl)-3-ethyl-2,6-dioxopiperidin-1yl)phenyl)acrylate (188). To a solution of the alcohol 189 (0.0976 g, 0.272 mmol) dissolved in THF (2.7 mL, 0.1 M) stirring at room temperature were added MsCl (10% in THF, 0.25 mL, 0.32 mmol) and Et₃N (10% in THF, 0.45 mL, 0.32 mmol). After 1.5 h, the solvent was exchanged for DMF (2.7 mL, 0.1 M) and NaN₃ (0.0893 g, 1.37 mmol) was added. After 17 hours, the reaction mixture was diluted with Et_2O and washed three times with saturated aqueous LiCl. The Et_2O solution was then dried over MgSO₄, filtered, and concentrated. The resulting oil was purified by flash column chromatography (7:3 hexanes: EtOAc) to give **188** (0.0906g, 0.236 mmol, 87%) as a colorless oil.

Data for **188**: $R_f 0.85$ (1:4 hexanes:EtOAc); IR (thin film) 2950, 2097, 1717, 1686 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) as a mixture of rotational isomers δ 7.72 (dd, J = 7.7, 1.4 Hz, 1 H), 7.47 (td, J = 7.0, 2.1 Hz, 1 H), 7.43 (td, J = 7.7, 1.4 Hz, 1 H), 7.47 (td, J = 7.0, 2.1 Hz, 1 H), 7.43 (td, J = 7.7, 1.4 Hz, 1 H), 7.38 (d, J = 16.1 Hz, 1 H), 7.04 (dd, J = 7.7, 1.4 Hz, 1 H), 6.41 (d, J = 16.1 Hz, 1 H), 3.77 (s, 3 H), 3.30–3.38 (m, 2 H), 2.87–2.97 (m, 2 H), 2.01–2.10 (m, 2 H), 1.75–1.87 (m, 4 H), 1.57–1.67 (m, 2 H), 0.96 (t, J = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) as a mixture of rotational isomers δ 176.48. 176.45, 172.0, 167.0, 166.9, 138.83, 138.77, 135.5, 135.4, 132.4, 132.3, 131.2, 129.5, 129.38, 129.36, 127.2, 120.7, 120.6, 51.97, 51.91, 51.74, 51.69, 45.34, 45.31, 32.5, 32.2, 29.3, 28.43, 28.40, 25.5, 23.7, 23.6, 8.2; HRMS (TOF MS ES+) calcd for C₂₀H₂₄N₄O₄Na [M+Na]: 407.1695, found 407.1704.

methyl (E)-3-(2-(3-(3-ethyl-2-oxopiperidin-3-yl)propanamido)phenyl)acrylate (191). To a solution of the azide 188 (0.0210 g, 0.0546 mmol) dissolved in THF (0.55 mL, 0.1 M) stirring at room temperature was added triphenyl phosphine (0.0246 g, 0.094 mmol). The mixture was heated to 50 °C. After 3 hours, the reaction mixture was cooled to room temperature and concentrated. The resulting mixture was purified by flash column chromatography (1:49 10% NH₄OH in MeOH : EtOAc) to give 191 (0.0166g, 0.0463 mmol, 85%) as a white solid.

Data for **191**: $R_f 0.50$ (9:1 EtOAc : 10% NH₄OH in MeOH); mp = 150–151 °C; IR (thin film) 2925, 1717, 1683 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.44 (br s, 1 H), 7.96 (d, *J* = 16.1 Hz, 1 H), 7.74 (d, *J* = 7.7 Hz, 1 H), 7.56 (d, *J* = 7.7 Hz, 1 H), 7.37 (t,

J = 7.0 Hz, 1 H), 7.16 (t, J = 7.7 Hz, 1 H), 6.58 (br s, 1 H), 6.40 (d, J = 16.1 Hz, 1 H), 3.79 (s, 3 H), 3.32 (t, J = 3.5 Hz, 2 H), 2.68 (quintet, J = 7.7 Hz, 1 H), 2.43 (quintet, J = 7.7 Hz, 1 H), 2.04 (quintet, J = 7.0 Hz, 1 H), 1.96 (quintet, J = 7.7 Hz, 1 H), 1.77– 1.84 (m, 4 H), 1.59–1.67 (m, 2 H), 0.90 (t, J = 7.0 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 177.6, 172.8, 167.9, 140.5, 136.7, 130.9, 127.2, 127.0, 125.4, 125.1, 119.5, 52.0, 44.8, 42.9, 33.6, 33.3, 30.5, 29.8, 19.5, 8.4; HRMS (TOF MS ES+) calcd for C₂₀H₂₆N₂O₄Na [M+Na]: 381.1790, found 381.1787.

methyl (E)-3-(2-(3-(3-ethyl-2-methoxy-3,4,5,6-tetrahydropyridin-3yl)propanamido)phenyl)acrylate (197). To a solution of 191 (0.0500 g, .140 mmol) dissolved in DCM (1.4 mL, 0.1 M) were added Cs_2CO_3 (0.1346 g, 0.419 mmol) and Me_3OBF_4 (0.0325 g, 0.220 mmol). The mixture was stirred at room temperature. After 80 minutes, the reaction mixture was diluted with DCM, washed with saturated aqueous NaHCO₃, dried over MgSO₄, filtered, and concentrated. The resulting mixture was purified by flash column chromatography (1:1 hexanes: EtOAc) to give 197 (0.0422 g, 0.113 mmol, 81%) as a colorless oil.

Data for **197**: $R_f 0.33$ (1:2 hexanes : EtOAc); IR (thin film) 2943, 1717, 1667cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 15.6 Hz, 1 H), 7.65–7.71 (m, 1 H), 7.51 (d, J = 7.6 Hz, 1 H), 7.35 (t, J = 7.6 Hz, 1 H), 7.16 (t, J = 7.2 Hz, 1 H), 6.36 (d, J = 15.6 Hz, 1 H), 3.77 (s, 3 H), 3.57 (br s, 3 H), 3.43 (br s, 2 H), 2.36–2.46 (m, 1 H), 2.24–2.34 (m, 1 H), 1.94–2.05 (m, 1 H), 1.81–1.91 (m, 1 H), 1.64–1.72 (m, 2 H), 1.51–1.63 (m, 3 H), 1.47–1.42 (m, 1 H), 0.82 (t, J = 7.2 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 167.3, 166.2, 139.8, 136.1, 130.9, 127.6, 127.2, 125.8, 125.3, 120.1, 52.1, 51.9, 47.3, 41.3, 34.1, 33.0, 31.4, 29.9, 20.7, 8.8; HRMS (TOF MS ES+) calcd for C₂₁H₂₉N₂O₄ [M+H]: 373.2127, found 373.2145.

3-(3-ethyl-2-oxopiperidin-3-yl)-N-(2-iodophenyl)propanamide (198). To a solution of the acid **209** (0.2102 g, 1.06 mmol) dissolved in THF (2.1 mL, 0.5 M) stirring at

room temperature were added freshly chromatographed 2-iodoaniline (0.4670 g, 2.13 mmol) and POCl₃ (0.1 mL, 1.07 mmol). The mixture was heated to 60 °C. After 0.5 hours, the reaction mixture was cooled to room temperature and concentrated. The solids were extracted with chloroform and the combined organic extracts were washed with saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride, dried over MgSO₄, filtered, and concentrated. The resulting oil was purified by flash column chromatography (1:4 hexanes: EtOAc) to give **198** (0.2964g, 0.741 mmol, 70%) as a white solid.

Data for **198**: $R_f 0.37$ (EtOAc); mp = 125–126 °C; IR (thin film) 2962, 1644 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.16 (d, J = 7.7 Hz, 1 H), 7.77 (dd, J = 8.4, 1.4 Hz, 1 H), 7.56 (br s, 1 H), 7.32 (td, J = 8.4, 0.7 Hz, 1 H), 6.83 (td, J = 7.7, 1.4 Hz, 1 H), 5.72 (br s, 1 H), 3.31 (td, J = 3.5, 2.1 Hz, 2 H), 2.52–2.57 (m, 1 H), 2.47–2.51 (m, 1 H), 2.06 (ddd, J = 14.0, 11.2, 5.6 Hz, 1 H), 1.99 (ddd, J = 14.0, 10.5, 5.6 Hz, 1 H), 1.82–1.87 (m, 2 H), 1.78–1.82 (m, 2 H), 1.66–1.70 (m, 1 H), 1.61 (sextet, J = 7.7 Hz, 1 H), 0.92 (t, J = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 176.6, 171.6, 139.0, 138.5, 129.3, 126.0, 122.5, 90.3, 44.5, 42.9, 33.5, 33.2, 30.5, 29.8, 19.5, 8.5; HRMS (TOF MS ES+) calcd for C₁₆H₂₂N₂O₂I [M+H]: 401.0726, found 401.0739.

3-(3-ethyl-2-methoxy-3,4,5,6-tetrahydropyridin-3-yl)-N-(2-

iodophenyl)propanamide (199). To a solution of the lactam **198** (0.0296 g, 0.0740 mmol) dissolved in DCM (0.75 mL, 0.1 M) stirring at room temperature were added Cs_2CO_3 (0.0741 g, 0.227 mmol) and Me_3OBF_4 (0.0170g, 0.115 mmol). After 2 hours, the reaction mixture was diluted with DCM and washed with saturated aqueous sodium bicarbonate. The DCM solution was then dried over MgSO₄, filtered, and concentrated. The resulting solids were purified by flash column chromatography (1:1 hexanes: EtOAc) to give **199** (0.0266g, 0.0642 mmol, 87%) as a white solid.

Data for **199**: $R_f 0.67$ (9:1 EtOAc : 10% NH₄OH in MeOH); mp = 74–76 °C; IR (thin film) 2938, 1668, 1519 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.21 (d, *J* = 7.7 Hz, 1 H), 7.77 (d, *J* = 7.7 Hz, 1 H), 7.42 (br s, 1 H), 7.33 (td, *J* = 8.4, 1.4 Hz, 1 H), 6.83 (t, *J* = 7.7 Hz, 1 H), 3.61 (s, 3 H), 3.47 (t, *J* = 5.6 Hz, 2 H), 2.43 (td, *J* = 15.4, 5.6 Hz, 1 H), 2.29 (ddd, *J* = 15.4, 11.9, 4.9 Hz, 1 H), 2.03 (ddd, *J* = 13.3, 11.9, 4.9 Hz, 1 H), 1.89 (ddd, *J* = 13.3, 11.2, 4.9 Hz, 1 H), 1.68–1.75 (m, 2 H), 1.54–1.66 (m, 3 H), 1.49 (sextet, *J* = 7.0 Hz, 1 H), 0.85 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 171.3, 165.9, 138.9, 138.3, 129.4, 126.0, 122.0, 90.0, 52.2, 47.5, 41.3, 34.2, 33.9, 31.4, 30.0, 20.8, 8.9; HRMS (TOF MS ES+) calcd for C₁₇H₂₄N₂O₂I [M+H]: 415.0883, found 415.0894.

methyl (E)-3-(2-(2,6-dioxopiperidin-1-yl)phenyl)acrylate (S19). To a solution of 2aminophenyl methylcinamate **184** (0.9930 g, 5.77 mmol) dissolved in THF (19 mL, 0.3 M) were added AcOH (0.07 mL, 1.22 mmol) and glutaric anhydride (0.9838 g, 8.62 mmol). The mixture was heated to reflux. After 20 hours, the reaction mixture was cooled to room temperature and Ac₂O (1.1 mL, 11.7 mmol) and Et₃N (2.4 mL, 17.2 mmol) were added. The mixture was heated to reflux again for an additional 20 minutes. After cooling, the reaction was dilluted with EtOAc, washed with saturated aqueous sodium chloride, dried over MgSO₄, filtered, and concentrated. The resulting mixture was purified by flash column chromatography (1:1 hexanes: EtOAc) to give **S19** (1.3983 g, 5.12 mmol, 89%) as a white solid.

Data for **S19**: $R_f 0.47$ (3:1 hexanes : EtOAc); mp = 125–126.5 °C; IR (thin film) 2952, 1715, 1689 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (dd, *J* = 7.6, 1.6 Hz, 1 H), 7.40–7.50 (m, 3 H), 7.09 (dd, *J* = 8.0, 1.6 Hz, 1 H), 6.41 (d, *J* = 16.0 Hz, 1 H), 3.77 (s, 3 H), 2.94–2.78 (m, 4 H), 2.10–2.22 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 167.1, 138.9, 134.9, 132.5, 131.1, 129.6, 129.5, 127.4, 120.8; HRMS (TOF MS ES+) calcd for C₁₅H₁₆NO₄ [M+H]: 274.1079, found 274.1082.

methyl (E)-3-(2-(2,6-dithioxopiperidin-1-yl)phenyl)acrylate (202). To a solution of the imide S19 (0.4122 g, 1.51 mmol) dissolved in toluene (5 mL, 0.3 M) stirring at room temperature was added Laweson's reagent (0.6730 g, 1.66 mmol). The mixture was heated to reflux. After 3 hours, the reaction mixture was cooled to room temperature and concentrated. The resulting mixutre was purified by flash column chromatography (9:1 hexanes: EtOAc) to give 202 (0.4165 g, 1.36 mmol, 90%) as a bright red solid.

Data for **202**: $R_f 0.27$ (3:1 hexanes : EtOAc); mp = 108–110 °C; IR (thin film) 2949, 1715, 1637 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (dd, J = 7.2, 1.6 Hz, 1 H), 7.41–7.49 (,m 2 H), 7.34 (d, J = 16.0 Hz, 1 H), 7.04 (dd, J = 8.0, 1.6 Hz, 1 H), 3.77 (s, 3 H), 3.46 (qdd, J = 18.0, 6.8, 5.2 4 H), 2.09–2.21 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 206.6, 167.1, 144.0, 138.6, 131.6, 131.3, 129.2, 129.1, 127.5, 120.9, 52.0, 44.9, 19.8; HRMS (TOF MS ES+) calcd for C₁₁H₁₁NS₂I [M+H]: 347.9378, found 347.9390.

methyl2-(4a-(benzylamino)-1-thioxo-2,3,4,4a-tetrahydro-1H,6H-benzo[d]pyrido[2,1-b][1,3]thiazin-6-yl)acetate (203). To a solution of 202 (0.0491g, .161 mmol) dissolved in THF (0.5 mL, 0.3 M) was added BnNH2 (0.04 mL, 0.37mmol). The mixture was stirred at room temperature. After 25 minutes, the reactionmixture was concentrated. The resulting mixture was purified by flash columnchromatography (2:1 hexanes: EtOAc) to give 203 (0.0608 g, 0.147 mmol, 92%) as ayellow solid.

Data for **203**: $R_f 0.11$ (3:1 hexanes : EtOAc); mp = 96.5–98.5 °C; IR (thin film) 3318, 3206, 2948, 1737 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 9.34 (br s, 1 H), 7.34–7.42 (m, 5 H), 7.22 (td, J = 7.0, 1.4 Hz, 1 H), 7.18 (td, J = 7.7, 1.4 Hz, 1 H), 7.10 (dd, J = 7.7, 1.4 Hz, 1 H), 6.61 (d, J = 7.7 Hz, 1 H), 4.84 (qd, J = 14.7, 4.9 Hz, 2 H), 4.43 (dd, J = 9.1, 7.0 Hz, 1 H), 3.64 (s, 3 H), 2.88–2.91 (m, 1 H), 2.81–2.85 (m, 1 H), 2.70 (ddd, J

= 14.7, 10.5, 4.9 Hz, 1 H), 2.54–2.60 (m, 3 H), 2.28–2.35 (m, 1 H), 2.13–2.19 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃) δ 203.9, 170.3, 164.3, 141.4, 136.4, 129.0, 128.9, 128.3, 128.1, 126.9, 126.8, 121.3, 52.2, 50.9, 44.4, 43.0, 38.9, 38.2, 27.6; HRMS (TOF MS ES+) calcd for C₂₂H₂₅N₂O₂S₂ [M+H]: 413.1357, found 413.1345.

1-(2-iodophenyl)piperidine-2,6-dione (S20). To a solution of 2-aminophenyl methylcinamate 184 (0.9930 g, 5.77 mmol) dissolved in THF (19 mL, 0.3 M) were added AcOH (0.07 mL, 1.22 mmol) and glutaric anhydride (0.9838 g, 8.62 mmol). The mixture was heated to reflux. After 20 hours, the reaction mixture was cooled to room temperature and Ac₂O (1.1 mL, 11.7 mmol) and Et₃N (2.4 mL, 17.2 mmol) were added. The mixture was heated to reflux again for an additional 20 minutes. After cooling, the reaction was dilluted with EtOAc, washed with saturated aqueous sodium chloride, dried over MgSO₄, filtered, and concentrated. The resulting mixture was purified by flash column chromatography (1:1 hexanes: EtOAc) to give S20 (1.3983 g, 5.12 mmol, 89%) as a white solid.

Data for **S20**: $R_f 0.41$ (1:1 hexanes : EtOAc); mp = 134–135 °C; IR (thin film) 1727, 1683 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (dd, J = 11.6, 1.6 Hz, 1 H), 7.44 (td, J = 8.0, 1.6 Hz, 1 H), 7.10–7.16 (m, 2 H), 2.73–2.91 (m, 4 H), 2.17–2.27 (m, 1 H), 2.04–2.14 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.8, 139.7, 138.5, 130.4, 129.7, 129.5, 99.1, 33.2, 17.2; HRMS (TOF MS ES+) calcd for C₁₁H₁₁NO₂I [M+H]: 315.9835, found 315.9836.

1-(2-iodophenyl)piperidine-2,6-dithione (204). To a solution of the imide **S20** (0.3203 g, 1.02 mmol) dissolved in toluene (3.4 mL, 0.3 M) stirring at room temperature was added Laweson's reagent (0.4574 g, 1.13 mmol). The mixture was heated to reflux. After 3.5 hours, the reaction mixture was cooled to room temperature and concentrated. The resulting mixture was purified by flash column

chromatography (9:1 hexanes: EtOAc) to give **204** (0.2638 g, 0.760 mmol, 75%) as a bright red solid.

Data for **204**: $R_f 0.41$ (6:1 hexanes : EtOAc); mp = 150–151 °C; IR (thin film) 2929, 1268, 1260, 1146 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.88 (dd, J = 8.4, 1.4 Hz, 1 H), 7.44 (td, J = 7.7, 0.7 Hz, 1 H), 7.14 (dd, J = 7.7, 1.4 Hz, 1 H), 7.09 (ddd, J = 8.4, 7.7, 2.1 Hz, 1 H), 3.44 (qq, J = 18.2, 4.2 Hz, 4 H), 2.16–2.21 (m, 1 H), 2.06–2.11 (m, 1 H); ¹³C NMR (176 MHz, CDCl₃) δ 205.4, 146.5, 140.0, 129.7, 129.6, 129.5, 98.2, 44.8, 19.5; HRMS (TOF MS ES+) calcd for C₁₁H₁₁NS₂I [M+H]: 347.9378, found 347.9390.

6-(benzylamino)-1-(2-iodophenyl)-6-mercaptopiperidine-2-thione (205). To a solution of 204 (0.0498 g, .143 mmol) dissolved in THF (0.7 mL, 0.2 M) was added benzylamine (0.02 mL, 0.183 mmol). The mixture was stirred at room temperature. After 22 hours, the reaction mixture was concentrated. The resulting mixture was purified by flash column chromatography (3:1 hexanes : EtOAc) to give 205 (0.0565 g, 0.134 mmol, 94%) as a colorless oil.

Data for **205**: $R_f 0.14$ (3:1 hexanes : EtOAc); IR (thin film) 3204, 2970, 1521, 1390cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.99 (br s, 1 H), 7.93 (dd, J = 7.7, 1.4 Hz, 2 H), 7.89 (dd, J = 7.7, 0.7 Hz, 1 H), 7.40 (td, J = 7.0, 0.7 Hz, 1 H), 7.31–7.36 (m, 5 H), 7.03 (td, J = 7.7, 0.7 Hz, 1 H), 4.85 (d, J = 4.9 Hz, 2 H), 3.01 (t, J = 7.0 Hz, 2 H), 2.92 (t, J = 7.0 Hz, 2 H), 2.42 (quin., J = 7.0 Hz, 2 H); ¹³C NMR (176 MHz, CDCl₃) δ 205.0, 204.2, 139.8, 139.5, 136.1, 129.2, 129.1, 128.9, 128.6, 128.3, 127.6, 95.5, 50.6, 45.8, 44.3, 28.6; HRMS (TOF MS ES+) calcd for C₁₈H₂₀N₂S₂I [M+H]:455.0113, found 455.0134.

3-(3-ethyl-2-oxopiperidin-3-yl)propanoic acid (209). To a solution of the known lactam **208** (0.5461 g, 3.01 mmol) dissolved in 1,4-dioxane (10 mL, 0.3 M) and water (10 mL, 0.3 M) stirring at room temperature were added NaIO₄ (2.5785 g, 0.12.1 mmol) and RuCl₃•H₂O (0.0311g, 0.150 mmol). After 6 hours, the reaction mixture was concentrated. The resulting solids were extracted with EtOAc, filtered through celite 535, and concentrated. The resulting oil was purified by flash column chromatography (1:20:79 AcOH : hexanes: EtOAc) to give **209** (0.4406g, 2.21 mmol, 73%) as a lightly colored oil which produced colorless crystals upon standing.

Data for **209**: $R_f 0.37$ (49:1 EtOAc : AcOH); mp = 124–125 °C; IR (thin film) 2944, 1697, 1626 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 12.76 (br s, 1 H), 7.75 (br s, 1 H), 3.23–3.31 (m, 2 H), 2.44 (ddd, J = 16.1, 8.4, 7.0 Hz, 1 H), 2.34 (ddd, J = 14.7, 7.7, 6.3 Hz, 1 H), 1.93 (ddd, J = 14.0, 7.7, 7.0 Hz, 1 H), 1.82–1.88 (m, 2 H), 1.72–1.80 (m, 3 H), 1.63 (ddd, J = 14.0, 8.4, 4.2 Hz, 1 H), 1.51 (sextet, J = 7.0 Hz, 1 H), 0.87 (t, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 178.4, 178.3, 43.7, 24.5, 32.4, 30.8, 30.1, 29.4, 19.5, 8.5; HRMS (TOF MS ES+) calcd for C₁₀H₁₇NO₃Na [M+Na]: 222.1106, found 222.1116.

methyl 3-(3-ethyl-2-oxopiperidin-3-yl)propanoate (207). To a solution of the carboxylic acid **209** (0.7505 g, 3.77 mmol) dissolved in PhH (7.5 mL, 0.5 M) and MeOH (3.8 mL, 1M) stirring at room temperature was added TMSCHN₂ (2M in hexanes, 2.8 mL, 5.6 mmol). After 10 minutes, the reaction was quenched by addition of glacial acetic acid until the yellow color was no longer visible. The reaction mixture was then concentrated. Purification by flash column chromatography (1:2 hexanes : EtOAc) gave **207** (0.7141g, 3.35 mmol, 89%) as a white solid.

Data for **207**: $R_f 0.31$ (EtOAc); mp = 48–50 °C; IR (thin film) 2950, 1737, 1655 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 6.11 (br s, 1 H), 3.64 (s, 3 H), 3.25 (td, *J* = 6.3, 2.8 Hz, 2 H), 2.40 (ddd, *J* = 21.0, 10.5, 4.9 Hz, 1 H), 2.34 (ddd, *J* = 16.1, 11.2, 5.6 Hz, 1 H), 1.92 (ddd, J = 14.0, 11.2, 5.6 Hz, 1 H), 1.84 (ddd, J = 14.0, 11.2, 5.6 Hz, 1 H), 1.77– 1.81 (m, 2 H), 1.70–1.75 (m, 2 H), 1.59 (ddd, J = 11.9, 7.7, 4.9 Hz, 1 H), 1.51 (sextet, J = 7.7 Hz, 1 H), 0.87 (t, J = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 176.5, 174.4, 51.7, 44.1, 42.7, 32.8, 30.5, 29.7, 29.5, 19.7, 8.5; HRMS (TOF MS ES+) calcd for C₁₁H₁₉NO₃Na [M+Na]: 236.1263, found 236.1272.

methyl 3-(3-ethyl-2-methoxy-3,4,5,6-tetrahydropyridin-3-yl)propanoate (211). To a solution of the lactam **207** (0.106 g, 0.498 mmol) dissolved in DCM (1.7 mL, 0.3 M) stirring at room temperature were added NaHCO₃ (0.252 g, 3.00 mmol) and Me₃OBF₄ (0.222g, 1.50 mmol). After 70 minutes, the reaction mixture was diluted with DCM and washed with saturated aqueous sodium chloride. The DCM solution was then dried over MgSO₄, filtered, and concentrated to give **211** (0.1132g, 0.498 mmol, 99%) as a colorless oil.

Data for **211**: $R_f 0.52$ (2:3 EtOAc : hexanes); IR (thin film) 2942, 2860, 1739, 1671 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 3.65 (s, 3 H), 3.55 (s, 3 H), 3.42 (t, *J*= 5.6 Hz, 2 H), 2.32 (ddd, *J* = 16.1, 11.9, 4.9 Hz, 1 H), 2.20 (ddd, *J* = 16.1, 11.9, 4.9 Hz, 1 H), 1.89 (td, *J* = 12.6, 4.9 Hz, 1 H), 1.74 (td, *J* = 12.6, 5.6 Hz, 1 H), 1.63–1.69 (m, 2 H), 1.54–1.61 (m, 2 H), 1.47–1.52 (m, 1 H), 1.41 (sextet, *J* = 7.0 Hz, 1 H), 0.81 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 174.3, 165.9, 52.0, 51.7, 47.4, 41.1, 33.6, 31.2, 29.99, 29.95, 20.8, 8.9; HRMS (TOF MS ES+) calcd for C₁₂H₂₂NO₃ [M+H]: 228.1600, found 228.1596.

methyl 3-(3-ethyl-2-thioxopiperidin-3-yl)propanoate (212). To a solution of the lactam **207** (0.4291 g, 2.01 mmol) dissolved in PhMe (6.7 mL, 0.3 M) stirring at room temperature was added Laweson's reagent (0.9018 g, 2.23 mmol). The mixture was heated to reflux. After 2 hours, the reaction mixture was cooled to room temperature and concentrated. Purification by flash column chromatography (3:1 hexanes : EtOAc) gave **212** (0.4394g, 1.92 mmol, 95%) as a white solid.


Data for **212**: $R_f 0.56$ (2:3 EtOAc : hexanes); mp = 85–87 °C; IR (thin film) 2952, 1735 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 8.67 (br s, 1 H), 3.66 (s, 3 H), 3.29 (ddd, J = 5.6, 5.6, 2.8 Hz, 2 H), 2.47 (ddd, J = 15.4, 11.2, 4.9 Hz, 1 H), 2.36 (ddd, J = 15.4, 11.9, 4.9 Hz, 1 H), 2.28 (ddd, J = 13.3, 11.9, 5.6 Hz, 1 H), 1.91–1.98 (m, 2 H), 1.81–1.89 (m, 2 H), 1.77 (ddd, J = 11.9, 7.0, 4.2 Hz, 1 H), 1.73 (sextet, J = 7.7 Hz, 1 H), 1.63 (ddd, J = 14.7, 8.4, 3.5 Hz, 1 H), 0.91 (t, J = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 210.5, 174.2, 51.8, 48.2, 45.4, 36.4, 35.0, 29.8, 27.6, 19.4, 8.7; HRMS (TOF MS ES+) calcd for C₁₁H₂₀NO₂S [M+H]: 230.1215, found 230.1207.


methyl 3-(3-ethyl-2-(methylthio)-3,4,5,6-tetrahydropyridin-3-yl)propanoate (213). To a solution of the thiolactam 212 (0.0486 g, 0.212 mmol) dissolved in DCM (0.7 mL, 0.3 M) stirring at room temperature were added NaHCO₃ (0.0361 g, 0.430 mmol) and MeI (0.13mL, 2.09 mmol). After 4.5 hours, the reaction mixture was diluted with DCM and washed with saturated aqueous sodium bicarbonate. The DCM solution was then dried over MgSO₄, filtered, and concentrated to give 213 (0.0485g, 0.200 mmol, 94%) as a colorless oil.


Data for **213**: $R_f 0.44$ (1:3 EtOAc : hexanes); IR (thin film) 2933, 1739, 1618 cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 3.66 (s, 3 H), 3.58 (qt, *J*= 16.8, 6.3 Hz, 2 H), 2.28–2.36 (m, 2 H), 2.20 (s, 3 H), 1.98 (ddd, *J* = 14.0, 11.2, 6.3 Hz, 1 H), 1.67–1.79 (m, 3 H), 1.48–1.62 (m, 4 H), 0.86 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 174.2, 172.1, 51.8, 50.9, 44.4, 35.2, 33.4, 29.7, 29.1, 20.6, 12.1, 8.8; HRMS (TOF MS ES+) calcd for C₁₂H₂₂NO₂S [M+H]: 244.1371, found 244.1360.


ethyl 2-oxo-1-phenyl-1,3,4,5,6,7-hexahydro-1,8-naphthyridine-4a(2H)carboxylate (218). To a solution of 178 (0.0309 g, .138 mmol), Cs_2CO_3 (0.0980 g, 301 mmol), 1,10-phenanthroline (0.0110 g, 0.056 mmol), and CuI (0.0055 g, 0.029 mmol) dissolved in dry, degassed 1,4-dioxane (0.6 mL, 0.25 M) was added iodobenzene (0.04 mL, 0.36 mmol). The mixture was sealed in a bomb and heated to 100 °C. After 24 hours, the reaction mixture was diluted with $CHCl_3$, filtered through celite 353, and concentrated. The resulting mixture was purified by preparative TLC (1:9 10% NH₄OH in MeOH: EtOAc) to give **218** (0.0144 g, 0.048 mmol, 35%) as a colorless oil.


Data for **218**: $R_f 0.30$ (1:9 10% NH₄OH in MeOH : EtOAc); IR (thin film) 2958, 1730, 1661, 1521cm⁻¹; ¹H NMR (700 MHz, CDCl₃) δ 7.40 (t, J = 7.7 Hz, 2 H), 7.26–7.29 (m, 1 H), 7.21 (d, J = 7.7 Hz, 2 H), 4.24–4.33 (m, 2 H), 3.73–3.77 (m, 1 H), 3.65–3.68 (m, 1 H), 2.53–2.57 (m, 1 H), 2.44–2.47 (m, 1 H), 2.35–2.40 (m, 2 H), 1.95–2.03 (m, 2 H), 1.86–1.94 (m, 2 H), 1.82 (td, J = 12.6, 4.9 Hz, 1 H), 1.32 (t, J = 7.0 Hz, 3 H); ¹³C NMR (176 MHz, CDCl₃) δ 180.6, 171.9, 170.0, 143.9, 129.7, 127.7, 126.3, 62.5, 52.0, 47.4, 32.2, 31.6, 30.6, 19.9, 14.3, ; HRMS (TOF MS ES+) calcd for C₁₇H₂₁N₂O₃ [M+H]: 301.1552, found 301.1561.
































DAS







DAS70541


294


































J

























.



































104 Abe, F.; Yamauchi, T. Phytochemistry 1994, 35, 169–171.

105 Gan, C. Y.; Low, Y. Y.; Thomas, N. F.; Kam, T. S. J. Nat. Prod. 2013, 76, 957–964.

106 (a) Xu, Z.; Wang, Q.; Zhu, J. J. Am. Chem. Soc. **2013**, 135, 19127–19130. (b) Umehara, A.; Ueda, H.; Tokuyama, H. Org. Lett. **2014**, 16, 2526–2529.

107 Marinescu, S. C.; Nishimata, T.; Mohr, J. T.; Stoltz, B. M. Org. Lett. 2008, 10, 1039–1042.

108 (a) Behenna, D. C.; Mohr, J. T.; Sherden, N. H.; Marinescu, S. C.; Harned, A. M.; Tani, K.; Seto, M.; Ma, S.; Novák, Z.; Krout, M. R.; McFadden, R. M.; Roizen, J. L.; Enquist, J. A., Jr.; White, D. E.; Levine, S. R.; Petrova, K. V.; Iwashita, A.; Virgil, S. C.; Stoltz, B. M. *Chem. Eur. J.* **2011**, *17*, 14199–14223. (b) Hong, A. Y.; Stoltz, B. M. *Eur. J. Org. Chem.* **2013**, 2745–2759.

109 Tokuyama, H.; Kaburagi, Y.; Chen, X.; Fukuyama, T. Synthesis 2000, 424–434.

110 Dwroniczak, M.; Leffek, K. T. Can. J. Chem. 1990, 68, 1657-1661.

111 Smissman, E. E.; Ayres, J. W. J. Org. Chem. 1972, 37, 1092–1094.

112 (a) Wamhoff, H.; Lichtenthaler, L. *Chem. Ber.* **1978**, *111*, 2813–2824. (b) Wamhoff, H.; Lichtenthaler, L. *Synthesis* **1975**, *7*, 426–427.

113 Michael, J. P.; De Koning, C. B.; Van der Westhuyzen, C. W.; Fernandes, M. A. J. Chem. Soc. Perkin Trans 1 2001, 17, 2055–2062.

114 Fukuyama, T.; Lin, S.-C.; Li, L. J. Am. Chem. Soc. 1990, 112, 7050-7051.

115 (a) Bruson, H. A.; Riener, T. W. J. Am. Chem. Soc. **1943**, 65, 23–25. (b) Park, S. B.; Alper, H. Org. Lett. **2003**, *5*, 3209–3212.

116 Waldvogel, S. R.; Pfleiderer, W. Helv. Chim. Acta 1998, 81, 46-58.

117 Dubé, D.; Scholte, A. A. Tetrahedron Lett. 1999, 40, 2295-2298.

118 for a review, see Palacios, F.; Alonson, C.; Aparicio, D.; Rubiales, G.; de los Santos, J. M. *Tetrahedron* **2007**, *63*, 523–575.

119 for examples, see (a) Cao, L.; Maciejewski, J. P.; Elzner, S.; Amantini, D.; Wipf, P. *Org. Biomol. Chem.* **2012**, *10*, 5811–5814. (b) Takeuchi, H.; Eguchi, S. *J. Chem. Soc., Chem. Commun.* **1989**, 602–603. (c) Okawa, T.; Sugimori, T.; Eguchi, S.; Kakehi, A. *Heterocycles* **1998**, *47*, 375–382.

120 (a) Wang, J.; He, Z.; Chen, X.; Song, W.; Ping, L.; Wang. Y. *Tetrahedron* **2010**, *66*, 1208–1214. (b) Charaette, A. B.; Grenon, M. *Tetrahedron Lett.* **2000**, *41*, 1677–1680.

121 Ponda, T.; Lazar, S.; Coudert, G.; Guillaumet, G. Tetrahedron 1993, 49, 4619–4626.

122 Zhou, J.; Magomedov, N. A. J. Org. Chem. 2007, 72, 3808-3815.

123 for examples of reactions of thiolactams with amines see (a) Kato, E.; Kumagai, T.; Ueda, M.; *Tetrahedron Lett.* **2005**, *46*, 4865–4869. (b) Pozo-Rodrigalvarez, A.; Gradillas, A.; Serrano, J.; Fernandez, A. P.; Martinez-Murillo, R.; Perez-Castells, J. *Eur. J. Med. Chem.* **2012**, *54*, 439–446. (c) Williams, S. J.; Hoos, R.; Withers, S. G. J. Am. Chem. Soc. **2000**, *122*, 2223–2235. for examples of dithioimides with amines see (d) Scherbakow, S.; Namyslo, J. C.; Gjikaj, M.; Schmidt, A. *Synlett* **2009**, *12*, 1964–1968. (e) Baguley, M. E.; Elvidge, J. A. *J. Chem. Soc.* **1957**, 709–719. (f) El-Sharief, A. M. Sh.; Zaher, M. R.; Hammad, N. I. *Indian J. of Chem., Sect. B: Org. Chem. Incl. Med. Chem.* **1981**, *20*,751–754.

124 Padwa, A.; Harring, S. R.; Semones, M. A. J. Org. Chem. 1998, 63, 44-54.

125 Fan, G.-T.; Lee, C.-C.; Lin, C.-C.; Fang, J.-M.; J. Org. Chem. 2002, 67, 7565–7568.

126 for a review of Laweson's reagent see Jesberger, M.; Davis, T. P. Synthesis, 2003, 13, 1929–1958.

127 Weinreb, S. M.; Anderson, G. T.; Nylund, C. S. Dimethylaluminium Amide *Encyclopedia of Reagents for Organic Syntheiss*. [Online] April 15, 2001, DOI: 10.1002/047084289X.rd296m (accessed Nov. 15th, 2014).

128 Basha, A.; Lipton, M.; Weinreb, S. M. Tetrahedron Lett. 1977, 48, 4171-4172.

129 Grigg, R.; Santhakumar, V.; Sridharan, V.; Stevenson, P.; Teasdale, A.; Thornton-Pett, M.; Worakun, T. *Tetrahedron* **1991**, *47*, 9703–9720.

130 For a review on the Ullman coupling see Sambiagio, C.; Marsden, S. P.; Blacker, J. A.; McGowan, P. C. *Chem. Soc. Rev.* **2014**, *43*, 3525–3550.

Chapter 5: Conclusion and Future Direction

5.1 Conclusion

The advancement of medicine relies greatly on the ability to efficiently construct new molecules for screening and derivatization. Because many biologically active molecules contain one or more nitrogen atoms, the development of new methods for their synthesis is an important endeavor. However, the complex reactivity of nitrogen can be problematic in synthesis. The ability to quaternize, the Lewis basic lone pair, and the weakly acidic N–H protons found in nitrogen-containing molecules often give rise to undesired reactivity.

As a means to mute the reactivity of nitrogen, synthetic chemists often employ protective groups. Other strategies which have proven successful for the synthesis of nitrogen-containing structures include opting to install nitrogen late in the synthesis or in the form of a less reactive functional group.

Free radical reactivity avoids the complications inherent in the synthesis of nitrogenrich molecules. Radicals are known to tolerate heteroatom lone pairs, and N–H bonds are resistive to homolytic cleavage. Free radical reactivity has proven useful for the synthesis of heterocycles and alkaloid natural products. This reactivity also allows for the strategic disconnection of bonds which would be difficult to form using standard cationic or anionic reaction conditions. For these reasons, free radical based methods are ideally suited to the synthesis of nitrogen containing molecules.

Despite the presence of the aminal functional group in several nitrogen-rich natural products which had attracted the attention of the synthetic community, very little

attention had been given to the development of reactions specific to the aminal. Although there were reports of fragmentation, protonation, and dimerization reactions of aminal radicals, there had been no reports of their synthetic utility prior to the work described in this dissertation. The goal of this work was to develop the reactivity of the aminal radical intermediate as a new tool for the construction of C–C bonds in the context of nitrogen-rich molecular architectures.

As detailed in the first chapter of this dissertation, preliminary investigations centered on the generation of aminal radicals under peroxide initiated conditions similar to those previously reported for the generation of α -amino radicals. The treatment of aminal containing molecules with di-*tert*-butyl peroxide in the presence of a radical acceptor produced either a complex mixture of products, or no reaction. Unable to determine if aminal radicals were being generated, a new method was sought.

Treatment of 2-iodobenzyl substituted aminals with AIBN and a hydrogen atom donor in the presence of an electron-poor alkene resulted in the formation of the desired aminal radical addition product. However, efforts to optimize this reactivity with non-acylated aminals were unsuccessful.

The second chapter was taken from the published paper Formation of Carbon–Carbon Bonds Using Aminal Radicals, Schiedler, D. A.; Vellucci, J. K.; Beaudry, C. M. *Org. Lett.* **2012**, *14*, 6092–6095. This chapter described the further development of this reactivity. Aminal radicals were successfully formed from 2-iodobenzyl substituted *N*-acyl aminals by radical translocation reactions using AIBN and a either Bu₃SnH or (TMS)₃SiH as a stoichiometric hydrogen atom donor. It was discovered that the installation of an acyl substituent on the aminal greatly enhances the reactivity of the aminal radical species, resulting in cleaner reactivity, increased reaction yields, and the ability to form aminal radicals in the presence of carbon atoms bearing a single nitrogen atom substituent. Chemical yields of the radical translocation reactions were as high as 91%.

The third chapter was taken from the published paper Reductive Synthesis of Aminal Radicals for Carbon–Carbon Bond Formation, Schiedler, D. A.; Lu, Y.; Beaudry, C. M. *Org. Lett.* **2014**, *16*, 1160–1163. This chapter described the development of an alternative means to access aminal radicals. It was demonstrated that the SmI₂ reduction of *N*-acyl amidines or amidinium ions in the presence of CSA or NH₄Cl and an electron deficient alkene yielded products of C–C bond formation. Chemical yields of these transformations were as high as 99% and diastereoselectivities were as high as 20:1. Mechanistic investigations of this reactivity indicated that these reactions likely proceed through an aminal radical intermediate.

The fourth chapter described our current investigations on the application of aminal radicals to the total synthesis of the alkaloid natural product leuconoxine. It was envisioned that the SmI_2 induced reductive alkylation reaction of a simple bicyclic *N*-acyl amidine would rapidly construct the fully substituted aminal stereocenter present in the natural product and could lead to an efficient synthesis of the target.

While similar amidines have been reported in the literature, no general strategy to access amidines of this type was known. Three distinct synthetic strategies towards the preparation of the desired bicyclic *N*-acyl amidine substrate were developed and investigated.

The first strategy relied on the formation of the amidine using the intramolecular aza-Wittig reaction of an imide and an azide. Unexpectedly, this reaction produced a amido lactam product rather than the desired *N*-acyl amidine. Attempts to induce an intramolecular condensation reaction of the amido lactam to give the desired amidine were unsuccessful. It was concluded that the poor nucleophilicity of the electron-poor aryl amide and the sterically congested nature of the desired site of attack were to blame for the lack of desired reactivity.


The second strategy disconnected the desired bicyclic *N*-acyl amidine through an intramolecular *N*-acylation reaction of an *N*-aryl amidine. It was envisioned that the amidine could be prepared from a bimolecular condensation reaction of an aniline and a lactam derivative. All attempts to form the desired amidine functionality were unsuccessful. It was again concluded that the poor nucleophilicity of the electron-poor aryl nucleophile coupled with the sterically congested nature of the desired site of attack were to blame for the lack of desired reactivity.

The third strategy depended upon an *N*-arylation reaction for the conversion of the bicyclic *N*-acyl amidine reported by Wamhoff into the desired substrate for the synthesis of leuconoxine (1). While the key intermediate for the synthesis of leuconoxine (1) utilizing an aminal radical disconnection has remained elusive, a model system of the key *N*-arylation reaction has successfully produced an *N*-aryl-*N*-acyl bicyclic amidine product. The investigation of this synthetic route is still underway.

5.2 Future Directions

The immediate goals for the future of this project are related to the total synthesis of leuconoxine (1). In order to determine if the key aminal radical cyclization reaction is likely to be successful, it would be instructive to perform a few model reactions (Scheme 5.1). The amidine reported by Wamhoff (178) has not successfully participated in an aminal radical reaction (see chapter 4). However, the reactions investigated do not closely resemble the key aminal radical cyclization reaction

proposed for the synthesis of **1**. The preparation of the alkylated amidine **219** and the investigation of its reactivity under the SmI_2 reaction conditions will be performed (eq. 1). If **220** is not obtained from this reaction, then the reaction of analogous TBS-protected alcohol **221** to give the product **222** will be investigated to determine if the electron-withdrawing nature of the ester functional group is the cause of the problematic reactivity (eq. 2). Similarly, the bimolecular aminal radical reactions of **218** to give **223** will be examined (eq. 3). Additionally, the reactions **178** with the 1,2-dihalogenated arenes (**224** and **225**) will be investigated in order to prepare the substrates **226** and **227** for further study (eq. 4).




Scheme 5.1. Future work on the synthesis of **1**

The long-term goals of the project include the development of new modes of reactivity and their application in total synthesis (Scheme 5.2). The development of the reaction between aminal radicals and a C-1 radical acceptor, such as the aldehyde

228, to give the alcoholic product **229** is currently being investigated by Mr. Yi Lu (eq. 1). Once successfully developed, this reactivity will be applied in the total synthesis of saxitoxin (**2**).

The reactions of aminal radicals described in this dissertation both require prefunctionalization of the reaction substrate. It would be advantageous to develop a means to access aminal radicals directly from unsubstituted aminal substrates. For example, the extension of the method developed by Tanaka using triethylborane and molecular oxygen for the formation of α -amino radicals to the generaton of aminal radicals (eq 2) would be particularly useful.



Scheme 5.2. Additional reactions to be developed

The main limitation of the amidine reduction method we have developed is the lack of general and robust methods for the synthesis of *N*-acyl amidines. We envision the development of an oxidation reaction wherein an amidine (**230**) is oxidized to give an *N*-acyl amidine (**231**). Reactions of this type have been reported, but have not been investigated systematically.¹³¹ If fully realized, this reactivity could greatly increase

the utility of the amidine reduction chemistry described in chapter 3 of this dissertation.

¹³¹ for examples see (a) Hutchinson, J. H.; Halczenko, W.; Brashear, K. M.; Breslin, M. J.; Coleman, P. J.; Duong, L. T.; Fernandez-Metzler, C.; Gentile, M. A.; Fisher, J. E.; Hartman, G. D.; Huff, J. R.; Kimmel, D. B.; Leu, C.-T.; Meissner, R. S.; Merkle, K.; Nagy, R.; Pennypacker, B.; Perkins, J. J.; Prueksaritanont, T.; Rodan, G. A.; Varga, S. L.; Wesolowski, G. A.; Zartman, A. E.; Rodan, S. B.; Duggan, M. E. *J. Med. Chem.* **2003**, *46*, 4790–4798. (b) Shakhidoyatov, Kh. M.; Mukarramov, N. I.; Utaeva, F. R. *Chem. Nat. Compounds* **2008**, *44*, 625–629. (c) Zhang, C.; De, K. C.; Seidel, D. *Org. Synth.* **2012**, *89*, 274–282.